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ABSTRACT  
   
Cognitive function declines with normal age and disease states, such as 
Alzheimer's disease (AD). Loss of ovarian hormones at menopause has been 
shown to exacerbate age-related memory decline and may be related to the 
increased risk of AD in women versus men. Some studies show that hormone 
therapy (HT) can have beneficial effects on cognition in normal aging and AD, 
but increasing evidence suggests that the most commonly used HT formulation is 
not ideal. Work in this dissertation used the surgically menopausal rat to evaluate 
the cognitive effects and mechanisms of progestogens proscribed to women. I also 
translated these questions to the clinic, evaluating whether history of HT use 
impacts hippocampal and entorhinal cortex volumes assessed via imaging, and 
cognition, in menopausal women. Further, this dissertation investigates how sex 
impacts responsiveness to dietary interventions in a mouse model of AD. Results 
indicate that the most commonly used progestogen component of HT, 
medroxyprogesterone acetate (MPA), impairs cognition in the middle-aged and 
aged surgically menopausal rat. Further, MPA is the sole hormone component of 
the contraceptive Depo Provera, and my research indicates that MPA 
administered to young-adult rats leads to long lasting cognitive impairments, 
evident at middle age. Natural progesterone has been gaining increasing 
popularity as an alternate option to MPA for HT; however, my findings suggest 
that progesterone also impairs cognition in the middle-aged and aged surgically 
menopausal rat, and that the mechanism may be through increased GABAergic 
activation. This dissertation identified two less commonly used progestogens, 
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norethindrone acetate and levonorgestrel, as potential HTs that could improve 
cognition in the surgically menopausal rat. Parameters guiding divergent effects 
on cognition were discovered. In women, prior HT use was associated with larger 
hippocampal and entorhinal cortex volumes, as well as a modest verbal memory 
enhancement. Finally, in a model of AD, sex impacts responsiveness to a dietary 
cognitive intervention, with benefits seen in male, but not female, transgenic 
mice. These findings have clinical implications, especially since women are at 
higher risk for AD diagnosis. Together, it is my hope that this information adds to 
the overarching goal of optimizing cognitive aging in women. 
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CHAPTER 1 
GENERAL INTRODUCTION 
Cognitive Aging and Alzheimer’s Disease 
 By the year 2050 there will be an estimated 90 million people in the 
United States who are over the age of 65 (U.S. Census Bureau, 2007). Many of 
these individuals will experience cognitive decline as aging ensues and some will 
develop Alzheimer’s disease (AD). Indeed, aging is the number one risk factor for 
developing AD (Alzheimer’s Association, 2010). Currently, there are more than 5 
million people in the U.S. diagnosed with AD and that number is expected to 
more than double by the year 2050 (Alzheimers Association, 2010). Despite the 
rapidly growing prevalence of this disease, there are still no demonstrably 
effective treatments to reverse or halt the pathology or symptoms. 
Alzheimer’s Disease: Sex Differences and Dietary Interventions 
 As women age, they are at a higher risk to develop AD than men 
(Andersen et al., 1999). Some evidence suggests that loss of ovarian hormones at 
menopause puts women at a greater risk for AD (Solerte et al., 1999) .Indeed, 
estrogen-containing HT has been shown to reduce AD risk (Zandi et al., 2002) 
and enhance cognition in postmenopausal women with AD (Asthana et al., 1999). 
However, the largest study to date evaluating the ability of HT to reduce risk of 
AD found that one type of hormone therapy (HT) regimen, Prempro, actually 
increased the risk of AD in post-menopausal women (Shumaker et al., 2003). 
Chapters 2 through 5 in this dissertation evaluate the cognitive effects of a 
primary hormone component in Prempro, medroxyprogesterone acetate (MPA), in 
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the surgically menopausal aged rodent model, and Chapter 6 assesses the effects 
of HT on cognition and brain volumes in menopausal women. 
 Another potential risk factor for AD is diet. Several epidemiological 
studies have demonstrated that nutrition is an important factor in susceptibility to 
AD (Morris, 2009), and in animal models of AD, there is support that a multitude 
of nutritional interventions can modulate disease-related cognitive decline and 
pathology (Frydman-Marom et al., 2011; Joseph et al., 2003; J. W. Lee et al., 
2009; Wang et al., 2008). However, in AD patients, there is only modest evidence 
that single nutrients can have favorable outcomes on cognition, while others fail 
to demonstrate any benefits (Kamphuis & Scheltens, 2010). One potential 
shortcoming of human trials evaluating dietary intervention as a potential AD 
treatment is the focus on single-nutrient treatments. Chapter 7 in this dissertation 
addresses whether or not a combination of multiple nutrients can have positive 
effects on cognition and brain markers in animal models of AD, and if these 
effects interact with sex.  
Menopause, Hormone Therapy, and Cognition 
Within our aging population, that is estimated to include 90 million people 
in the United States who are over the age of 65 by the year 2050, over half will be 
postmenopausal women (U.S. Census Bureau, 2007). Menopause, occurring 
typically in the fifth decade of life, is characterized by loss of ovary-derived 
circulating hormones, including estrogen and progesterone (Timaras, Quay, & 
vernadakis, 1995). Menopause-induced hormone loss has been linked to many 
symptoms that affect quality of life in women including hot flashes, urogenital 
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atrophy, and memory decline (Freedman, 2002; Nappi et al., 1999; Sherwin, 
1988). HT is given to women to attenuate menopause-induced symptoms.  
Several clinical studies in menopausal and postmenopausal women have 
demonstrated positive effects of estrogen-containing HT on memory and 
cognition (Campbell & Whitehead, 1977; Duka, Tasker, & McGowan, 2000; 
Kantor, Michael, & Shore, 1973; Ohkura et al., 1995; Phillips & Sherwin, 1992; 
Sherwin, 1988; Wolf et al., 1999). However, recently the cognitive effectiveness 
of HT has been of much debate, due to the unexpected findings of the large, 
placebo-controlled, randomized Women’s Health Initiative Memory Study 
(WHIMS) conducted by the National Institute of Health. Post-menopausal women 
taking Premarin (estrogens) alone did not differ significantly from those taking 
placebo for dementia diagnoses (Shumaker et al., 2004). In contrast, twice as 
many women receiving Prempro (estrogens + a progestin) were diagnosed with 
dementia as compared to the placebo group, a significant effect (Shumaker et al., 
2003).  
Hormone Therapy and Mesial Temporal Lobe Structure Volumes 
The hippocampus is a brain structure intimately involved in learning and 
memory, and loss of hippocampal volume is a hallmark brain change seen in AD 
progression (Buckner et al., 2005; Scahill, Schott, Stevens, Rossor, & Fox, 2002) 
which is related to cognitive functioning (Jack et al., 2000; Jack et al., 1999). 
Hippocampal volumes have also been shown to be modulated by HT. In the 
WHIMS trial, a subset of women underwent a follow-up MRI regional volumes 
study, including evaluation of the hippocampus, and results were consistent with 
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HT-associated changes in dementia risk. Specifically, Premarin (conjugated 
equine estrogens) treatment led to no significant changes in hippocampal 
volumes, compared to placebo (p=.18); however, in women receiving Prempro 
(conjugated equine estrogens + the progestin MPA), there was a marginally 
significant effect (p=.09), with HT-treated women having smaller hippocampi 
than placebo (Resnick et al., 2009). These findings are in disagreement with other 
trials that have shown estrogen-containing HT to prevent hippocampal volume 
loss in a mix of healthy and demented women (Eberling et al., 2003) and women 
at genetic risk for AD (Yue et al., 2007). Multiple factors seem to modulate 
whether or not HT is associated with a protection or exacerbation of hippocampal 
volume loss, such as the interval between menopause and HT initiation (e.g., 
critical window hypothesis) (Erickson, Voss, Prakash, Chaddock, & Kramer, 
2010) and current versus past HT use (Boccardi et al., 2006; Lord, Buss, Lupien, 
& Pruessner, 2008).  
The entorhinal cortex is a brain structure heavily implicated in AD 
progression (Braak & Braak, 1991; Hyman, Van Hoesen, Damasio, & Barnes, 
1984; Hyman et al., 1984; Braak and Braak, 1991)   and cognitive performance in 
normal individuals (Fernandez, Brewer, Zhao, Glover, & Gabrieli, 1999), but 
much less studied for responsiveness to HT-induced atrophy protection. However, 
one voxel-based morphometry MRI study did evaluate HT effects on entorhinal 
cortex volumes and found that HT use was associated with larger entorhinal 
cortex volumes, as compared to non-users (Boccardi et al., 2006). Chapter 6 
examined the ability of continuous or discontinuous HT to alter volumes of the 
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hippocampus and entorhinal cortex, as well as cognitive function, in post-
menopausal women. 
Progestins and Memory: MPA 
Premarin, a complex combination of horse-derived estrogens, is the most 
widely used estrogenic component of HT (Hersh, Stefanick, & Stafford, 2004). 
Women with a uterus that are taking estrogens must include a progestin in their 
regimen because of increased risk of endometrial hyperplasia associated with 
unopposed estrogen treatment (Smith, Prentice, Thompson, & Herrmann, 1975; 
Ziel & Finkle, 1975). Prempro is the most widely prescribed progestin-containing 
HT in the United States, with an estimated 20 million prescriptions written per 
year within the last decade (Hersh et al., 2004). 
The progestin, MPA, may be a key factor in Prempro that induced 
cognitive impairments in the WHIMS trials, although many variables could be 
involved in this negative outcome (Sherwin, 2005). Until recently, there had been 
no study directly testing the hypothesis that MPA is detrimental to cognition in 
women or an animal model, however, there is indirect evidence that MPA is 
detrimental to the brain and its function. Indeed, MPA exacerbated neuronal death 
by glutamate-induced excitotoxicity (Nilsen, Morales, & Brinton, 2006), reduced 
estrogen-mediated neural protection against excitotoxicity (Nilsen & Brinton, 
2002b), and completely blocked the glutamate-stimulated calcium increase 
produced by 17 β-estradiol, a positive mechanism by which estrogens may 
modulate cognitive functioning (Nilsen & Brinton, 2002a). Chapter 2 tested the 
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cognitive effects of MPA in the surgically menopausal aged rat, and Chapters 3, 
4b, and 5b tested these effects in the surgically menopausal middle-aged rat. 
MPA is also the sole hormone component of the contraceptive Depo 
Provera. Depo Provera was approved by the Food and Drug Administration in 
1992 (Bakry et al., 2008), and has been prescribed to over 10 million women in 
the United States since this time (Mosher, Martinez, Chandra, Abma, & Willson, 
2004). This widely prescribed contraceptive is often the choice for women who 
cannot take estrogen-containing contraceptives because of medical conditions 
(Spencer, Bonnema, & McNamara, 2009), for nursing mothers (Rodriguez & 
Kaunitz, 2009), and for those who prefer the convenience of an intermittent 
injection once every three months over the daily pill. There have been no 
methodical clinical evaluations of the cognitive effects of Depo Provera in 
women; however, there is a documented case study of amnestic effects 
corresponding with Depo Provera use (Gabriel & Fahim, 2005). Chapter 3 studied 
the long-term cognitive effects of MPA administration, giving MPA to young 
ovary-intact rats and then testing at the middle-age time point, with or without 
MPA given at middle-age as well. This addressed how MPA treatment during 
young-adulthood could interact with subsequent MPA treatment at middle-age. 
Progestins and Memory: NETA and LEVO 
With evidence mounting that MPA is not the optimal progestin to be used 
in HT and birth control taken by women, it is important to determine if there are 
safer progestins, with respect to cognition. Based on chemical structures, 
synthetic progestins either structurally resemble progesterone or testosterone, 
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considering the A-ring and the functional group in the 17 beta position of the 
steroidal skeleton (Brinton et al., 2008; Stanczyk, 2003). Progesterone-related 
drugs, including acetylated (e.g., MPA; Figure 12b) and non-acetylated pregnans 
and 19-norpregnans, respectively, are commonly used for HT and contraception 
in the USA. The majority of testosterone- and especially 19-nortestosterone- 
resembling progestins contain an ethynyl group in the 17 alpha position with (e.g., 
norethindrone acetate, NETA, Figure 12c) or without acetylation of the 17 beta 
hydroxyl group.  A homologous subcategory within this series consists of those 
progestins that carry a C-13 substitution with an ethyl group (Stanczyk, 2003).  
These progestins are often referred to as 13-ethyl gonanes, and a typical 
representative of this subgroup of progestins is levonorgestrel (LEVO, Figure 
12d), a popular choice of progestin in Europe (Brinton et al, 2008).   
MPA is in the acetylated progesterone derivative category. When 
exploring progestins not in the acetylated progesterone derivative category, the 
two most commonly used choices for HT and birth control are NETA  from the 
ethynylated 19-nortestosterone  family, and LEVO from the homologous 17 alpha 
ethynyl nortestosterone (“13-ethyl gonane”) series (P. A. Murphy & Brixner, 
2008; Curtis, 2006). There have been limited scientific investigations for HT 
regarding the effects of NETA, paired with ethinyl- or 17β- estradiol, on cognition 
and brain processes in healthy menopausal women. In these studies the 
combination HT was associated with greater brain activation during a memory 
test (Persad et al., 2009; Smith et al., 2006), protection from memory decline after 
one and two years of treatment (Tierney et al., 2009), or no impact on self-report 
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of memory and concentration difficulties (Gambacciani et al., 2003). Chapters 4a 
and 4b tested the cognitive effects of NETA at different doses and treatment 
parameters in the surgically menopausal middle-aged rat. 
There have been no scientific investigations of the effects of LEVO on 
cognition, neither when included as a part of combination therapy in menopausal 
women, nor when given alone in rodents, leaving little information to hypothesize 
the safety of this progestin on the brain and its function. However, differences in 
chemical structure from the cognitively-impairing progestin, MPA, and its global 
use, make LEVO a worthy candidate for scientific studies evaluating this 
endpoint. Chapter 4b tested the cognitive effects of LEVO in the surgically 
menopausal middle-aged rat. 
Progesterone and Memory 
In both clinical and preclinical studies, natural progesterone has been 
associated with detrimental cognitive effects. In healthy women, a large oral 
progesterone dose is detrimental to memory (Freeman, Weinstock, Rickels, 
Sondheimer, & Coutifaris, 1992). In aged rats, ovariectomy (Ovx) improves 
cognition (Bimonte-Nelson, Singleton, et al., 2003), which is likely related to 
removal of elevated progesterone levels (Lu, Hopper, Vargo, & Yen, 1979), since 
progesterone administration reverses the beneficial effects of Ovx (Bimonte-
Nelson, Singleton, Williams, & Granholm, 2004). However, the literature on 
progesterone effects on cognition in young Ovx rodents is mixed, with some 
studies showing benefits, mostly related to non-spatial memory (Frye, Duffy, & 
Walf, 2007; Frye & Walf, 2008; Harburger, Pechenino, Saadi, & Frick, 2008; Orr, 
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Lewis, & Frick, 2009). When combined with 17 β-estradiol, progesterone 
abolishes 17 β-estradiol-induced memory enhancements (Bimonte-Nelson, 
Francis, Umphlet, & Granholm, 2006; Gibbs, 2000; Harburger, Bennett, & Frick, 
2007; but see Gibbs, 2000) and attenuates 17 β-estradiol’s neurotrophic effects in 
vivo (Bimonte-Nelson, Nelson, & Granholm, 2004), and in cell culture (Aguirre 
& Baudry, 2009; Nilsen & Brinton, 2002a). Further, administration of the 
progesterone metabolite, allopregnanolone, can impair cognition in healthy 
women (Kask, Backstrom, Nilsson, & Sundstrom-Poromaa, 2008) and young rats 
(Frye & Sturgis, 1995; Johansson, Birzniece, Lindblad, Olsson, & Backstrom, 
2002). Chapter 2 aimed to replicate the cognitive impairing effects of 
progesterone in aged Ovx rats, and Chapter 5a tested these effects in the middle-
aged Ovx rat. 
Progestogens and GABA   
Because the ring-A reduced metabolites of progesterone have a high 
affinity for the GABAA receptor, and several are potent positive allosteric 
modulators (Paul & Purdy, 1992), it is a reasonable hypothesis that progesterone-
induced memory impairments are related to GABAergic system alterations. 
Providing support for this hypothesis, experimental manipulation of progesterone 
alters the GABAergic system. For example, progesterone administration 
decreases glutamic acid decarboxylase (GAD), the synthesizing enzyme and rate 
limiting step of GABA production, activity in the rodent dorsal hippocampus 
(Wallis & Luttge, 1980), and can alter mRNA expression of subunits of the 
GABAA receptor in the hippocampus of Ovx rats (Pazol, Northcutt, Patisaul, 
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Wallen, & Wilson, 2009; Weiland & Orchinik, 1995). Further, MPA has been 
shown to enhance GABAA receptor-mediated inhibition (Belelli & Herd, 2003), 
possibly by alter progesterone’s metabolic conversions (Penning, Sharp, & 
Krieger, 1985). Chapters 2 and 3 tested the effects of progesterone and MPA 
administration on protein levels of GAD in cognitive brain regions. Chapter 5 
directly tested the hypothesis that progesterone- (Chapter 5a) and MPA- (Chapter 
5b) induced memory impairments are via activation of the GABAA receptor. This 
was done via pharmacologically manipulating the GABAergic system, by treating 
middle-aged Ovx animals concomitantly with progesterone or MPA plus the 
GABAA antagonist, bicuculline. Chapter 5a also tested the effects of 
progesterone, MPA, and/or bicuculline on number of GABA-producing cells in 
the hippocampus. 
Progestogens and Neuronal Health 
While we have shown that progesterone impairs cognition in aged rats 
(Bimonte-Nelson et al., 2004b) and reverses the cognitive benefits of 17β-
estradiol in middle-age rats (Bimonte-Nelson et al., 2006), in young rodent 
models of cortical contusion, progesterone improves cognitive performance 
(Roof, Duvdevani, Braswell, & Stein, 1994), and reduces oedema and neuronal 
degeneration (Roof et al., 1994; Roof, Duvdevani, Heyburn, & Stein, 1996; Roof, 
Duvdevani, & Stein, 1993). Further, progesterone modulates cyclooxygenase-2 
(Cox-2), a key enzyme in the formation of prostaglandins in the inflammatory 
response that is found in the cortex and other subcortical structures in the rat brain 
(Breder, Dewitt, & Kraig, 1995), and induced in glutamate excitotoxicity (Tocco 
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et al., 1997). One study found that progesterone decreased Cox-2 expression in 
the frontal cortex following cortical contusion (Cutler et al., 2007), while another 
found that progesterone increased Cox-2 expression in response to 
lipopolysaccharide (LPS)-induced cerebrovascular inflammation (Sunday, Tran, 
Krause, & Duckles, 2006). MPA has also been tested in these models of 
neuroprotection, wherein others have found that MPA reduces cerebral oedema 
but does not protect against cognitive impairments (Wright, Hoffman, Virmani, & 
Stein, 2008), and exacerbates Cox-2 expression in response to LPS-induced 
cerebrovascular inflammation (Sunday et al., 2006). Indeed, on global measures 
of neuroprotection in cell culture, progesterone protects against glutamate-
induced excitotoxicity (Nilsen & Brinton, 2002b). Conversely, MPA does not 
seem to demonstrate neuroprotective properties in vitro (Nilsen & Brinton, 
2002b), but in fact exacerbates glutamate- induced excitotoxicity (Nilsen et al., 
2006). Further, MPA results in a greater attenuation of 17 β-estradiol’s 
neurotrophic actions than natural progesterone (Nilsen & Brinton, 2002a). 
Chapter 5 tested the effects of progesterone (Chapter 5a) and MPA (Chapter 5b) 
treatment on number of Cox-2-positive cells in the frontal cortex, in middle-aged 
Ovx rats. 
Neurotrophins, such as nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF), is another system that is influenced by progesterone, 
and is involved in neuronal function and age-related memory changes (Backman 
et al., 1996). Progesterone counteracts estrogen-induced increases in entorhinal 
and frontal cortex neurotrophin levels in aged Ovx rats (Bimonte-Nelson, Nelson, 
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et al., 2004). This same effect is seen in hippocampal slice cultures for BDNF 
(Aguirre & Baudry, 2009); however, in cerebral cortex slice cultures, 
progesterone treatment alone increases BDNF levels (Kaur et al., 2007). It has yet 
to be determined whether progesterone or MPA impacts neurotrophin levels in 
vivo, and if these changes are related to the cognitive impairing effects of 
progestogens. Chapter 2 tested the effects of progesterone and MPA treatment on 
BDNF levels in cognitive brain regions of aged Ovx rats that were cognitively 
characterized.  
Work in this dissertation used the surgically menopausal rat to provide 
insight into the cognitive effects and mechanisms of multiple progestogens 
clinically used in women. I also translated these questions to the clinic, evaluating 
whether the history of HT use impacts volumes of cognitive brain structures and 
memory measures in menopausal women. Further, this dissertation adds insight 
into how sex impacts responsiveness to dietary interventions in a mouse model of 
AD. Together, it is my hope that this information adds to the overarching goal of 
optimizing cognitive aging in women. 
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CHAPTER 2 
MEDROXYPROGESTERONE ACETATE IMPAIRS MEMORY AND 
ALTERS THE GABAERGIC SYSTEM IN AGED SURGICALLY 
MENOPAUSAL RATS  
By the year 2050 there will be an estimated 90 million people in the 
United States who are over the age of 65, and over half of these individuals will 
be postmenopausal women (U.S. Census Bureau, 2007). Menopause, occurring 
typically in the fifth decade of life, is characterized by loss of ovary-derived 
circulating hormones, including estrogen and progesterone (Timaras et al., 1995). 
Menopause-induced hormone loss has been linked to many symptoms that affect 
quality of life in women including hot flashes, urogenital atrophy, and memory 
decline (Freedman, 2002; Nappi et al., 1999; Sherwin, 1988). HT is given to 
women to attenuate menopause-induced symptoms. Premarin, a complex 
combination of horse-derived estrogens, is the most widely used estrogenic 
component of HT (Hersh, et al., 2004). Women with a uterus that are taking 
estrogens must include a progestin in their regimen because of increased risk of 
endometrial hyperplasia associated with unopposed estrogen treatment (Smith et 
al., 1975; Ziel and Finkle, 1975). Prempro (Premarin + MPA) is the most widely 
prescribed progestin-containing HT in the United States, with an estimated 20 
million prescriptions written per year within the last decade (Hersh et al., 2004). 
Further, over 10 million women in the United States have been prescribed MPA 
as the injectable contraceptive Depo Provera (Mosher et al., 2004). Thus, MPA is 
widely clinically utilized. 
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Several clinical studies in menopausal and postmenopausal women have 
demonstrated positive effects of estrogen-containing HT on memory and 
cognition (Campbell and Whitehead, 1977; Duka et al., 2000; Kantor et al., 1973; 
Ohkura et al., 1995; Phillips and Sherwin, 1992; Sherwin, 1988; Wolf et al., 
1999). However, recently the cognitive effectiveness of HT has been of much 
debate, due to the unexpected findings of the large, placebo-controlled, 
randomized WHIMS conducted by the National Institute of Health. Menopausal 
women taking Premarin alone did not differ significantly from those taking 
placebo for dementia diagnoses (Shumaker et al., 2004). In contrast, twice as 
many women receiving Prempro were diagnosed with dementia as compared to 
the placebo group, a significant effect (Shumaker et al., 2003).  
MPA may be a key factor in Prempro that caused cognitive impairments, 
although many variables could be involved in this negative outcome (Sherwin, 
2005). There has been no study directly testing the hypothesis that MPA is 
detrimental to cognition in women or an animal model, however, there is indirect 
evidence that MPA is detrimental to the brain and its function. Indeed, MPA 
exacerbated neuronal death by glutamate-induced excitotoxicity (Nilsen et al., 
2006), reduced estrogen-mediated neural protection against excitotoxicity (Nilsen 
& Brinton, 2002b), and completely blocked the glutamate-stimulated calcium 
increase produced by 17 β-estradiol, a positive mechanism by which estrogens 
may modulate cognitive functioning (Nilsen & Brinton, 2002a). In both clinical 
and preclinical studies, progesterone has been associated with detrimental 
cognitive effects. In healthy women, a large oral progesterone dose is detrimental 
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to memory (Freeman et al., 1992). High circulating progesterone levels are 
observed in most rats following estropause (reproductive senescence) (Lu et al., 
1979). It is noteworthy that Ovx in aged rats improves cognition (Bimonte-
Nelson, Singleton, et al., 2003), which is likely related to progesterone removal, 
since progesterone administration reverses the beneficial effects of Ovx 
(Bimonte-Nelson et al., 2004b). Additionally, administration of the ring-A 
reduced progesterone metabolite, allopregnanolone, can impair cognition in 
healthy women (Kask et al., 2008) and young rats (Frye & Sturgis, 1995; 
Johansson et al., 2002).  
Because the ring-A reduced metabolites of progesterone have a very high 
affinity for the GABAA receptor (Paul & Purdy, 1992), we hypothesize that 
progesterone-induced memory impairments are related to GABAergic system 
alterations. Providing support for this hypothesis, the hippocampus and related 
brain regions affected by aging and mediating memory processing are largely 
controlled by the GABAergic system (Izquierdo et al., 1993; Mora, Segovia, & 
del Arco, 2007), and experimental manipulation of progesterone alters the 
GABAergic system. For example, progesterone administration decreases GAD, 
the synthesizing enzyme and rate limiting step of GABA production, activity in 
the rodent dorsal hippocampus (Wallis & Luttge, 1980). Additionally, after 17 β-
estradiol priming, progesterone but not MPA decreased mRNA expression of the 
α4 subunit of the GABAA receptor in the CA1 of Ovx rats (Pazol et al., 2009). 
Indeed, MPA results in different ring-A reduced metabolites (dihydroMPA and 
tetrahydroMPA) that do not influence binding at the benzodiazepine site of the 
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GABAA receptor as the progesterone ring-A reduced metabolites do, as seen with 
allopregnanelone (McAuley, Kroboth, Stiff, & Reynolds, 1993). 
Neurotrophins, such as nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF), is another system that is influenced by progesterone, 
is involved in neuronal function and in age-related memory changes (Backman et 
al., 1996). Progesterone counteracts 17β-estradiol-induced increases in entorhinal 
and frontal cortex neurotrophin levels in aged Ovx rats (Bimonte-Nelson et al., 
2004a). This same effect is seen in hippocampal slice cultures for BDNF (Aguirre 
& Baudry, 2009); however, in cerebral cortex slice cultures, progesterone 
treatment alone increases BDNF levels (Kaur et al., 2007). Thus, alteration of 
neurotrophin levels is a neuronal mechanism by which progesterone-induced 
memory changes may be mediated. 
While studies suggest that progesterone has a profound impact on 
GABAergic and neurotrophic systems, as well as cognition, these findings cannot 
be extrapolated to effects of the synthetic progesterone, MPA. Given that MPA is 
the progestin component in Prempro, the most widely used combination HT, the 
negative in vitro findings regarding this hormone are particularly salient. 
Methodical investigations are warranted to determine whether these detrimental in 
vitro effects translate to brain functions such as learning and memory. The goal of 
the present study was to determine whether MPA exerts detrimental effects on the 
brain and its function. To do this, we tested the cognitive, GABAergic, and 
neurotrophic effects of MPA in the aged surgically menopausal rat, comparing 
effects to natural progesterone and vehicle control Ovx and Sham animals. 
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Methods 
Subjects  
Subjects were 37 eighteen month-old Fischer-344 female rats born and 
raised at the aging colony of the National Institute on Aging at Harlan 
Laboratories (Indianapolis, IN). Rats were acclimated for several weeks before 
surgery, had access to food and water ad-lib, and were maintained on a 12-hour 
light/dark cycle at the Arizona State University animal facility. All procedures 
were approved by the local IACUC committee and adhered to NIH standards.  
Ovariectomy and Hormone Treatment 
Rats were randomly assigned to one of five treatment groups: Sham 
(ovary-intact), Ovx, Ovx+Prog, Ovx+Low MPA, and Ovx+High MPA. 
Approximately two months before behavioral testing, all rats received Ovx or 
sham surgery. All rats were anesthetized via isofluorene inhalation. Rats receiving 
Ovx underwent bilateral dorsolateral incisions in the skin and peritoneum, and the 
ovaries and tips of uterine horns were ligatured and removed. Muscle and skin 
were then sutured. Rats receiving sham surgery underwent identical skin incision 
and suture. At the time of surgery, Alzet osmotic pumps (2ML4; Durect Co., 
Cupertine, CA) containing either proplyene glycol (vehicle, Sigma-Aldrich, St. 
Louis, MO, USA), progesterone (PROG; 21mg dissolved in 2mL propylene 
glycol, Sigma-Aldrich, St. Louis, MO, USA), or MPA (low dose: 14mg; high 
dose: 21mg, dissolved in 2mL propylene glycol (Sigma-Aldrich, St. Louis, MO, 
USA)) were implanted in the neck scruff. Hormone administration continued 
throughout behavior testing and sacrifice. Doses were based on prior research 
  18 
(Zhang, Fishman, & Huang, 1999), multiplied by a factor of 10 to account for the 
increased weight from the mouse to the rat. After surgery, rats received Rimadyl 
(5mg/mL/kg) for pain and saline (2 mL) to prevent dehydration. Animals 
underwent pump reinsertion surgery every 31-32 days; behavioral testing began 
66 days after the first pump insertion. Thus, hormone administration continued 
throughout behavior testing and sacrifice. 
Vaginal Smears and Uterine Weights 
 Vaginal smears were taken 16 days after Ovx and pump insertion. Smears 
were classified as proestrus, estrous, metestrus or diestrus, per prior protocols 
(Acosta, Mayer, Talboom, Zay, et al., 2009; Goldman, Murr, & Cooper, 2007). 
As expected, all Ovx animals, regardless of treatment, showed leukocytic smears, 
while sham animals showed one of the four phases of the estrous cycle. To 
examine drug effects on uterine tissues, at sacrifice the uteri of all subjects were 
removed, trimmed of visible fat and immediately weighed (wet weight).  
Water Radial-Arm Maze (WRAM) 
Subjects were tested for 13 days on the eight-arm win-shift WRAM to 
evaluate spatial working and reference memory, including performance as 
working memory load increased, as described previously (Bimonte & Denenberg, 
1999, 2000; Bimonte, Granholm, Seo, & Isacson, 2002; Bimonte, Hyde, Hoplight, 
& Denenberg, 2000). The maze contained escape platforms hidden under the 
water surface in the ends of 4 of the 8 arms. Each subject had different platform 
locations that remained fixed throughout the experiment. A subject was released 
from the start arm and had 3 minutes (m) to locate a platform. Once a platform 
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was found, the animal remained on it for 15 seconds (s), and was then returned to 
its heated cage for a 30s inter-trial interval (ITI) until its next trial. During the 
interval, the just-chosen platform was removed from the maze. The animal was 
then placed again into the start alley and allowed to locate another platform. For 
each animal a daily session consisted of four trials, with the number of platformed 
arms reduced by one on each subsequent trial. Thus, the working memory system 
was increasingly taxed as trials progressed, allowing us to access working 
memory load. Each subject was given one session a day for 12 consecutive days.  
Quantification and blocking were based on prior studies (Bimonte & 
Denenberg, 2000; Bimonte et al., 2002; Bimonte et al., 2000; Hyde, Hoplight, & 
Denenberg, 1998; Hyde, Sherman, & Denenberg, 2000). An arm entry was 
counted when the tip of a rat’s snout reached a mark delineated on the outside of 
the arm (11 cm into the arm). Errors were quantified using the orthogonal 
measures of working and reference memory errors (Jarrard, Okaichi, Steward, and 
Goldschmidt, 1984), as done previously in WRAM studies (Bimonte et al., 2002; 
Bimonte et al., 2000; Hyde et al., 2000). Working Memory Correct (WMC) errors 
were the number of first and repeat entries into any arm from which a platform 
had been removed during that session. Trial 1 is not analyzed for WMC errors 
because no platform has yet been removed. Reference memory (RM) errors were 
the number of first entries into any arm that never contained a platform. Working 
Memory Incorrect (WMI) errors were repeat entries into a RM arm.  
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Morris Maze (MM) 
The MM was tested for 6 trials/day for 5 days using a tub (188 cm 
diameter) filled with black water made opaque using non-toxic paint. A hidden 
platform (10 cm wide) remained in a fixed location, thereby testing spatial 
reference memory (Bimonte-Nelson et al., 2006; R. G. Morris, Garrud, Rawlins, 
& O'Keefe, 1982). The rat was placed in the maze from the North, South, East, or 
West location, and had 60s to locate the hidden platform (10 cm wide), which 
remained in a fixed location (Northeast quadrant) throughout testing. Once the rat 
found the platform the trial was terminated. After 15s platform time, the rat was 
placed into its heated cage until its next trial. The approximate ITI was 15m. To 
evaluate whether rats localized the platform to the spatial location, after all test 
trials on day 5, a 60s probe trial was given whereby the platform was removed. 
For each trial, a camera suspended above the maze tracked each rat’s path and a 
tracking system (Ethovision 3.1, Noldus Instruments) analyzed each rat’s tracing. 
MM performance was assessed by swim path distance (cm) and latency (s) 
to the platform. For probe trial data, percent of total distance in the previously 
platformed (target) quadrant was compared to the quadrant diagonally opposite 
the platform. Rats that learned the platform location were expected to spend the 
greatest percent distance in the target quadrant (Stavnezer, Hyde, Bimonte, 
Armstrong, & Denenberg, 2002). 
 Visible Platform Maze 
 Since the MM and WRAM rely on spatial navigation, it was necessary to 
confirm that all subjects had intact vision and could perform the procedural task 
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components without difficulty. A visible platform (VP) water-escape task was 
used in this regard. A rectangular tub (39 x 23 in) was filled with clear water and 
a black platform (10 cm wide) with a white flag (2 x 3 in) was elevated above the 
water surface. Opaque curtains covered extramaze cues. The drop off location 
remained the same across trials, and the platform location for each trial varied in 
space semi-randomly. Animals had to locate the flagged platform protruding from 
the water, and were given 8 trials/day for 2 days. Performance was assessed by 
latency (s) to the platform.  
Brain Dissections  
Two days after conclusion of behavior testing, animals were anesthetized, 
decapitated and brains rapidly dissected and frozen. Dissected tissues were stored 
in preweighed microcentrifuge tubes at -70°C until analysis. Dissections were 
according to plate designations in Paxinos and Watson (1998) and were as 
follows: frontal cortex (plates 5-14), cingulate cortex (plates 5-14), basal forebrain 
(plates 14-16), perirhinal cortex (plates 39-42), entorhinal cortex (plates 39-42), 
and CA1/CA2 region of the dorsal hippocampus (plates 33-35). For each brain the 
frontal cortex was taken first from the dorsal aspect of the intact brain. Next, the 
cingulate cortex was taken with the longitudinal fissure as the medial border, and 
the medial border of the frontal cortex cut as the lateral border. Next, the brain 
was cut in the coronal plane to obtain access to the basal forebrain. For the basal 
forebrain, both medial septum and ventral diagonal band were included with the 
posterior landmark being the crossing point of the anterior commissure. The brain 
was then cut in the coronal plane to obtain access to the last three brain regions. 
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For the CA1/CA2 region of the hippocampus, the dentate gyrus and the alveus 
were excluded. For the entorhinal cortex, the tissue was dissected from the same 
slice as the hippocampal sample, taking a 2- to 3-mm sample ventral to the 
hippocampus. The perirhinal cortex was also collected from this same slice, 
taking a 2- to 3-mm sample around the perirhinal fissure. 
Western Blot Analyses of GAD 65+67 
GAD 65+67 protein expression levels were analyzed in frontal, cingulate, 
perirhinal, and entorhinal cortices, and hippocampus, from the right hemisphere, 
and the basal forebrain. Samples were sonicated in RIPA buffer (150mM NaCl, 
1% Triton X-100, 0.1% SDS, 0.5% Na Deoxycholate, 50mM Tris) equivalent to 
10 times the weight of the sample and centrifuged at 10,000 RPM for 10m at 4°C. 
Protein concentrations were determined using BCA protein assays (ThermoFisher 
Scientific, Pittsburgh, PA, USA) and 10 µg of protein from each sample was run 
on a NuPAGE Bis-Tris gel, using the SureLock mini-cell (Invitrogen, Carlsbad, 
CA, USA). Gels were counterbalanced by group and each region was run on two 
gels. Approximately half of each group was loaded onto a single gel, 
corresponding to 2-4 subjects from each treatment group. Proteins were 
transferred onto a PVDF membrane (Millipore, Bedford, MA, USA) and 
immunoblotting was performed with working dilutions of a rabbit anti-GAD 
65+67 (ab11070) and rabbit anti-beta Actin (ab25894) primary antibodies 
(Abcam Inc., Cambridge, MA, USA). Antibody dilutions were 1:10,000 for GAD 
65+67 and 1:2,000 for beta Actin primary antibodies. Membranes were then 
exposed to a peroxidase-conjugated goat anti-rabbit secondary antibody, 1:10,000 
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dilution (111-035-003; Jackson Immuno Research, West Grove, PA, USA) and 
visualized using Pierce ECL Western Blotting Substrate (ThermoScientific, 
Rockford, IL, USA) on a Biospectrum Biochemi 500 Imaging System (UVP, 
Upland, CA, USA). Bands were identified as the protein of interest, based on 
molecular weight, using Precision Plus Protein WesternC Standards (Bio Rad, 
Hercules, CA, USA). The density of GAD 65+67 and beta Actin (control protein) 
were then quantified using ImageJ software (Rasband, 1997-2004). The 
dependent measure was a proportion of each subject’s GAD 65+67 density to 
their beta Actin density, brought to percent control of Ovx subjects run on the 
same gel, per prior protocols (Pandey, Zhang, Mittal, & Nayyar, 1999).  
Growth Factor ELISAs 
NGF and BDNF levels were assessed in frontal, cingulate, and entorhinal 
cortex, and hippocampus, from the left hemisphere. Using Promega kits 
(Madison, WI), NGF and BDNF can be quantified in the range of 7.8–500 pg/mL, 
and cross-reactivity with other trophic proteins is < 2–3%. This procedure has 
been utilized routinely in our laboratory with excellent replicability (Bimonte-
Nelson et al., 2004a). In brief, flat-bottom plates were coated with the 
corresponding capture antibody, which binds the neurotrophin of interest. The 
captured neurotrophin was bound by a second specific antibody, which was 
detected using a species-specific antibody conjugated to horseradish peroxidase as 
a tertiary reactant. All unbound conjugates were removed by subsequent wash 
steps according to the Promega protocol. After incubation with chromagenic 
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substrate, color change was measured in an ELISA plate reader at 450nm. The 
dependent measure was pg of BDNF or NGF/mg tissue.  
Blood Serum Analyses for MPA 
Liquid-liquid extraction of aliquots (1 mL) from serum samples was 
performed according to (Kim & Kim, 2001) after adding 10 ng/mL of d9-
progesterone (C/D/N Isotopes, Pointe-Claire, Quebec, Canada) as an internal 
reference compound. MPA concentrations were determined by liquid 
chromatography–atmospheric-pressure ionization tandem mass spectrometry. A 
reversed-phase column and isocratic elution were used for chromatographic 
separation of MPA and internal reference. Measurements were performed on a 
Surveyor – LTQ-FT system from Thermo Fisher (San Jose, CA). In 13x100 mm 
glass tubes, aliquots (1 mL) of serum were diluted with identical volumes of 
potassium phosphate buffer (100 mM, pH 7.0) followed by addition of an internal 
reference compound (d9-progesterone, 10 µL from an 1-µg/mL solution in 
ethanol). Pentane (4 mL) was then added and the mixture was vortexed for 1 min. 
After centrifugation at 1000g for 10 min, the organic layer was removed and the 
extraction was repeated. The pooled organic extracts were dried under nitrogen 
stream at room temperature and, then, reconstituted in 100 µL acetonitrile before 
analysis. MPA concentrations were determined by liquid chromatography–
atmospheric-pressure ionization tandem mass spectrometry (LC–APCI-MS/MS). 
Analytes were separated on a 50 mm x 2.1 mm i.d. Supelco (Bellefonte, PA) 
Discovery HS C18 reversed-phase column. Isocratic elution was used with a 
mobile phase of water (22.5% v/v), acetonitrile (77% v/v) and  acetic acid (0.5% 
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v/v) delivered at 0.25 mL/min flow rate by a Surveyor MS pump (Thermo Fisher, 
San Jose, CA). Injections (6 µL each) were made by an autosampler (Leap 
Technologies, Carrboro, NC). The entire column effluent was introduced to the 
APCI source of an LTQ-FT instrument (Thermo Fisher) whose linear ion trap was 
used to perform MS/MS data acquisitions. Selected-reaction monitoring (SRM) 
was employed to record MPA and d9-progesterone signals. MPA and d9-
progesterone were measured through SRM chromatograms obtained by 
monitoring the fragments m/z 327 and m/z 306, respectively, which represented 
fragments of the protonated compounds (m/z 387 for MPA and m/z 324 for d9-
progesterone). MPA concentrations were determined by performing calibrations 
from the analysis of serum samples spiked with 1, 2, 5 and 10 ng/mL of analyte, 
respectively, and using the added d9-progesterone as an internal reference to 
compensate for slight changes in extraction efficiency and LC–APCI-MS/MS 
conditions among samples. The dependent measure was ng/mL of MPA in serum. 
Statistical Analyses  
For behavior assessments, data were analyzed separately for each maze, 
first using an omnibus repeated measures ANOVA with Treatment as the between 
variable and Days and/or Trials as the within variable/s, as appropriate for the 
specific maze test. This was done to allow interpretation of Days and/or Trials 
repeated measures effects in the context of potentially complex Treatment 
interactions, and for these omnibus analyses all Treatment groups were included. 
Since our interest was to evaluate effects of Ovx, progesterone, and dose-specific 
MPA administration, two-group planned comparisons were run on the specific 
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measures of the last WRAM testing day, the delay WRAM testing day, and 
Morris maze overnight forgetting (described below), noting that Type I error 
correction is not necessary with orthogonal planned comparisons (Keppel & 
Wickens, 2004).  
For WRAM analyses, for all three orthogonal measures of WMC, RM and 
WMI, learning across all testing days was evaluated in order to detect Day x 
Treatment interactions. Performance on the final day of regular testing, Day 12, 
was evaluated at the highest working memory load (Trial 4), as this has revealed 
Ovx-induced benefits and progesterone-induced impairments in aged animals in 
our laboratory (Bimonte-Nelson et al., 2003b; Bimonte-Nelson et al., 2004b). On 
Day 13, a two hour delay was imposed between trials 2 and 3 to assess memory 
retention for numerous items of information (i.e., the found platform locations on 
trials 1 and 2).   Treatment effects and Trial x Treatment interactions were 
analyzed for the post-delay trials (Trials 3 and 4) in order to detect impairing 
effects of the delay within that day. Errors committed on the post-day trials were 
also compared to errors on the last day of regular testing, Day 12 (baseline) in 
order to detect impairing effects of a two hour delay versus the 30s ITI.  
For MM, in addition to the learning evaluation across all days, in order to test 
overnight forgetting of the platform location on the MM, we compared distance 
scores from the last trial of each day (Trial 6) to the first trial of the following day 
(Trial 1), collapsed across all testing days, as done previously (Acosta, Mayer, 
Talboom, Zay, et al., 2009; Bimonte-Nelson et al., 2006; Markham, Pych, & 
Juraska, 2002). Using a priori two-group planned comparisons we examined 
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Treatment x Trial interactions for effects of Ovx, and progesterone and MPA 
administration across the overnight interval (Trial 6 to Trial 1). We also examined 
within group trial comparisons of the overnight interval (Trial 6 to Trial 1) in 
order to determine which treatment groups increased their distance swum across 
the overnight interval, thus showing overnight forgetting of the platform location.   
Uterine weight, neurotrophins, and GAD protein levels were assessed via 
a priori planned comparisons using t-tests. Alpha was set at 0.05, two-tailed, for 
all analyses except for the Sham vs. Ovx working memory load effect, as we have 
previously established that Ovx decreases errors on this measure (Bimonte-
Nelson et al., 2003). 
Results 
Water Radial-Arm Maze 
 There were no Treatment main effects or interactions across the 12 testing 
days for WMC, WMI, or RM errors.  
Working memory load effects 
  On the final testing day with a 30s ITI (Day 12), for the omnibus 
ANOVA there was a Treatment x Trial interaction for WMC errors [F(8, 64) = 
2.078, p = .05]; both progesterone and high MPA impaired ability to handle 
numerous items of information as working memory load increased [Treatment x 
Trial interaction: Ovx vs. Ovx+Prog: F(2, 24) = 11.01; p < .0005; Ovx vs. 
Ovx+High MPA: F(2, 26) = 8.671; p < .005]. At the highest memory load on 
Trial 4 there was a Treatment main effect for the omnibus ANOVA [F(4, 32) = 
2.77; p < .05]. As we have shown previously in aged rats, Ovx improved 
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performance [Sham vs. Ovx: t(14) = 1.77; p < .05], and Ovx+Prog impaired 
performance [Ovx vs. Ovx+Prog: t(12) = 4.483; p < .001] (Figure 1a). High MPA 
impaired memory on the trial with the highest working memory load as well [Ovx 
vs. Ovx+High MPA: t(13) = 3.357; p < .01] (Figure 1a). There was not a 
significant difference between Ovx+Prog and OVX+High MPA treated animals. 
Also, there were no group differences for RM or WMI errors. 
Delayed memory retention on the WRAM 
On Day 13 a two hour delay was given between Trials 2 and 3. There was 
a Treatment x Trial interaction on Day 13 for WMC errors for the omnibus 
ANOVA with Trials 2-4 included [F(8, 64) = 2.540; p < .05].  High MPA 
impaired performance on Day 13, as compared to OVX [Treatment x Trial 
interaction including trials 2-4: F(2, 26) = 6.448; p < .01] (Figure 1b). Further, 
there was a Treatment x Trial interaction for WMC errors across Trials 3 and 4 
for Day 13 [F(4, 32) = 2.752; p < .05; Ovx vs. Ovx+High MPA F(1, 13) = 7.626; 
p < .05], where Ovx+High MPA animals showed an increase in WMC errors 
across these post-delay trials [t(9) = 3.109; p < .05], while errors committed by 
OVX animals remained stable across these post-delay trials (ns) (Figure 1b). 
There was no effect of low MPA, progesterone or Ovx on Day 13, nor were there 
treatment group differences for WMI or RM errors. 
It is important to note that Ovx+High MPA animals did not commit any 
more errors after the delay of two hours as they did on the previous baseline day 
(Day 12) with an ITI of 30 s. Indeed, scores on Day 12 did not differ from scores 
on Day 13 for Ovx+High MPA animals. Ovx+Prog animals improved 
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performance from baseline Day 12 to the delay Day 13 [t(6) = 3.158; p < .05], and 
were no longer different from Ovx animals (ns), showing no delay induced 
impairment but instead a continuation of their learning curve. There were also no 
longer differences between Sham and Ovx groups (ns), again showing no delay-
induced impairment.  
Morris Maze 
 There were no Treatment effects for MM performance as measured by 
Distance or Latency to reach the platform (data not shown). There was a Day 
main effect for each measure for the omnibus ANOVA [Distance: F(4, 24) = 
12.153; p < .0001 (Figure 2a); Latency: F(4, 24) = 10.526; p < .0001 (Figure 2b)], 
with Distance and Latency scores decreasing across days, and no Treatment x 
Day interaction for either variable. Ovx+High MPA animals showed overnight 
forgetting, while Ovx animals did not, as evidenced by a Treatment x Trial 
interaction for the Ovx vs. Ovx+High MPA comparison [F(1, 12) = 8.526; p < 
.05]. Distance scores remained stable after the overnight interval in the Ovx group 
[t(6) = .307; p = .77], and increased after the overnight interval in the Ovx+High 
MPA group [t(6) = 4.059; p < .01] (Figure 2c). There were no interactions 
between Ovx and Ovx+Prog [F(1, 10) = 3.166; p = .11], Ovx+Low MPA [F(1, 9) 
= 2.417; p = .15], or Sham [F(1, 11) = 1.01; p = .34] animals, nor was there a 
significant increase across the overnight interval for any of these groups [Sham: 
t(5) = .96; p = .38; Ovx+Prog: t(4) = 2.02; p = .11; Ovx+Low MPA: t(3) = 1.32; p 
= .28], indicating that only the Ovx+High MPA group showed an impaired ability 
to remember the location of the platform overnight. 
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          Traditional probe analyses comparing distance swum in the target quadrant 
(NE) to the opposite quadrant (SW) showed no overall Quadrant preference 
(Quadrant main effect, ns) indicating animals did not localize to the previously 
platformed spatial location. There was a null Treatment x Quadrant interaction 
suggesting groups did not differ in this pattern (Figure 2d). Because the probe trial 
indicated that animals did not localize to the target quadrant, we further assessed 
probe trial data by analyzing the annuli. Indeed, we and others have shown that 
animals can use a motoric pattern of circling the middle annulus to locate the 
platform (Bimonte-Nelson et al., 2006; Stavnezer et al., 2002). This was not the 
case in the current study, however. Analysis of the probe trial showed an Annulus 
main effect [F(2, 24) = 112.785; p < .0001], and no Treatment main effect nor 
Treatment x Annulus interaction (ns), suggesting that treatments did not differ in 
annuli preference. Animals showed a preference for the outer annulus when 
compared to both the inner [t(24) = 12.766; p < .0001] and middle [t(24) = 8.898; 
p < .0001] annuli (figure 2e). This was further confirmed by visual, qualitative 
inspection of the swim paths during regular testing (figure 2f) and the probe trial 
(figure 2g). It appeared that animals circled in the outer annulus until they made a 
direct trajectory to the platform.  
The decrease in Distance scores across days described above, suggests that 
animals swam a lesser distance within the allotted maximum search time, or until 
the platform was located. To confirm that animals were not floating or showing a 
decrease in movement within the maximum search time, and that this was not 
why distance scores decreased across days, we quantified the number of trials 
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within a day that each animal successfully found the platform (and thus escaped) 
within the 60s time limit. The number of trials escaped increased across days 
[Day main effect: F(4, 24) = 22.92; p < .0001] (Figure 2h inset), with a null 
Treatment x Day interaction. Every group showed an increase in the number of 
Escapes across days, suggesting learning by every group [Sham: F(4, 5) = 7.899; 
p < .0001; Ovx: F(4, 6) = 2.984; p < .05; Ovx+Prog: F(4, 4) = 3; p = .05; 
Ovx+Low MPA: F (4, 3) = 4.123; p < .05; Ovx+High MPA: F(4, 6) = 13.552; p < 
.0001] . There was no effect of Treatment on Escapes across all testing days, and 
no group significantly differed from any other group. Please see Figure 2H for 
Escapes. 
Visible Platform 
 There were no Treatment main effects or interactions. There was a Day x 
Trial interaction [F(7, 168) = 3.483; p < .0016] , with Time decreasing across all 
trials of testing (Figure 3). By the second day of testing, all subjects found the 
visible platform within 6 s. Together, these data confirm visual and motor 
competence to perform the maze tasks.  
GAD 65 & 67 
 Differences in GAD levels across groups were present in the hippocampus 
and entorhinal cortex. Because GAD protein levels did not differ between the 
Ovx+Low MPA and Ovx+High MPA groups, they were combined for statistical 
analyses. In the hippocampus, MPA treatment (doses combined) significantly 
[t(15) = 2.251; p < .05], and Prog treatment marginally [t(10) = 1.96; p < .10], 
decreased GAD levels as compared to Ovx (Figure 4a). However, in the 
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entorhinal cortex, both progesterone and MPA (doses combined) treatment 
increased GAD levels as compared to Ovx [Ovx vs. Ovx+MPA: t(15) = 2.542; p 
< .05; Ovx vs. Ovx + Prog: t(9) = 2.428; p < .05] (Figure 4b). There was no 
Treatment effect or any group differences for the loading control, beta Actin (ns).  
Neurotrophins 
 There were no group differences in BDNF or NGF levels in any brain 
region analyzed (Table 1).  
Blood Serum Levels of MPA 
 Low MPA (mean = 4.9 ng/mL) and High MPA (mean = 6.67 ng/mL) -
treated groups were the only groups to show MPA concentrations in serum, as 
expected, since this is not a naturally occurring hormone. Therefore, this confirms 
presence of the drug (Table 2).  
Uterine Weights 
Uteri of Sham animals weighed more than those of all other treatment 
groups [Sham vs. Ovx: t(11) = 9.239; p < .0001; Sham vs. Ovx+Prog: t(9) = 
6.057;  p < .0005; Sham vs. Ovx+Low MPA: t(8) = 5.028;  p < .001; Sham vs. 
Ovx+High MPA: t(11) = 7.208;  p < .0001]. MPA uterine weights were greater 
than those of Ovx [Ovx vs. Ovx+Low MPA: t(9) = 4.079; p < .005; Ovx vs. 
Ovx+High MPA: t(12) = 3.523;  p < .005] (Table 2). 
Discussion 
           The current study is the first to test the synthetic progestin MPA, the most 
commonly utilized progestin component of HT given to women in the United 
States (Hersh et al., 2004), for learning and memory in the female rodent. We 
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found that MPA impairs cognition and alters the GABAergic system in the aged 
surgically menopausal rat. Specifically, MPA impaired the ability to handle an 
increasing working memory load on the WRAM across 30 second and 2 hour 
delays, and exacerbated overnight forgetting on the MM spatial reference memory 
task. MPA effects were dose specific, with only the highest dose showing 
detrimental effects. Natural progesterone also impaired performance on the 
WRAM at the highest working memory load with a 30 second delay, which is in 
agreement with our prior findings of progesterone administration to aged Ovx rats 
(Bimonte-Nelson et al., 2004b). We also replicated our previous findings, the 
herein being our third report, that Ovx is beneficial in aged rats, by improving 
performance on the WRAM at the highest working memory load at the lattermost 
portion of testing (Bimonte-Nelson et al., 2003b; Bimonte-Nelson et al., 2004b), 
likely mediated in part by the removal of high endogenous progesterone levels 
(Bimonte-Nelson et al., 2004b). It is noteworthy that the current working memory 
load findings in aged female rats correspond with prior findings that decrements 
at the highest working memory load on the WRAM are exacerbated with aging 
(Bimonte, Nelson, & Granholm, 2003). Additionally, working memory deficits 
associated with an elevated demand on the system via increasing the number of 
items to be remembered (Bimonte & Denenberg, 1999) or extended temporal 
delays (Engler-Chiurazzi et al., 2009) can be attenuated by 17 β-estradiol or 
conjugated equine estrogen administration, further demonstrating that different 
types of working memory demand increases are sensitive to steroid hormones.  
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Our data also concur with findings that the progesterone metabolite, 
allopregnanolone, impairs reference memory in young male rats (Johansson et al., 
2002) and can impair reference memory and working memory in female rats 
(Frye & Sturgis, 1995). Progesterone’s detrimental effects on cognition have also 
been seen in women. Data suggest that in pregnant women the “maternal 
amnesia” phenomenon is due to high circulating progesterone levels (Brett & 
Baxendale, 2001; Freeman et al., 1992). Moreover, as demonstrated by the 
WHIMS collective findings, there is evidence that the combination of estrogen 
and MPA has a greater negative impact on cognition (Shumaker et al., 2003), than 
estrogen alone (Shumaker et al., 2004). 
The current findings demonstrate that both natural progesterone and the 
synthetic MPA either significantly or marginally alter GAD levels in the 
hippocampus and entorhinal cortex. GAD is the synthesizing enzyme and rate 
limiting step of GABA synthesis. There is a strong positive correlation between 
GAD mRNA levels and GABA neuronal activity (Erlander & Tobin, 1991), 
making GAD a good neuronal marker for GABAergic function (Bauer, Brozoski, 
Holder, & Caspary, 2000; Milbrandt, Holder, Wilson, Salvi, & Caspary, 2000; 
Raol, Zhang, Budreck, & Brooks-Kayal, 2005). Our findings that progesterone 
marginally, and MPA significantly, decreases GAD in the hippocampus are 
consistent with the literature for progesterone. Others have shown that 
progesterone decreased GAD activity in the dorsal hippocampus (Wallis & 
Luttge, 1980), and reversed 17 β-estradiol-induced increases in GAD mRNA in 
hippocampal CA1 and hilus (Weiland, 1992). This same decrease of GAD in the 
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hippocampus is observed after treatment with the GABAA agonist diazepam (Raol 
et al., 2005), suggesting that progesterone- and MPA-induced GAD decreases 
may result from increased GABAA receptor activation. Recent work testing both 
progesterone and MPA found that after 17 β-estradiol priming, progesterone but 
not MPA decreased mRNA expression of the α4 subunit of the GABAA receptor 
in the CA1 of young Ovx rats (Pazol et al., 2009). Our effects somewhat conflict 
with these findings in that both progesterone and MPA impacted the GABAergic 
system; however, our animals were not estradiol primed and were much older.  
To our knowledge, the current report is the first to measure the impact of 
progesterone or MPA on the GABAergic system in the entorhinal cortex. In 
contrast to the progesterone- and MPA- mediated decreases seen in the 
hippocampus, both progesterone and MPA treatment increased GAD levels in the 
entorhinal cortex. Although no study has measured progesterone or MPA-related 
changes in the GABAergic system in the entorhinal cortex, it has been shown that 
alteration of the GABAergic system in this region affects memory function.  Post-
training infusion of the GABAA agonist muscimol into the entorhinal cortex 
blocked memory formation (Ferreira, Da Silva, Medina, & Izquierdo, 1992), and 
lesions of the GABAergic system in entorhinal cortex layer III disrupted 
hippocampal CA1 place fields, causing impaired spatial representation (Brun et 
al., 2008). The entorhinal cortex and the hippocampus are intimately associated 
(Knowles, 1992), and both play crucial roles in memory processing, which 
increasing evidence suggests is facilitated in part through the GABAergic system 
(Izquierdo et al., 1993).  
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Given the strong links between progesterone and memory, and the 
GABAergic system and memory, it is tempting to speculate that the progesterone- 
and MPA-induced alterations of the GABAergic system begin to explain the 
cognitively-impairing effects of progestins. However, our data do not allow clear 
interpretations of these links. Indeed, in the current study there was a dissociation 
of progestin-induced memory changes and progestin-induced GAD changes. 
Specifically, while GAD levels were altered with the low-dose and high-dose 
MPA treatments, low-dose MPA had no impact on behavior, while high-dose 
MPA did. Thus, it is not clear whether the alterations in GAD levels underlie the 
observed differences in cognitive performance. Progesterone and MPA both bind 
to the progesterone receptor, and progesterone is known to interact with several 
other steroid receptors (Pluchino et al., 2006; Pridjian, Schmit, & Schreiber, 
1987), presumably all of which may lead to altered synaptic function through 
changes in gene transcription. Several of progesterone’s ring-A reduced 
metabolites are potent agonists of the GABAA receptor (Paul & Purdy, 1992). 
While MPA’s ring-A reduced metabolites do not seem to influence the GABAA 
receptor (McAuley et al., 1993), MPA has been shown to alter progesterone’s 
metabolic conversions (Penning et al., 1985), wherein these alterations might lead 
to enhanced synaptic and extrasynaptic GABAA receptor-mediated inhibition 
(Belelli & Herd, 2003). However, at supraphysiological levels, MPA moderately 
inhibits benzodiazepine binding at the GABAA receptor (McAuly et al., 1993). 
Additionally, MPA pretreatment exacerbates neuronal death induced by glutamate 
excitotoxicity in cultured hippocampal neurons (Nilsen et al., 2006). Therefore, 
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while the specific mechanism(s) by which progestins alter GAD levels in the 
hippocampus and entorhinal cortex is unknown, several neuronal actions of these 
compounds are documented which could independently or interactively contribute 
to altered GAD levels. Further studies manipulating the GABAergic system after 
progestin administration will be integral to this mechanistic understanding.  
Although previous literature shows that progesterone increases 
neurotrophins in cerebral cortex slice cultures (Kaur et al.,  2007) and counteracts 
estrogen-induced increases in neurotrophins in the entorhinal and frontal cortices 
(Bimonte-Nelson et al., 2004a) and hippocampal slice cultures (Aguirre & 
Baudry, 2009), we found no effects of progesterone or MPA treatment on 
neurotrophin levels in several cognitive brain regions. Perhaps in vivo, progestins 
do not have independent, but only regulatory actions, of estrogen’s effects on 
neurotrophins. More research is necessary to investigate this hypothesis. 
We were able to confirm presence of MPA in serum with mass 
spectrometry. Not only was this verification of hormone administration, but it also 
allowed us to compare resulting hormone levels in our animals to known serum 
concentrations of hormones in women taking HT that includes MPA. According 
to the prescribing information of Prempro (Prempro Prescribing Information, 
2009), women administered the most common dose of MPA given as HT (5mg), 
achieved peak plasma concentrations of 4.8 ng/mL. This corresponds almost 
exactly to our low-dose MPA serum blood levels (4.9 ng/ml) and is still strikingly 
similar to our high-dose MPA (6.67 ng/ml). These data confirm the clinical 
relevance of the MPA doses used in this study. 
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Several lines of evidence converge to suggest that progestins such as MPA 
have a negative consequence on neuronal health yielding detrimental effects on 
brain functions such as learning and memory. This is exemplified across multiple 
realms of the literature, from clinical to basic science.  Clinical evidence shows 
detrimental cognitive effects of combined HT (Shumaker et al., 2003). Basic 
science evidence shows that both MPA (current report) and progesterone 
(Bimonte-Nelson et al., 2004b) impair cognition, and that progesterone abolishes 
17 β-estradiol-induced memory enhancements (Bimonte-Nelson et al., 2006; 
Harburger et al., 2007; but see Gibbs, 2000) and attenuates 17 β-estradiol’s 
neurotrophic effects in vivo (Bimonte-Nelson et al., 2004a) and in cell culture 
(Aguirre & Baudry, 2009). Moreover, when comparing MPA and progesterone, it 
is noteworthy that MPA does not demonstrate neuroprotective properties, while 
progesterone does (Nilsen & Brinton, 2002b), and that MPA causes a greater 
attenuation of 17 β-estradiol’s neurotrophic actions (Nilsen & Brinton, 2002a). 
This in vitro work is in accordance with our current findings that MPA has 
broader detrimental effects for learning and memory, as compared to 
progesterone. In fact, progesterone’s detrimental effect on learning of the WRAM 
seemed to be more of a transient nature, as effects were only seen on the last 
testing day with a 30 second ITI, and not after a two-hour delay to challenge 
extended memory retention. Furthermore, while no study has directly evaluated 
the impact of MPA on cognitive health in younger women using this 
pharmaceutical as a contraceptive, it should be noted that these effects could 
translate to cognitive impairments in these younger women as well, and account 
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for some of the negative effects reported with use of this drug. Indeed, a 
documented case study reports amnesic effects corresponding with use of Depo 
Provera, a contraceptive wherein MPA is the sole hormone component (Gabriel & 
Fahim, 2005).  
In conclusion, the current study is the first to show that not only natural 
progesterone, but also the synthetic progestin MPA, the most common progestin 
included in HT, impairs memory and alters the GABAergic system in cognitive 
brain regions in the aged surgically menopausal rat. To our knowledge, there has 
been no study directly evaluating MPA-mediated cognitive effects in younger, or 
older, women. Increasing evidence suggests that this is clearly warranted. The 
current study has significant implications for the components of HT that might 
impact cognitive functioning, and suggest that MPA is detrimental within this 
domain. 
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CHAPTER 3 
COGNITIVE-IMPAIRING EFFECTS OF MEDROXYPROGESTERONE 
ACETATE IN THE RAT: INDEPENDENT AND INTERACTIVE EFFECTS 
ACROSS TIME  
Nearly every woman will face the decision of whether to take exogenous 
hormones, either for contraception or for HT. MPA, a synthetic progestin, is the 
sole hormone component of the contraceptive Depo Provera, and the most 
commonly prescribed progestin component of HT (Prempro and Premphase: 
MPA + conjugated equine estrogen). Depo Provera was approved by the Food 
and Drug Administration in 1992 (Bakry et al.,2008), and has been prescribed to 
over 10 million women in the United States since this time (Mosher et al., 2004). 
This widely prescribed contraceptive is often the choice for women who cannot 
take estrogen-containing contraceptives because of medical conditions (Spencer et 
al., 2009), for nursing mothers (Rodriguez & Kaunitz, 2009), and for those who 
prefer the convenience of an intermittent injection once every three months over 
the daily pill. Prempro has been prescribed since 1995 (Stefanick, 2005) with as 
many as 19.7 million prescriptions written per year (Hersh et al., 2004). At 
menopause, many women choose to take HT to attenuate menopause-induced 
symptoms, including memory decline (Freedman, 2002). Women with a uterus 
must include a progestin in their HT regimen to offset the increased risk of 
endometrial hyperplasia related to unopposed estrogen treatment (Smith et al. 
1975; Ziel & Finkle 1975). While there have been no methodical clinical 
evaluations of the cognitive effects of MPA alone in any population of women, 
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there is evidence implicating that MPA is detrimental to cognition. For Depo 
Provera, there is a documented case study of amnestic effects corresponding with 
its use (Gabriel & Fahim, 2005). Moreover, the large, placebo-controlled, 
randomized WHIMS reported that twice as many women receiving Prempro were 
diagnosed with dementia as compared to the placebo group, a significant finding 
(Shumaker et al., 2003). Those women taking Premarin (conjugated equine 
estrogen only) showed a nonsignificant increase in risk of dementia compared to 
those taking placebo (p = .18) (Shumaker et al., 2004).  
Recently, we showed that MPA impaired learning and memory in aged 
ovariectomized (Ovx) rodents (Braden et al., 2010; Chapter 2). In that study we 
also replicated previous findings (Bimonte-Nelson et al., 2004b) that natural 
progesterone impairs cognition in aged Ovx rodents. Others have shown that 
infusions of the progesterone metabolite, allopregnanolone, into the lateral 
ventricles of young Ovx rats can lead to impaired spatial reference and working 
memory performance (Frye & Sturgis, 1995). Progesterone and allopregnanolone 
have also been shown to impair working and reference memory, respectively, in 
young intact male and female rats (Johansson et al., 2002; Sun et al., 2010). 
However, the literature on progesterone and allopregnanolone cognitive effects in 
young rodents reports mixed results, with task-specific benefits noted sometimes, 
but not always (Frye et al., 2007; Frye et al., 2010; Frye & Walf, 2008; Harburger 
et al., 2008; Lewis et al., 2008; Orr et al., 2009). The animal study findings of 
progestin-induced cognitive impairments are corroborated by clinical reports of 
the detrimental effects of progesterone and allopregnanolone on memory in 
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women (Freeman et al., 1992; Kask et al., 2008). Yet, progesterone can enhance 
other cognitive processes such as attention, response/processing speed, cognitive 
flexibility and visuomotor coordination (Sofuoglu, Mouratidis, & Mooney, 2011). 
These clinical findings highlight the need for more scientific investigations, both 
clinical and preclinical, of the negative impact progestins could have on 
cognition. A progestin is included in every contraceptive, and in HT when given 
to women with a uterus; thus, safe progestin use is a critical medical issue 
affecting every woman who chooses to take exogenous hormones.   
MPA’s cognitive-impairing effects may be mediated via the GABAergic 
system. Indeed, we have shown that both progesterone and MPA alter the 
GABAergic system in cognitive brain regions of behaviorally tested aged Ovx 
animals; in this study MPA decreased GAD, the synthesizing enzyme for GABA, 
in the dorsal hippocampus and increased GAD in the entorhinal cortex (Braden et 
al. 2010). MPA has also been shown to enhance synaptic and extrasynaptic 
GABAA receptor-mediated inhibition (Belelli & Herd, 2003). Further, in vitro 
evidence implicates that MPA has a negative effect on neuronal function by 
exacerbating glutamate-induced excitotoxicity (Nilsen et al., 2006). Taken 
together, in vitro, preclinical, and clinical evidence of MPA’s negative effects on 
the brain and its function are particularly salient. Moreover, there have been no 
evaluations of the possible long-term effects of MPA administration on cognition 
or interactions with subsequent MPA use as HT, nor whether there is a long-term 
impact on the GABAergic system in vivo. These issues are especially relevant as 
we embark on a new generation of menopausal women who were much more 
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likely to have been prescribed contraceptives, as compared to generations before 
(Diczfalusy, 1991). We hypothesize that MPA treatment during young adulthood 
and middle-age impairs cognition in the rat model, by enhancing GABAA 
receptor-mediated inhibition in the hippocampus, as evident by a compensatory 
decrease in GAD. Thus, the current study investigated the long-lasting effects of 
MPA given in young adulthood (to model contraception) on cognition and the 
GABAergic system in middle-age, and how such early treatment interacts with 
later MPA use as HT, in the rat model.  
Methods 
Subjects  
Subjects were 44 Fischer-344 female rats born and reared at the aging 
colony of the National Institute on Aging at Harlan Laboratories (Indianapolis, 
IN). Rats were four months old at the beginning of the study, had unrestricted 
access to food and water, and were maintained on a 12-hour light/dark cycle at the 
Arizona State University animal facility. All procedures were in accordance with 
the local IACUC committee and follow NIH standards.  
Hormone Treatment and Ovariectomy 
Rats were randomly assigned to one of four treatment groups: Control, 
Early-MPA, Late-MPA, and Early+Late-MPA. The study was divided into two 
phases of injections (Figure 5). Phase 1 of weekly injections of either vehicle 
(0.4ml sesame oil + 0.02ml dimethyl sulfoxide [DMSO], both from Sigma-
Aldrich, St. Louis, MO, USA) or MPA (3.5mg, Sigma-Aldrich, St. Louis, MO, 
USA) dissolved in 0.4ml sesame oil + 0.02ml DMSO, began at 4 months of age 
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and continued until 8 months of age. This regimen of MPA treatment was selected 
based on previously established anti-ovulatory effects (Bhowmik & Mukherjea, 
1988), in order to mimic the biological action of Depo Provera taken by women 
(Depo Provera Prescribing Information, 2006). We chose to keep animals ovary-
intact to most closely model the hormone milieu of fertile women prescribed 
Depo Provera.  
At 10 months of age, all rats received Ovx surgery. Rats were anesthetized 
via isofluorane inhalation, bilateral dorsolateral incisions were made in the skin 
and peritoneum, and the ovaries and tips of uterine horns were ligatured and 
removed. Finally, muscle and skin were sutured. At time of surgery, rats received 
a single injection of Rimadyl (carprofen; 5mg/ml/kg) for pain and saline (2ml) to 
prevent dehydration. Phase 2 of weekly injections (either vehicle or MPA) began 
2-3 days after Ovx surgery and continued throughout behavior testing until 
sacrifice. Testing began at 12 months of age, approximately 2 months after the 
beginning of phase 2 injections.  
Animals in the Control group received vehicle injections during both 
injection phases. Early-MPA animals received MPA injections during phase 1 and 
vehicle injections during phase 2, Late-MPA animals received vehicle injections 
during phase 1 and MPA injections during phase 2, and Early+Late-MPA animals 
received MPA injections during both phases (Figure 1). During both injection 
phases, body weights were recorded weekly.  
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Vaginal Smears and Uterine Weights 
 To assess the long-term effects of 4 months of MPA injections on 
ovulation, vaginal smears were taken at 8 months of age for three days in the 
behaviorally tested animals, starting 9 days after the last injection (Figure 1). 
Smears were classified as proestrus, estrous, metestrus or diestrous per prior 
protocol (Acosta et al., 2009; Goldman et al., 2007). At sacrifice, the uteri of all 
subjects were removed, trimmed of visible fat, and immediately weighed (wet 
weight), in order to examine drug effects on uterine tissues (Braden et al. 2010, 
Chapter 2), 
Water Radial-Arm Maze  
Two months after initiation of phase 2 of injections, subjects were tested 
for 11 days on the 8-arm win-shift water radial-arm maze (WRAM) to evaluate 
spatial working and reference memory, including performance as working 
memory load increased, as described previously (e.g., Bimonte & Denenberg, 
1999). There were escape platforms hidden under the water surface in the ends of 
4 of the 8 arms. The temperature of the water was 18° Celsius (C). Platform 
locations varied across subjects, but remained fixed for each individual subject, 
throughout the experiment. Once released from the start arm, a subject had 3 
minutes (m) to locate a platform. After a platform was found, the animal remained 
on it for 15 seconds (s), and was then placed in its heated cage for a 30s inter-
trial-interval (ITI) until its next trial. During the interval, the just-chosen platform 
was removed from the maze. This process was repeated until each platform was 
found. This totaled to four trials in each animal’s daily session, with the number 
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of platformed arms reduced by one on each subsequent trial. The working 
memory system was increasingly challenged as trials progressed, allowing us to 
access working memory load. Each subject was given one session a day for 11 
consecutive days.  
Quantification and blocking into acquisition and asymptotic phases were 
based on prior studies (e.g., Bimonte & Denenberg, 200). An arm entry was 
counted when the tip of a rat’s snout reached a mark 11cm into the arm. 
Orthogonal measures of working and reference memory errors were quantified as 
done previously in WRAM studies (Bimonte et al., 2000; Braden et al., 2010, 
Chapter 2). Working Memory Correct (WMC) errors were the number of first and 
repeat entries into an arm that previously contained a platform during that session. 
Reference memory (RM) errors were the number of first entries into an arm that 
never contained a platform. Working Memory Incorrect (WMI) errors were repeat 
entries into a reference memory arm. Errors were analyzed across all Days (1-11) 
of testing and on the latter portion of regular testing at the highest working 
memory load, as this has revealed progesterone- and MPA- induced impairments 
(Bimonte-Nelson et al., 2003b; Bimonte-Nelson et al., 2004b; Braden et al., 2010, 
Chapter 2). 
Morris Maze  
Two days after WRAM completion, subjects were tested on the Morris 
maze (MM) for 4 trials/day for 4 days. To test spatial reference memory 
(Bimonte-Nelson et al., 2006; Morris et al., 1982), a tub (188cm diameter) filled 
with black water made opaque using non-toxic paint was used, with a hidden 
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platform (10cm wide) remaining in a fixed location. The temperature of the water 
was 18° C. During initial testing (Days 1-4) the rat was started at the North, 
South, East, or West location in the maze, and had 60s to locate the hidden 
platform in the Northeast (NE) quadrant. The trial was terminated once the rat 
found the platform. After 15s on the platform, the rat was placed into its heated 
cage until its next trial. The ITI was approximately 10m. Swim path distance (cm) 
and latency (s) to the platform across all days of initial testing (Days 1-4) were 
used to asses MM performance. Distance scores from the last trial of each day 
(Trial 6) were compared to the first trial on the following day (Trial 1) in order to 
test overnight forgetting of the platform location (Bimonte-Nelson et al., 2006; 
Markham et al., 2002), as this measure has revealed MPA-induced impairments 
(Braden et al., 2010, Chapter 2). The first overnight interval was omitted from this 
analysis, as we noted that all animals were extending their learning curve without 
forgetting during this time interval (Figure 7a). In order to determine which 
treatment groups increased their swim distance across the overnight interval, thus 
showing overnight forgetting of the platform location we examined within-group 
trial comparisons of the overnight interval (Trial 6 to Trial 1). 
After all test trials on day 4, a 60s probe trial was initiated whereby the 
platform was removed. This was used to evaluate whether rats localized the 
platform to the spatial location. Percent of total distance in the previously 
platformed (target) quadrant was compared to the quadrant diagonally opposite 
the platform. Rats that spent the greatest percent distance in the target quadrant 
were interpreted as localizing the platform to the spatial location. To attenuate the 
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possibility of extinction due to the probe trial, rats were placed back into the maze 
immediately following the probe trial with the platform replaced in the NE 
quadrant. Next, to test relearning of a novel platform location, on Day 5 the 
platform was switched from the NE quadrant to the Southwest (SW) quadrant, 
and rats were given 8 trials with the new platform location. Distance and latency 
were analyzed across all trials for the platform switch (Day 5).To evaluate 
whether rats localized the new platform to the spatial location, after the eighth 
trial, a 60s probe trial was given whereby the platform was again removed. For 
each trial, a rat’s path was recorded from a camera suspended above the maze, 
and a tracking system (Ethovision 3.1, Noldus Instruments) analyzed each rat’s 
tracing.  
Visible Platform Maze 
 To confirm that all subjects had intact vision and could perform the 
procedural task components of MM and WRAM spatial navigation without 
difficulty, subjects were tested on a visible platform water-escape task, as 
previously described (Braden et al., 2010, Chapter 2). Briefly, animals were 
placed into a rectangular tub (39 x 23in) where they had to locate a flagged 
platform protruding from the water. The temperature of the water was 18° C. 
Extramaze cues were covered by opaque curtains. Animals were given 6 trials, 
with the drop off location the same across trials, and the platform location for 
each trial varied in space semi-randomly. Performance was assessed by latency (s) 
to the platform across all trials.  
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Brain Dissections  
One day after the conclusion of behavior testing, animals were 
anesthetized with isofluorane and brains were rapidly dissected and frozen. 
Dissected tissues were stored at -70°C in preweighed microcentrifuge tubes until 
analysis. Plate designations (Paxinos & Watson, 1998) for dissections were as 
follows: frontal cortex (plates 5-14), anterior cingulate cortex (plates 5-14), 
posterior cingulate cortex (plates 15-35), entorhinal cortex (plates 39-42), and the 
CA1/CA2 region of the dorsal (plates 33-35) and ventral (plates 39-42) 
hippocampus. For each brain the frontal cortex was taken first from the dorsal 
aspect of the intact brain. The medial border of the frontal cortex cut served as the 
lateral border for the cingulate cortex dissection, with the longitudinal fissure as 
the medial border. Designation between anterior and posterior cingulate cortex 
was made according to Paxinos & Watson (1998) plate 14. Next, the brain was 
cut in the coronal plane at plate 33 to obtain access to the dorsal CA1/CA2 region 
of the hippocampus. Finally, the brain was cut again in the coronal plane at plate 
39 to obtain access to the last two brain regions (the hippocampus and entorhinal 
cortex). It was here that the ventral CA1/CA2 region of the hippocampus was 
taken. For the hippocampus, the dentate gyrus and the alveus were excluded. For 
the entorhinal cortex, the tissue was dissected from the same slice as the ventral 
hippocampus sample, taking a 2- to 3- mm sample ventral to the hippocampus. 
Western Blot Analyses of GAD 65+67 
GAD 65+67 protein expression levels were analyzed in frontal, anterior 
cingulate, posterior cingulate and entorhinal cortices, and the dorsal and ventral 
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hippocampus, from the right hemisphere. Each sample was sonicated in RIPA 
buffer (150mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% Na Deoxycholate, 
50mM Tris) equivalent to 10 times its weight and centrifuged at 10,000 rpm for 
10m at 4°C.  BCA protein assays determined protein concentration 
(ThermoFisher Scientific, Pittsburgh, PA, USA) and 10µg of protein from each 
sample were run on a NuPAGE Bis-Tris gel, using the SureLock mini-cell 
(Invitrogen, Carlsbad, CA, USA). PVDF membranes were used for transfer 
(Millipore, Bedford, MA, USA) and immunoblotting was performed with 
working dilutions of a rabbit anti-GAD 65+67 (ab11070) and rabbit anti-beta 
Actin (ab25894 or ab8227) primary antibodies (Abcam Inc., Cambridge, MA, 
USA). Antibody dilutions were 1:10,000 for GAD 65+67 and a range of 1:400 - 
1:20,000 for beta Actin primary antibodies. Membranes were then incubated with 
a peroxidase-conjugated goat anti-rabbit secondary antibody, 1:10,000 dilution 
(111-035-003; Jackson Immuno Research, West Grove, PA, USA) and visualized 
using Pierce ECL Western Blotting Substrate (ThermoScientific, Rockford, IL, 
USA) in a film developer. Precision Plus Protein WesternC Standards (Bio Rad, 
Hercules, CA, USA) were used to identify bands as the protein of interest, based 
on molecular weight. ImageJ software (Rasband, 1997-2004) was used to quantify 
the density of GAD 65+67 and beta Actin (loading control protein). The 
dependent measure was a ratio of each subject’s GAD 65+67 density to their beta 
Actin density, brought to percent control of Control subjects run on the same gel, 
per prior protocol (Braden et al., 2010, Chapter 2; Pandey et al., 1999).  
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Blood Serum Analyses for MPA, Progesterone, and Allopregnanolone 
Serum MPA determinations were performed according to the method 
reported earlier (Braden et al., 2010, Chapter 2). In addition, the assay was 
extended to measure progesterone and allopregnanolone, similar to an earlier 
procedure (Prokai, Frycak, Stevens, & Nguyen, 2008). Briefly, levels were 
measured by the isotope dilution method through the addition of deuterium-
labeled internal standards d9-progesterone and d4-allopregnanolone (C/D/N 
Isotopes, Pointe-Claire, Quebec, Canada); 10µL each from an 1µg/mL solution in 
ethanol to 1ml of serum. Progesterone, d9-progesterone, allopregnanolone and d4-
allopregnanolone were measured through selected-reaction monitoring (SRM) 
signals of m/z 315 → 297, 324 → 306, 301 → 287 and 305 → 287, respectively, 
obtained by liquid chromatography–atmospheric-pressure chemical ionization 
tandem mass spectrometry (LC–APCI-MS/MS). Progesterone and 
allopregnanolone concentrations were calculated by dividing the areas under their 
corresponding SRM peaks in the LC–APCI-MS/MS chromatograms with those of 
d9-progesterone and d4-allopregnanolone, respectively, multiplied with the known 
concentrations (10ng/mL each) of these added internal standards. Calibrations 
from the analysis of serum samples spiked with 1, 2, 5 and 10ng/mL of analyte, 
respectively, were used to determine MPA concentrations. Additionally, d9-
progesterone was used as an internal reference to compensate for slight changes in 
extraction efficiency and LC–APCI-MS/MS conditions among samples. The 
dependent measures of the assay were ng/mL of MPA, progesterone, and 
allopregnanolone in serum, respectively. 
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Statistical Analyses  
For behavior assessments, data were analyzed separately for each maze. 
Since our interest was to evaluate Treatment effects regarding timing of MPA 
administration, two-group planned comparisons were run on specific measures. 
To evaluate potentially complex higher order Treatment interactions with Days or 
Trials, we utilized an omnibus repeated measures ANOVA including all groups, 
with Treatment as the between variable and Days and/or Trials as the within 
variable/s. For GAD protein levels, serum levels of MPA, progesterone, and 
allopregnanolone, uterine weights, and body weights, data were assessed via a 
priori planned comparisons using t-tests. For all of these analyses, alpha was two-
tailed and set at 0.05, with two exceptions where analyses were one-tailed: for the 
Trial 4 WMC effects for the latter portion of testing, as we have previously 
established that MPA impairs performance on this measure (Braden et al., 2010, 
Chapter 2), and uterine weights comparisons (Control vs. Late-MPA and Control 
vs. Early+Late-MPA), as we have previously shown that MPA administration 
after Ovx increases uterine weight (Braden et al., 2010, Chapter 2). For all 
planned comparisons, it was noted that Type I error correction is not necessary 
(Keppel & Wickens, 2004). 
Correlations  
Pearson r correlations were run between GAD levels in each brain region 
and 1) serum MPA levels, 2) serum progesterone levels, 3) serum 
allopregnanolone levels, and, 4) memory scores from each of the mazes tested. 
Additionally, correlations were run between each serum hormone and memory 
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scores. The memory scores used for correlations were, for WRAM: WMC, WMI, 
and RM errors across all days of regular testing; for MM: distance across all days 
of testing, and overnight forgetting on the last two overnight intervals. Alpha was 
adjusted to 0.01 to account for multiple correlations. 
Results 
Table 3 summarizes the significant behavior effects. 
Water Radial-Arm Maze 
Two group planned comparisons revealed that animals treated with MPA 
at any time point made more WMC errors than Control animals, across all days of 
testing [Control vs. Early-MPA: t(20) = 2.17; p < .05 ; Control vs. Late-MPA: 
t(18) = 2.817; p < .05 ; Control vs. Early+Late-MPA: t(21) = 2.285; p < .05] 
(Figure 6a). For WMI errors, only animals that received MPA at both time points 
(Early+Late-MPA) made more errors than Control animals [t(21) = 2.431; p < 
.05] (Figure 6b). There were no differences between Control and Early-MPA, or 
Control and Late-MPA, groups for WMI errors, and no Treatment group 
differences for RM. Across all testing days (Days 1-11), there was a Day main 
effect for each error type for the omnibus ANOVA [WMC: F(10, 39) = 5.627; p < 
.0001 ; WMI: F(10, 39) = 13.009; p < .0001 ; RM: F(10, 39) = 10.288; p < .0001], 
with errors decreasing across days demonstrating learning. There was no Day x 
Treatment interaction. 
During the asymptotic phase of testing (Days 5-11), we investigated group 
differences at the highest working memory load, Trial 4, as we have previously 
shown memory load impairments at the end of testing after progesterone 
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treatment (Bimonte-Nelson et al., 2004b; Braden et al., 2010, Chapter 2), and 
MPA treatment given to Ovx animals in old age (Braden et al., 2010, Chapter 2). 
For WMC errors on Trial 4, animals treated with MPA at any time point made 
more errors than Control animals [Control vs. Early-MPA: t(20) = 1.973; p < .05 ; 
Control vs. Late-MPA t(18) = 2.681; p < .05 ; Control vs. Early+Late-MPA: t(21) 
= 1.990; p < .05] (Figure 6c). For WMI errors, only animals that received MPA at 
both time points (Early+Late-MPA) made more errors on Trial 4 than Control 
animals [t(21) = 2.270; p < .05] (Figure 6d). There were no differences between 
Control and Early-MPA, or Control and Late-MPA for Trial 4 WMI errors, and 
no Treatment group differences for Trial 4 RM errors. 
Morris Maze 
Initial Testing (Days 1-4, platform in the NE quadrant) 
 Planned comparisons revealed no effect of MPA treatment on initial MM 
performance, as measured by distance and latency. There was a Day main effect 
for Distance and Latency for the omnibus ANOVA [Distance: F(3, 40) = 114.966; 
p < .0001 (Figure 7a) ; Latency: F(3, 40) = 107.947; p < .0001 (data not shown)], 
with scores decreasing across days, demonstrating learning of the task. There was 
no Day x Treatment interaction for initial MM testing (NE platform location) 
performance as measured by Distance or Latency. 
As we have shown previously (Braden et al., 2010, Chapter 2), animals 
who received MPA after Ovx only (Late-MPA) showed overnight forgetting. 
Distance scores increased across the overnight interval in the Late-MPA group 
[t(8) = 2.538; p < .05], while they remained stable across the overnight interval in 
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the Control group [t(10) = 1.717; p = .12] (Figure 7b). There were no significant 
increases across the overnight interval for Early-MPA or Early+Late-MPA 
animals.  
The first probe trial, assessing learning of the initial platform location (NE 
quadrant), revealed a main effect of Quadrant [F(1, 40) = 221.798; p < .0001]. We 
confirmed that each group spent more percent Distance in the target NE quadrant 
as compared to the opposite SW quadrant, showing localization of the platform 
location [Control: t(10) = 9.931; p < .0001; Early-MPA: t(11) = 6.134; p < .0001 ; 
Late-MPA: t(8) = 6.202; p < .0005; Early+Late-MPA: t(11) = 9.628; p < .0001 
(Figure 7c)]. 
Platform Switch (Day 5, platform in the SW quadrant) 
 For the MM testing where the platform was moved from the NE to the SW 
quadrant (platform switch), planned comparisons revealed no effect of MPA 
treatment on distance or latency.  There was a Trial main effect for both Distance 
and Latency for the omnibus ANOVA [Distance: F(7, 40) = 20.789; p < .0001 
(Figure 8a) ; Latency: F(7, 40) = 30.257; p < .0001 (data not shown)], with both 
decreasing across Trials. It is noteworthy that, when comparing distance for the 
first eight trials of the original location to the distance for the eight trials of the 
platform switch, there was an Original vs. Platform Switch main effect [F(1, 40) = 
44.171; p < .0001], and an Original vs. Platform Switch x Trial interaction [F(7, 
280) = 4.325; p < .0001], for the omnibus ANOVA. Collapsed across all groups, 
animals learned the platform switch location at a much faster rate than the original 
platform location [Trial 2: F(1, 40) = 55.572; p < .0001; Trial 3: F(1, 40) = 
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11.133; p < .005; Trial 4: F(1, 40) = 28.501; p < .0001; Trial 5: F(1, 40) = 6.783; 
p < .05; Trial 6: F(1, 40) = 6.857; p < .05; Trial 7: F(1, 40) = 4.607; p < .05 
(Figure 8a)], demonstrating understanding of the rules of the task. There were no 
interactions with Treatment.  
The second probe trial, assessing learning of the new platform location 
(SW quadrant), revealed a main effect of Quadrant [F(1, 40) = 33.950; p < .0001 
(Figure 8b)] with a preference for the SW quadrant, and no interactions with 
Treatment or Treatment main effect.  
Visible Platform 
Planned comparisons revealed no Treatment effects for latency to the 
visible platform. There was a Trial main effect [F(5, 40) = 13.259; p < 
.0001(Figure 9)], with Latency decreasing across all trials, demonstrating learning 
of the task. By the fourth trial, all subjects found the visible platform within 6s, 
confirming visual and motor competence to perform swim maze tasks for all 
groups.  
Blood Serum Levels of MPA, Progesterone, and Allopregnanolone, Vaginal 
Smears, Uterine Weights and Body Weights 
Groups with MPA administered in middle-age were the only groups to 
show MPA concentrations in serum at sacrifice. Indeed, Late-MPA (mean = 9.538 
ng/mL) and Early+Late-MPA (mean = 11.126 ng/mL) -treated groups 
demonstrated detectable MPA concentrations, and these groups did not 
significantly differ from each other. Control and Early-MPA animals had no 
detectable levels of MPA. This confirms presence of MPA in animals receiving 
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the drug at sacrifice, and successful clearing of the drug in animals that were not 
receiving MPA at time of sacrifice but had received it as earlier treatment (Figure 
10a). For progesterone, Control animals had higher levels than all MPA-treated 
groups [Control vs. Early-MPA: t(21) = 2.553; p < .05 ; Control vs. Late-MPA: 
t(18) = 3.734; p < .005 ; Control vs. Early+Late-MPA: t(21) = 3.92; p < .001] and 
animals that received MPA only during young adulthood (Early-MPA) had 
greater progesterone levels than animals treated with MPA during middle-age 
[Early-MPA vs. Late-MPA: t(19) = 3.288; p < .005 ; Early-MPA vs. Early+Late-
MPA: t(22) = 2.642; p < .05] (Figure 10b). Only Control animals had detectable 
allopregnanolone levels (Figure 10c). There were no significant correlations 
between serum hormone concentrations and memory scores. 
Although it has previously been shown by Bhowmik & Mukherjea (1988) 
that weekly injections of 3.5mg of MPA are sufficient to halt ovulation for at least 
7 days, we confirmed this in a pilot study with animals, not included in behavioral 
testing, at 3 months of age and of the same strain as the behaviorally tested 
animals. Animals were given one injection of 3.5mg MPA, and smears were then 
performed, classified as proestrus, estrous, metestrus or diestrous per prior 
protocol (Acosta et al., 2009; Goldman et al., 2007). This one injection proved to 
be the minimum dose sufficient to inhibited ovulation for 9±2 days in these 
animals, as evidenced by continually diestrous smears, and no cornified estrous 
smears, which would indicate ovulation (Goldman et al., 2007). Smears were 
taken at 8 months of age for three days in the behaviorally tested animals, starting 
9 days after the last injection (Figure 5). Eighty-eight % of the MPA-treated 
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animals (Early-MPA and Early+Late-MPA groups) showed the diestrous phase 
while 12% had begun cycling again; all animals given vehicle injections showed 
indication of cycling as evident by at least one day of cornified estrous smears. 
Similar to our prior findings (Braden et al., 2010, Chapter 2), animals 
treated with MPA during middle age had heavier uteri than Control animals 
[Control vs. Late-MPA: t(18) = 1.914; p < .05 ; Control vs. Early+Late-MPA: 
t(21) = 1.787; p < .05]. Control and Early-MPA uteri weights did not differ (Table 
4). 
 During phase 1 of injections, both groups receiving MPA had greater body 
weights than the Control group [Control vs. Early-MPA: t(21) = 7.724; p < .0001; 
Control vs. Early+Late-MPA: t(21) = 4.147; p < .001] (Table 4), and the group 
not receiving MPA (Late-MPA) did not differ from the Control group. During 
phase 2, animals that had received MPA during phase 1 (Early-MPA and 
Early+Late-MPA) still had greater body weights than the Control group [Control 
vs. Early-MPA: t(21) = 5.227 ; p < .0001; Control vs. Early+Late-MPA: t(21) = 
2.353; p < .05] (Table 4), but the Late-MPA animals did not weigh more than the 
Control group, even though they were receiving MPA at the time [Control vs. 
Late-MPA: t(18) = .217; p  .83], which is in accordance with other reports of 
MPA treatment to middle-aged rodents (Isserow et al., 1995). 
GAD 65 & 67 
 There were no Treatment effects for any brain region analyzed (Table 5). 
Pearson r correlations revealed that in animals that had detectable levels of serum 
MPA (Late-MPA and Early+Late-MPA), there was a negative correlation 
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between MPA levels and GAD protein in the dorsal hippocampus [r (19) = -.571, 
p = .0059] (Figure 11) indicating that higher MPA serum levels were associated 
with decreased GAD protein levels in the dorsal hippocampus. There were no 
correlations between GAD protein and the memory scores evaluated. 
Discussion 
The synthetic progestin MPA is widely prescribed as the contraceptive 
Depo Provera, and is in the HTs Prempro and Premphase. The current study 
supports the hypothesis that MPA has detrimental effects on cognition in the 
female rodent. We previously found that MPA impaired learning and memory in 
aged Ovx rats, when given in old age (Braden et al., 2010, Chapter 2). Here, we 
show that MPA administered during young adulthood, middle-age, or both, 
impaired working memory in middle-aged Ovx rats. Specifically, MPA given at 
any time point tested herein increased WMC errors on the WRAM across all days 
of testing and at the highest working memory load on the latter portion of testing, 
relative to vehicle treatment. MPA given at both time points was particularly 
detrimental to WRAM performance, as evidenced by a concomitant increase in 
errors on two orthogonal working memory measures. Notably, the detrimental 
effects of MPA were especially prominent when the task was most taxing and the 
load on working memory was highest. Compared to working memory, MPA 
seems to have less of an impact on reference memory. In fact, the only finding on 
a reference memory measure tested here was the replication of our prior work 
showing that MPA induced overnight forgetting, as shown when administered 
after Ovx only (Braden et al., 2010, Chapter 2). Indeed, the current results show 
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that the Late-MPA group, who only received MPA post-Ovx, had poorer retention 
of the platform location overnight. Table 3 summarizes the significant behavior 
effects. 
The current findings are in agreement with clinical evidence implicating 
MPA as detrimental to cognition in young women when given as a contraceptive, 
as reported in one case study (Gabriel & Fahim, 2005), and may be related to the 
increased risk of dementia seen in the WHIMS MPA + conjugated equine 
estrogen trial (Shumaker et al., 2003). Further, administration of progesterone or 
its metabolite, allopregnanolone, is detrimental to memory in healthy pre-
menopausal women (Freeman et al., 1992; Kask et al., 2008). In rodents, we and 
others have shown progesterone-related decrements in working memory 
(Bimonte-Nelson et al., 2004b; Braden et al., 2010, Chapter 2; Frye & Sturgis, 
1995; Sun et al., 2010) and reference memory (Bimonte-Nelson et al., 2004b; 
Braden et al., 2010, Chapter 2; Johansson et al., 2002). However, the literature on 
progesterone and allopregnanolone’s effects on cognition in young rodents is 
mixed, with some studies showing benefits and others not showing benefits (Frye 
& Walf, 2008; Frye et al., 2007; Frye et al., 2010; Harburger et al., 2008; Orr et 
al., 2009). Likewise, in ovary-intact middle-aged rodents, for some memory tasks 
higher levels of progesterone or allopregnanolone in cognitive brain regions were 
associated with better performance, while for others, lower levels were associated 
with better performance (Paris, Walf, & Frye, 2010). In similar age populations, 
post-training injections of progesterone had no effect on MM performance in 
middle-age rodents, but attenuated overnight forgetting in aged Ovx rodents, as 
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well as differentially facilitated object recognition across different age groups 
(Lewis, Orr, & Frick, 2008). 
It must be considered that the water maze tasks used in the present study 
could involve a stress response, exacerbated by colder water temperatures which 
can facilitate memory formation (Sandi, Loscertales, & Guaza, 1997)(Sandi et al. 
1997). Although MPA does bind to the glucocorticoid receptor at one-tenth of the 
potency as the synthetic glucocorticoid, dexamethasone (Pridjian et al., 1987), and 
at high doses has been shown to curb the stress response seen in cancer patients 
(Lang, Zielinski, Templ, Spona, & Geyer, 1990), in the current report the working 
memory load effect lends support to the hypothesis that MPA modulates memory, 
specifically.  The nature of the working memory load in the radial-arm maze is 
such that the only aspect that changes across trials is the memory demand and not 
the motivator involved. Indeed, in the earlier trials when memory load was lowest 
but the non-cognitive stressors of the task were the same, MPA had no effect on 
performance. 
MPA, progesterone, and allopregnanolone have each been shown to affect 
the GABAergic system (Belelli & Herd, 2003; Braden et al., 2010, Chapter 2; 
Paul & Purdy, 1992; Pazol et al., 2009; Wallis & Luttge, 1980). In the current 
report, there was a negative correlation between serum MPA levels and GAD in 
the dorsal hippocampus. In animals receiving MPA treatment at test (Late-MPA 
and Early+Late-MPA), higher MPA levels correlated with less GAD in the dorsal 
hippocampus, which is in agreement with our previous findings of MPA-induced 
decreases in GAD in the dorsal hippocampus in aged Ovx animals (Braden et al., 
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2010, Chapter 2). There is an increasing focus on research, including both in vitro 
and in vivo studies, evaluating how MPA could impact the GABAergic system. 
Findings have indicated that although MPA’s ring-A reduced metabolites do not 
directly bind to the GABAA receptor (McAuley et al., 1993) like natural 
progesterone’s ring-A reduced metabolites (Paul & Purdy, 1992). MPA alters 
progesterone’s metabolic conversions (Penning et al., 1985) which may be 
responsible for MPA-induced enhanced GABAA receptor-mediated inhibition 
(Belelli & Herd, 2003) as well as changes in GAD (Braden et al., 2010, Chapter 
2). Similar to the relation between reduced GAD levels in dorsal hippocampus 
and serum MPA levels we show here, Raol et al (2005) demonstrated a decrease 
in GAD levels in the dorsal hippocampus after administration of the GABAA 
agonist diazepam in rodents, in turn suggesting that MPA-induced GAD 
decreases may be a consequence of increased GABAA receptor activation. In fact, 
increased GABAA receptor activation impaired learning as well as immediate and 
delayed recall in humans (Curran, 1986). There is also evidence that MPA has a 
negative effect on neuronal function via exacerbation of glutamate-induced 
excitotoxicity when tested in vitro (Nilsen et al., 2006) and lacks neuroprotective 
effects seen with natural progesterone (Nilsen & Brinton, 2002b). However, 
further research is needed to understand the complete mechanism behind MPA’s 
detrimental effects on neuronal function and cognition in order to determine safe 
progestin use.  
In aged Ovx rats, we previously found a main effect whereby MPA 
treatment decreased GAD levels in the dorsal hippocampus (Braden et al., 2010, 
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Chapter 2). Here, we show a similar relationship via correlation, in the absence of 
a main effect, in middle-aged Ovx rats. We hypothesize it is a difference in age of 
the animals in the current study (12 months old) versus our previous report (20 
months old; Braden et al. 2010, Chapter 2). This may represent that some animals 
receiving MPA when middle-aged still showed resilience to MPA-induced 
GABAergic changes while others did not, thereby enriching variability conducive 
to significant correlations among individual subjects rather than main effects via 
ANOVA. While the relation between progestins (including MPA, progesterone 
and allopregnanolone) and the GABAergic system has been evaluated using in 
vitro techniques with tissues from young adult animals (Paul & Purdy, 1992; 
Pazol et al., 2010; McAuley et al., 1993; Belelli & Herd, 2003), whether these 
findings translate to similar effects in vivo, or in aged animals, is an exciting and 
clinically relevant question that remains to be explored. Specifically, how brain 
aging alters the trajectory of progestin-induced GABAergic changes has yet to be 
methodically detailed. 
There were MPA-induced changes in serum levels of MPA, progesterone, 
and allopregnanolone. For serum MPA, animals receiving MPA at test (Late-
MPA and E+Late-MPA) were the only groups to show MPA concentrations in 
serum at sacrifice, confirming presence of the drug after administration, as well as 
successful clearing of the drug in blood for the group that received MPA 
treatment in young adulthood only. Further, serum MPA levels are within the 
range of MPA used clinically (Depo Provera Prescribing Information 2006; 
Prempro Prescribing Information 2009). The prescribing information for Depo 
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Provera and Prempro states that MPA is absorbed, distributed, metabolized, and 
excreted in an identical manner for both formulations. Presence of progesterone is 
assumed to be from the adrenal glands which have been shown to significantly 
contribute to total circulating progesterone levels in rodents (Fajer, Holzbauer, & 
Newport, 1971). MPA administration at any time inhibited serum levels of both 
progesterone and allopregnanolone, as compared to Controls. For progesterone, 
our data suggest that this inhibition was partially recovered over time as the 
Early-MPA animals had greater levels than animals treated with MPA during 
middle-age. The long-lasting effects of the MPA-induced decrease in endogenous 
progesterone and allopregnanolone levels represent another possible mechanism 
by which MPA may impair cognition. This outcome of MPA treatment is 
particularly striking because it is the only biological effect that is present in all 
groups that showed cognitive impairments. Indeed, ovarian hormone removal via 
Ovx (thereby removing endogenous progesterone as well as estrogen) impairs 
cognition in young rats (Bimonte & Denenberg, 1999; Talboom, Williams, 
Baxley, West, & Bimonte-Nelson, 2008), but not in middle-aged or aged rats 
(Savonenko & Markowska, 2003; Talboom et al., 2008), under normal test 
conditions without pharmacological challenge. Removal of elevated progesterone 
levels may be one mechanism by which Ovx improves cognitive performance in 
aged rats (Bimonte-Nelson et al., 2003b; Bimonte-Nelson et al., 2004b). Indeed, 
while in some cases progesterone treatment can improve cognitive performance in 
Ovx rats (Frye et al., 2007; Walf, Rhodes, & Frye, 2006), and in stroke and 
cortical contusion rodent models (Roof et al., 1993; Roof & Hall, 2000), these 
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improvements were seen in young animals. The collected findings suggest that 
age may be a factor in these effects since progesterone treatment impairs 
cognition in aged Ovx rats (Bimonte-Nelson et al., 2004b; Braden et al., 2010, 
Chapter 2), and hormone status at middle-age impacts cognition (Markowska, 
1999) with estropause status characterized with high progesterone levels related to 
poorer cognitive performance (Warren & Juraska, 2000). Additionally, in one 
study, progesterone treatment improved memory in young Ovx mice, but 
progesterone plus MPA did not (Frye, Koonce, & Walf, 2010), further 
demonstrating the lack of efficacy of MPA on improving cognition in the rodent 
model, even when tested in young adulthood. Recently, there have been 
investigations of combined estrogens and MPA treatment in middle-aged rodents. 
In Ovx animals, long-term treatment of 17β-estradiol plus MPA led to impaired 
spatial memory performance as compared to chronic or cyclic 17β-estradiol alone 
or 17β-estradiol plus progesterone, suggesting that the addition of MPA was 
detrimental to cogntiion (Lowry, Pardon, Yates, & Juraska, 2010).  
Another possible mechanism of MPA-related memory impairment is 
halting ovulation. It is tempting to speculate that the negative effects on cognition 
in Early-MPA and Early+Late-MPA could be due to prolonged acyclicity in 
young adulthood, as opposed to direct effects of MPA on the brain. Inherent to the 
complexities associated with administration of a contraceptive to evaluate 
cognition, is that we are stopping ovulation. While we cannot rule out the 
possibility that the cascade of events related to a lack of ovulation might have 
impacted our findings, a recent publication shows no effect of MPA treatment on 
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plasma 17β-estradiol levels in middle-aged ovary intact rodents (Frye et al., 
2010). Further, we observed memory impairment in the Late-MPA group that had 
no evidence of acyclicity in young adulthood, because they were ovary-intact and 
not exposed to MPA at that time.  
MPA impacted uterine and body weights. For uterine weight, we 
replicated our previous findings that animals treated with MPA after Ovx had 
heavier uterine weights than Control animals (Braden et al., 2010, Chapter 2), 
while Early-MPA animals did not differ from Control animals. Finally, for body 
weight, MPA treatment in young adulthood but not middle-age (Isserow et al., 
1995) caused an increase in body weight as compared to Control. The body 
weights of animals treated with MPA during young adulthood only (Early-MPA) 
did not return to Control-like weights after the cessation of treatment suggesting 
that early MPA treatment causes long lasting weight gain, in the rodent model. 
There is some evidence of this in clinical research as well (Bigrigg et al., 1999; 
Hani, Imthurn, & Merki-Feld, 2009).  
In conclusion, the current report indicates that in the rodent model: 1) 
MPA administration during young adulthood results in long lasting working 
memory impairments evident later in life (middle-age), even in the absence of 
circulating MPA levels at the time of test; 2) MPA administered during middle-
age, extending through time of test, impairs working memory and overnight 
retention; 3) MPA administered during young adulthood and again at middle-age 
impairs working memory, an effect that is robust as it is seen on two orthogonal 
working memory measures. Based on the latter result, our study suggests there is 
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added risk to working memory when MPA is given both in young adulthood and 
middle-age. These detrimental effects may, in part, be mediated by changes to the 
GABAergic system in the dorsal hippocampus. Overall, the current study builds 
on earlier in vivo and vitro research indicating that MPA is detrimental to brain 
health and function. Given the large number of prescriptions that are written every 
year containing MPA, as it is contained in both contraceptives and HTs, more 
investigation into this synthetic hormone’s effect on cognition and brain is 
warranted.  
  68 
CHAPTER 4 
PROGESTINS DIFFERENTIALLY IMPACT LEARNING AND MEMORY 
DEPENDING ON HORMONE CLASS AND REGIMEN  
A progestin, the synthetic form of progesterone, is included in every 
hormone therapy prescribed to women with a uterus, as well as every birth control 
formulation.  The need to develop this class of steroids was due to the poor 
bioavailability and short biological half-life of the natural hormone, although 
micronized progesterone somewhat overcomes these caveats (Sitruk-Ware, 2002). 
The necessity to include a progestin in hormone therapies and contraceptives is 
well documented, as it offsets the increased risk of endometrial hyperplasia 
related to unopposed estrogen treatment (Smith et al., 1975; Ziel & Finkle, 1975). 
However, the potential risks to cognition and other crucial processes that 
progestins pose have been largely unexplored. There is indirect evidence via the 
large, placebo-controlled, randomized WHIMS that the most commonly 
prescribed progestin in the USA, MPA, may adversely affect cognition. Indeed, a 
series of studies found that the combination hormone therapy Prempro 
(conjugated equine estrogens; CEE, plus MPA) was associated with a significant 
increased risk of dementia (Schumaker et al., 2003), while CEE-only hormone 
therapy produced a nonsignificant increase in risk of dementia (p = 0.18), 
compared to those taking placebo (Shumaker et al., 2004). Further, MPA is the 
only active ingredient in the contraceptive Depo Provera, and a documented case 
study revealed amnestic effects associated with its use (Gabriel & Fahim, 2005).  
Recently we were the first to methodically investigate the cognitive effects of 
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MPA in a rat model. We found that MPA impairs cognition in aged (Braden et al., 
2010, Chapter 2) and middle-aged (Braden et al., 2011, Chapter 3) 
ovariectomized (Ovx) rats, as well as initiates long-lasting cognitive-impairing 
effects when given to young adult, ovary-intact rodents, evident when these 
animals reach middle-age (Braden et al., 2011, Chapter 3). With evidence 
mounting that MPA is not the optimal progestin to be used in hormone therapy 
and birth control taken by women, it is imperative to determine if there are safer 
progestins, with respect to cognition. 
Based on their chemical structures, synthetic progestins either structurally 
resemble progesterone or testosterone considering the A-ring and the functional 
group in the 17 beta position of the steroidal skeleton (Stanczyk, 2003; Brinton et 
al., 2008). Progesterone-related drugs include acetylated (e.g., MPA, Figure 12b) 
and non-acetylated pregnans and 19-norpregnans, respectively, commonly used 
for hormone therapy and contraception in the USA. The majority of testosterone- 
and especially 19-nortestosterone-resembling progestins contain an ethynyl group 
in the 17 alpha position with (e.g., norethindrone acetate, NETA, Figure 12c) or 
without acetylation of the 17 beta hydroxyl group.  A homologous subcategory 
within this series consists of those progestins that carry C-13 substitution with an 
ethyl group (Stanczyk, 2003).  These progestins are often referred to as 13-ethyl 
gonanes, although the use of gonane as the parent name for these progestins only 
is misleading as a broad range of steroids are “gonane” per se (Edgren & 
Stanczyk, 1999; Moss, 1989). The term gonane refers to the parent tetracyclic 
hydrocarbon without C-10 and C-13 methyl groups and C-17 substitution (Moss, 
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1989). A typical representative of this subgroup of progestins is levonorgestrel 
(LEVO, Figure 12d), a popular choice of progestin in Europe (Brinton et al, 
2008).   
Having already established an acetylated progesterone derivative (MPA) 
as being cognitively impairing under certain parameters, it is reasonable to 
explore the safety of other frequently used progestins, as well as MPA when given 
under different treatment regimen .We selected NETA from the ethynylated 19-
nortestosterone  family of progestins for investigating its impact on cognition, 
because  NETA is commonly used in both hormone therapy and contraceptive 
formulations (Curtis, 2006; Murphy & Brixner, 2008) in the USA and Europe.  
There have been limited scientific investigations of the effects of NETA, paired 
with ethinyl- or 17β-estradiol as hormone therapy, on cognition and brain 
processes in healthy menopausal women. In these studies the combination 
hormone therapy was associated with greater brain activation during a memory 
test (Smith et al., 2006; Persad et al., 2009), protection from memory decline after 
one and two years of treatment (Tierny et al., 2009), or no impact on self-report of 
memory and concentration difficulties (Gambacciani et al., 2003). While these 
investigations are encouraging in that they indicate potential beneficial cognitive 
effects of combination therapies, it still remains to be methodologically seen how 
NETA alone impacts the brain and its function. Another type of frequently used 
progestin, within the homologous 17 alpha ethynyl nortestosterone (“13-ethyl 
gonane”) series is LEVO which is commonly prescribed in contraceptive 
formulations (Murphy and Brixner, 2008) but is a part of only one hormone 
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therapy regiment (Curtis et al., 2006). Unfortunately there have been no scientific 
investigations of the effects of LEVO on cognition neither in combination therapy 
in menopausal women nor alone in rodents, leaving little information to 
hypothesize the safety of this progestin on the brain and its function. However, 
differences in chemical structure from the cognitively-impairing progestin, MPA, 
and its global use make LEVO a worthy candidate for scientific studies evaluating 
this endpoint. In two separate studies, the current investigation aims to evaluate 
both NETA and LEVO’s effects on cognition in the middle-age Ovx rat when 
given tonically, via injections, or both as compared to vehicle. We will also be 
exploring the cognitive effects of MPA, previously shown to impair cognition, 
under a new (daily injections) schedule of administration.  
Study 3a 
 This study was designed to investigate whether the progestin NETA, given 
tonically, alters cognitive performance in the Ovx rat. 
Methods 
Subjects 
 Subjects were 33 twelve month old, Fisher-344 female rats born and raised 
at the National Institute on Aging colony at Harlan Laboratories (Indianapolis, 
IN). Animals were acclimated for several weeks and pair housed with an identical 
treatment assigned cage-mate in the Arizona State University animal facility. All 
animals had exposure to food and water ad-lib, and were maintained on a 12-h 
light/dark cycle at 23°C. Procedures were approved by the ASU IACUC 
committee and adhered to NIH standards. 
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Ovariectomy and Hormone Treatment 
Rats were Ovx at 12 months of age and divided into three treatment 
groups. Each rat was randomly assigned to either vehicle (propylene glycol, 
Sigma-Aldrich, St. Louise, MO) or one of two doses of NETA (Steraloids, Inc., 
Newport, RI), administered tonically via a Alzet osmotic pump (2006; Durect 
Co., Cupertine, CA). Treatment groups included: Ovx+Vehicle (n=8), Ovx+Tonic 
NETA-Low (4µg/day, n=9), and Ovx+Tonic NETA-Moderate (20µg/day, n=5). 
The low and moderate doses of NETA were based on doses given to women 
taking NETA hormone therapy; 1mg in FemHRT and 5mg in Aygestin (Curtis et 
al., 2006), respectively, adapted for body weight of the rat1. Ovx was performed 
on all rats while under isoflurane inhalation. Bilateral dorsolateral incisions were 
made in the skin and peritoneum, followed by ligature and removal of the ovaries 
and tips of the uterine horns. Muscle and skin were then sutured. At the time of 
surgery, Alzet osmotic pumps containing propylene glycol alone for vehicle 
animals, or propylene glycol plus the appropriate dose of NETA for drug-assigned 
animals, were inserted under the skin at the scruff of the neck. This pump model 
released hormone for a 6 week duration. After surgery, rats received Rimadyl (5 
mg/mL/kg) for pain and saline (2 mL) to prevent dehydration. Animals underwent 
pump re-insertion surgery 35 days after Ovx. Behavioral testing began 42 days 
after the first pump insertion (7 days after the second pump re-insertion; Figure 
13a). Thus, hormone administration continued throughout behavior testing and 
sacrifice.  
                                                 
1
 mg/kg calculations were based on a 70kg woman. 
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Initially, we included an Ovx+Tonic NETA-High (65µg/day) dose 
because therapeutic efficacy of higher NETA doses have not been determined, 
and we wanted to capture a dose response curve for NETA effects. We chose this 
higher dose to be one-tenth of the dose of MPA we have shown to alter cognition 
(Braden et al., 2010, Chapter 2), since NETA is 10 times more potent than MPA 
(King & Whitehead, 1986). However, upon inspection of the Alzet pumps at 
sacrifice, we found pump failure (pumps had cracked) for all animals in the 
Ovx+Tonic NETA-high group and for three animals in the Ovx+Tonic NETA-
Moderate group. These animals were not used for analyses as the company 
informed us drug release is halted with pump cracking, thereby leaving analyses 
of only Ovx+Tonic NETA-Low and Ovx+Tonic NETA-Moderate animals with 
confirmed intact pumps. 
Vaginal Smears and Uterine Weights 
 Vaginal smears were performed 36 days after Ovx.  Each smear was 
identified as proestrus, estrous, metestrus or diestrus, per prior protocols (Acosta 
et al., 2009; Goldman et al., 2007).  Smears were repeated four days later.  At 
sacrifice, uteri from all subjects were removed, trimmed of fat and weighed 
immediately (wet weight) in order to examine drug effects.    
General Considerations for Statistics on Behavioral Data 
For behavior assessments, data were analyzed separately for each maze. 
Specific days, trials and blocking details are given below for each maze. First, in 
order to determine learning on each maze, an omnibus ANOVA including all 
groups was run to investigate a significant main effect of all Days and/or Trials. 
  74 
For Treatment effects, since our interest was to determine whether each dose 
enhanced or impaired performance relative to the Ovx-Vehicle group, two-tailed, 
two-group planned comparisons were conducted and alpha was set at 0.05.  
Water Radial-arm Maze 
Subjects were tested for 13 days on the eight-arm, win-shift, WRAM to 
evaluate spatial working and reference memory, including performance as 
working memory load increased, as described previously (e.g., Bimonte & 
Denenberg, 1999, 2000; Bimonte et al., 2000, 2002). The maze contained escape 
platforms hidden under the water surface in the ends of four of the eight arms. 
Each subject had different platform locations that remained fixed throughout the 
experiment. A subject was released from the start arm and had three minutes (m) 
to locate a platform. Once a platform was found, the animal remained on it for 15 
seconds (s), and was then returned to its heated cage for a 30s inter-trial interval 
(ITI) until its next trial. During the interval, the just-chosen platform was removed 
from the maze. The animal was then placed again into the start alley and allowed 
to locate another platform. For each animal a daily session consisted of four trials, 
with the number of platformed arms reduced by one on each subsequent trial. 
Thus, the working memory system was increasingly taxed as trials progressed, 
allowing us to access working memory load. Each subject was given one session a 
day for 12 consecutive days. On day 13 a six hour delay was instilled between 
trials 2 and 3.  
Quantification and blocking were based on prior studies (e.g., Bimonte & 
Denenberg, 2000; Bimonte et al., 2000, 2002; Hyde et al., 1998, 2000). An arm 
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entry was counted when the tip of a rat’s snout reached a mark delineated on the 
outside of the arm (11 cm into the arm). Errors were quantified using the 
orthogonal measures of working and reference memory errors (Jarrard, Okaichi, 
Steward, & Goldschmidt, 1984), as done previously in WRAM studies (Bimonte 
et al., 2000, 2002; Hyde et al., 2000). Working memory correct (WMC) errors 
were the number of first and repeat entries into any arm from which a platform 
had been removed during that session. Trial 1 is not analyzed for WMC errors 
because no platform has yet been removed. Reference memory (RM) errors were 
the number of first entries into any arm that never contained a platform. Working 
memory incorrect (WMI) errors were repeat entries into a reference memory arm. 
Data were blocked into days 2-6, which is considered the acquisition 
phase, and 7-12, which is considered the asymptotic phase. Blocking data into 
these two phases is the traditional protocol for analyzing WRAM data (Bimonte 
& Denenberg, 1999, 2000; Bimonte et al., 2000; Hyde et al., 1998, 2000).  
For WMC, WMI, and RM errors, the Ovx-Vehicle group was compared to 
each progestin group using planned comparison two-group repeated measures 
ANOVAs. To analyze effects of the 6 hour delay, Day 12 Trial 3 was considered 
the baseline day/trial (the last day of regular testing) and this was compared to the 
post delay trial given on Day 13, Trial 3. This was done to examine memory 
retention after a 6 hour delay. Each group was analyzed separately using a 2-
within (baseline trial and post-delay trial) repeated measures ANOVA. 
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Morris Maze 
The MM consisted of testing for 6 trials/day for three days using a tub 
(188 cm diameter) filled with black water made opaque with non-toxic paint. A 
hidden platform (10 cm wide) remained in a fixed location, thereby testing spatial 
reference memory (Bimonte-Nelson et al., 2006; Morris et al., 1982). The rat was 
placed in the maze from the North, South, East, or West location, and had 60 s to 
locate the hidden platform (10 cm wide), which remained in a fixed location 
(Northeast quadrant) throughout testing. Once the rat found the platform the trial 
was terminated. After the 15s platform time, the rat was placed into its heated 
cage until its next trial. The approximate ITI was 10m. To evaluate whether rats 
localized the platform to the spatial location, after all test trials on day 3, a 60s 
probe trial was given whereby the platform was removed. For each trial, a camera 
suspended above the maze tracked each rat’s path and a tracking system 
(Ethovision 6, Noldus Instruments) analyzed each rat’s tracing.  
MM analyses tested distance (cm) to the platform by comparing Ovx-
Vehicle to each progestin group using a planned comparison two-group repeated 
measures ANOVAs. For probe trial data, percent distance in the previously 
platformed (target) quadrant was compared to the diagonally opposite quadrant 
using an omnibus ANOVA (Talboom et al., 2008). Rats that learned the platform 
location should spend the greatest percent distance in the target vs. opposite 
quadrant (Stavnezer et al., 2002). For Treatment effects, an omnibus ANOVA 
with Treatment as the between variable, and Quadrant as repeated-measures, was 
used.  
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Visible Platform Maze 
Since the WRAM and MM rely on spatial navigation, it was necessary to 
confirm that all subjects had intact vision and could perform the procedural swim 
task components without difficulty. A visible platform water-escape task was 
used. A rectangular tub (39 x 23 in) was filled with clear water and a black 
platform (10 cm wide) was elevated above the water surface. Opaque curtains 
covered extramaze cues. The drop off location remained the same across trials, 
and the platform location for each trial varied in space semi-randomly. Animals 
had to locate the platform protruding from the water, and were given 8 trials. 
Performance was assessed by latency (s) to the platform.  
Results 
Vaginal Smears and Uterine Weights 
All animals, regardless of treatment group, exhibited diestrous vaginal 
smears with primarily leukocytic cells.  Uterine weights were analyzed using 
ANOVA with Treatment as the between variable.  Mean ± SE uterine weights 
were: Ovx+Vehicle (0.163 ± 0.038), Ovx+Tonic NETA-Low (0.114 ± 0.006), and 
Ovx+Tonic NETA-Moderate (0.152 ± .038).  Uterine weights did not differ 
between treatment groups [F(2, 19) = 0.869; p =0 .44]. These results are in 
agreement with the known non-estrogenic activity of NETA (e.g., Sitruk-Ware, 
2006).  
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Water Radial-arm Maze 
Acquisition and Asymptotic Testing Phases 
Across Days 2-12 (combined acquisition and asymptotic testing phases) 
there was a Day main effect for the omnibus ANOVA for each type of error 
[WMC: F (10, 190) = 3.564; p < 0.0005; WMI: F (10, 190) = 2.913; p < 0.005; 
RM: F (10, 190) = 3.661; p < 0.0005], with errors decreasing across days, 
demonstrating learning of the task. 
For the acquisition phase, there was a main effect of Treatment for the 
Ovx+Vehicle vs. Ovx+Tonic NETA-Moderate comparison for WMC [t (11) = 
2.68;  p <0.05 (Figure 14a)], WMI [t (11) = 2.96; p < 0.05 (Figure 14b)], and RM 
[t (11) = 2.20; p < 0.05 (Figure 14c)], with the moderate NETA dosed group 
committing more of all three error types and therefore, showing impaired 
performance. There were no main effects or interactions of Treatment for 
Ovx+Vehicle vs. Ovx+Tonic NETA-Low on the acquisition phase or either 
NETA dose for the asymptotic phase.  
Delay Testing 
 To evaluate which groups were impaired by the 6 hour delay, we 
compared performance on Day 12 Trial 3 (baseline), to Day 13 Trial 3 (post-
delay). For WMC errors, on Trial 3, the trial immediately following the delay, the 
Ovx+Tonic NETA-Low and the Ovx+Tonic NETA-Moderate groups each made 
more errors as compared to baseline [Ovx+Tonic NETA-Low Day effect for 
baseline day vs. delay day: t (8) = 4.00; p < 0.05; Ovx+Tonic NETA-Moderate 
Day effect for baseline day vs. delay day: t (4) = 3.5; p <0.05 (Figure 15)], 
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indicating that the delay impaired performance in both NETA groups. This delay-
induced decrement was not observed in Vehicle treated rats (Ovx+Vehicle Day 
effect for baseline day vs. delay day: p = 0.57). There were no delay-induced 
effects for WMI or RM errors.  
Morris Maze 
There was a Day main effect for distance for the omnibus ANOVA 
[Distance: F(2, 58) = 237.316; p < 0.0001], with scores decreasing across days, 
demonstrating learning of the task. For the Ovx+Vehicle vs. Ovx+Tonic NETA-
Moderate comparison, there was a Day x Treatment interaction [F(2, 22) = 3.44; p 
<0.05], with Ovx+Tonic NETA-Moderate animals exhibiting higher distance 
scores as compared to Ovx+Vehicle animals on Days 2 and 3 [Treatment effect 
for Days 2 and 3 combined: t (11)=2.16; p = 0.05 (Figure 16a)]. The Day x 
Treatment interaction was not significant for the Ovx+Vehicle vs. Ovx+Tonic 
NETA-Low comparison (p = 0.73), and there were no Treatment main effects for 
either dose. 
For the probe trial, a higher percent distance was spent in the previously 
platformed (NE) versus the opposite (SW) quadrant [Quadrant main effect: F (1, 
19) = 77.77; p < 0.0001 (Figure 16b)]. This pattern did not differ by Treatment 
[null Quadrant x Treatment interaction], suggesting that all groups localized the 
platform location by the end of testing. 
Visible Platform 
 There was a main effect of Trial [F(5, 95) = 7.985; p < 0.0001 (Figure 
17)], with latency decreasing across trials. There were no Treatment effects for 
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either Vehicle vs. NETA dose group for the visible platform task. The average 
time to find the platform was 7 s by the last trial of testing, confirming visual and 
motor competence for solving a water-escape swim task. 
Study 3b 
 In Study 3a, the progestin NETA impaired cognition in the middle-age 
Ovx rat when given tonically via osmotic pump. Study 3b was designed to 
investigate whether it is the tonic schedule of administration of NETA, in Study 1, 
and MPA, in a previous study (Braden et al., 2010, Chapter 2), that led to the 
observed impairing effects. Study 3b also examines the cognitive effects of a 
progestin novel to cognitive testing, LEVO, which is of a different chemical 
structure category than NETA and MPA. Thus, in Study 3a, the effects of MPA 
and NETA, given via injections, on cognition were investigated and compared to 
the progestin novel to cognitive testing, LEVO. Additionally, in keeping with the 
Food and Drug Administrations’ recommendation of limiting the length of 
hormone therapy use (Food and Drug Administration, 2009), we reduced the 
duration of progestin treatment before test. 
Methods 
Subjects 
 Subjects were 42 thirteen month old, Fisher-344 female rats born and 
raised at the National Institute on Aging colony at Harlan Laboratories 
(Indianapolis, IN). Acclimation, housing, food and water, and light/dark 
procedures were identical to study 3a.  
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Ovariectomy and Hormone Treatment 
All rats were ovariectomized (Ovx) at 13 months of age, 15 days prior to 
behavioral testing, under isoflurane inhalation. The Ovx procedure was identical 
to Study 3a. Rats were randomly assigned to one of five treatment groups, with 
vehicle (0.4mL sesame oil + 0.02mL  dimethyl sulfoxide [DMSO], both from 
Sigma-Aldrich, St. Louis, MO, USA) or drug given via injection (inj): 
Ovx+Vehicle (n=8), Ovx+Inj MPA (700 µg, n=9; Sigma-Aldrich, St. Louise, 
MO), Ovx+Inj NETA-Moderate (20 µg, n=8; Steraloids, Inc., Newport, RI), 
Ovx+Inj NETA-High (70 µg, n=4), Ovx+Inj LEVO-Low (0.06 µg, n=9; Sigma-
Aldrich, St. Louise, MO), and Ovx+Inj LEVO-High (0.6 µg, n=9). The dose of 
MPA was based on that of a previous study (Braden et al., 2010, Chapter 2). The 
NETA-Moderate dose was based on a dose given to women in HT (5mg in 
Aygestin; Curtis et al., 2006) adapted for the body weight of a rat, and the NETA-
High dose was one-tenth of the dose of MPA since NETA is 10 times more potent 
than MPA (King and Whitehead, 1986). The low and high doses of LEVO were 
based on doses given to women taking LEVO clinically, 0.015mg in Climara Pro 
and 0.15mg in Seasonalle (Climara Pro Prescribing Information; Seasonique 
Prescribing Information), respectively, adapted for body weight of the rat2. 
Behavioral testing began 13 days after hormone administration was initiated and 
continued throughout the study (4 weeks; Figure 13b). The last treatment injection 
was administered 1 hour before sacrifice.  
 
                                                 
2
 mg/kg calculations were based on a 70kg woman. 
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Vaginal Smears 
 Vaginal smears were performed 2 weeks after Ovx, one day prior to 
behavioral testing.  Each smear was identified as either proestrus, estrous, 
metestrus or diestrus, per prior protocols (Acosta et al., 2009; Goldman et al., 
2007).   
Uterine Weights, Statistical, Water Radial-arm Maze and Morris Water 
Maze procedures 
Procedures were identical to study 3a.  
Results 
Water Radial-arm Maze 
Acquisition and Asymptotic Testing Phases 
Across Days 2-12 (combined acquisition and asymptotic testing phases) 
there was a Day main effect for the omnibus ANOVA for each type of error 
[WMC: F (10, 390) = 13.567; p < 0.0001; WMI: F (10, 390) = 6.565; p < 0.0001; 
RM: F (10, 390) = 7.912; p < 0.0001], with errors decreasing across days, 
demonstrating learning of the task. 
For the asymptotic phase, there was a main effect of Treatment for the 
Ovx+Vehicle vs. Ovx+Inj NETA-High comparison for WMC [t (10) = 2.31; p < 
0.05 (Figure 18a)], with the high NETA dose group committing fewer errors and 
therefore, showing enhanced performance. This difference was also evident at 
Trial 4, at the highest working memory load [t (10) = 2.57; p < 0.05 (Figure 18b)].  
There were no effects of the high NETA dose on WMI or RM errors for the 
asymptotic phase, or any of the three error types for the acquisition phase. For 
  83 
each of three error types, the moderate NETA dose, MPA, and both doses of 
LEVO had no effect on the acquisition or asymptotic phases yielding no main 
effect or interactions with Treatment. 
End of Testing: Days 11-12 
 In order to examine a potential replication of our previously published 
MPA- (Braden et al., 2010, Chapter 2) and progesterone- (Bimonte-Nelson et al., 
2004b; Braden et al., 2010, Chapter 2) induced impairments, we investigated 
group differences at the end of testing. For Days 11-12, there was a main effect of 
Treatment for the Ovx+Vehicle vs. Ovx+Inj MPA comparison for WMI [t (15) = 
1.86; p < 0.05 (Figure 19a)] and RM [t (15) = 1.86; p < 0.05 (Figure 19b)], with 
the MPA group committing more errors and therefore, showing impaired 
performance. There were no differences between Ovx+Vehicle and Ovx+Inj 
MPA groups for WMC Errors. For each of the three error types, both doses of 
NETA and both doses of LEVO had no effect at the end of testing.  
Delay Testing 
 To evaluate which groups were impaired by the 6 hour delay, we 
compared performance on Day 12 Trial 3 (baseline), to Day 13 Trial 3 (post-
delay). For WMC errors, on Trial 3, the trial immediately following the delay, all 
groups made significantly more errors as compared to baseline [effect for baseline 
day vs. delay day: Ovx+Vehicle: t (7) = 8.28; p < 0.0001; Ovx+Inj MPA: t (8) = 
5.5; p < 0.001; Ovx+Inj NETA-Moderate: t (7) = 4.96; p < 0.005; Ovx+Inj 
LEVO-Low: t (8) = 3.46; p < 0.01; (Figure 20)], except for Ovx-Inj NETA-High 
who made marginally more errors [t (3) = 3; p = 0.06] and Ovx+Inj LEVO-High, 
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who were not impaired [t (6) = 1; p = 0.36]. These findings indicate that the delay 
impaired performance in Vehicle, MPA, NETA-Moderate, and LEVO-Low 
groups. This delay-induced decrement was marginally observed in NETA-High 
treated rats (p =0.06) and not seen at all in LEVO-High treated rats. There were 
no delay-induced effects for WMI or RM.  
Morris Water Maze 
There was a Day main effect for distance for the omnibus ANOVA 
[Distance: F (2, 78) = 241.328; p < 0.0001 (Figure 21a)], with scores decreasing 
across days, demonstrating learning of the task. There were no Treatment main 
effects or Day x Treatment interactions between Ovx-Vehicle versus any 
progestin-treated group. 
For the probe trial, a higher percent distance was spent in the previously 
platformed (NE) versus the opposite (SW) quadrant [Quadrant main effect: t (40) 
= 20.1; p < 0.0001 (Figure 21b)]. This pattern did not differ by Treatment [null 
Quadrant x Treatment interaction], suggesting that all groups localized the 
platform location by the end of testing. 
Discussion 
 The effectiveness of clinically used progestins in offsetting the increased 
risk of endometrial hyperplasia associated with unopposed estrogen treatment is 
well documented (Smith et al., 1975; Ziel and Finkle, 1975); however, little is 
known about the potential risks to cognition due to clinically-used progestins. 
With a progestin included in every HT given to women with a uterus, and in every 
birth control formulation, this is an essential line of research both clinically and 
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preclinically. The current study corroborates previous evidence from our 
laboratory that the most commonly used progestin in the USA for HT, MPA, 
impairs learning and memory in the Ovx middle-aged rodent. The study also 
present for the first time conditions under which two other types of frequently 
used progestins for hormone therapy and contraception, via NETA and LEVO, 
improve and/or impair cognition in the Ovx female rat.  
In Study 3a, both the low and moderate doses of NETA, given tonically, 
impaired working memory retention of a six hour delay on the WRAM, as 
compared to vehicle treated rats. While this was the only impairment seen in the 
tonic low dose NETA rats, the tonic moderate dose NETA rats were impaired in 
working and reference memory performance during the acquisition of the WRAM 
and on reference memory performance on the MM, as compared to vehicle. In 
Study 3b this same moderate dose of NETA, as well as a high NETA dose, was 
investigated using a treatment regimen of daily injections. Under the method of 
daily injections, the moderate NETA dose that previously impaired cognition 
when given tonically had no effect as compared to vehicle-treated rats. Further, 
the high NETA dose, when given via injections, improved working memory 
performance during the asymptotic phase of testing on the WRAM and partially 
protected against a six hour delay-induced impairment on the same task, both 
effects as compared to vehicle. It was at the six hour delay on the WRAM that we 
also saw cognitive enhancements as a result of daily injections with the high dose 
of LEVO, as compared to vehicle. Finally, in Study 3b we examined the effects of 
daily injections of MPA at a dose that we have previously shown to impair 
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cognition when given tonically (Braden et al., 2010, Chapter 2) or via weekly 
injections (Braden et al., 2011, Chapter 3). Indeed, daily injections of MPA 
resulted in impaired working and reference memory performance during the latter 
part of testing on the WRAM, as compared to vehicle. Taken together, our past 
(Braden et al., 2010 & 2011, Chapter 2 & 3) and present results with MPA 
treatment clearly show the detrimental effect of this 17α-acetoxy-6α-methyl 
progesterone on cognition independently from the treatment regimen. Figure 22 
summarizes the significant behavior effects. 
Most notable in our results are the divergent effects of NETA depending 
on the parameters associated with its treatment. In Study 3a, NETA animals were 
treated tonically for six weeks prior to test at doses of 4 and 20 µg/day, both of 
which led to cognitive impairments. In Study 3b, NETA animals were treated via 
daily injections for two weeks prior to test at doses of 20 and 70 µg/day, with the 
70µg/day dose leading to cognitive enhancements. Thus, we conclude that longer 
durations of lower doses of NETA given tonically are associated with impaired 
cognition, while short durations of higher doses of NETA given cyclically 
improve cognition, in the middle-aged Ovx rodent. Further research needs to be 
done to determine exactly which of these three parameters (dose, schedule of 
treatment, and treatment duration) are critical in modulating the cognitive 
decrements or enhancements associated with NETA treatment. The cognitive 
enhancing effects of NETA are in line with clinical studies examining the effects 
of combined HT using this progestin (Smith et al., 2006; Persad et al., 2009; 
Tierny et al., 2009). It is noteworthy that in our studies NETA only enhanced 
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cognition in Study 3b when the route of administration was daily injections, 
presumably inducing pharmacokinetics and pharmacodynamics more similar to a 
woman taking a daily oral pill, as in the clinical investigations. Metabolism and 
bioavailability under various route of administration may also be a significant 
parameter influencing NETA’s, or in general progestins’, impact on brain 
functions.  
The current study is the first to investigate the cognitive effects of LEVO 
in any basic science or clinical setting. Here we found that while LEVO did not 
have a profound effect on cognition, it did prevent a delay induced impairment on 
the WRAM, suggesting that LEVO may enhance memory retention. Taken 
together, our hypothesis was supported in that progestins with a different 
chemical structure (Figure 12c, d) than the cognitively impairing MPA (an 
acetylated pregnane derivative, Figure 12b) can enhance cognition in the middle-
age Ovx rat, given the right parameters. 
This is now our third report showing that MPA when given alone impairs 
cognition in the rodent model. Other rodent studies have shown that long-term 
treatment of 17β-estradiol plus MPA led to impaired spatial memory 
performance, as compared to 17β-estradiol, in Ovx rats (Lowry et al., 2010). 
Additionally, in young Ovx mice, the addition of MPA to natural progesterone 
treatment reversed the cognitive benefits seen with progesterone alone (Frye et 
al., 2010). In other basic science work, MPA has attenuated or blocked the 
beneficial effects of 17β-estradiol on neuronal health in hippocampal cell cultures 
(Nilsen & Brinton, 2002a, 2002b), and exacerbated glutamate-induced toxicity 
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when given alone (Nilsen et al., 2006). Further, our findings are corroborated by a 
case study of amnesia corresponding with the use of MPA in the contraceptive 
depo provera (Gabriel & Fahim, 2003) and indirect clinical evidence, via the 
combined estrogen alone and estrogen+progestin trials, that the addition of MPA 
to hormone therapy increases risk of dementia (Shumaker et al., 2003, 2004). 
It is critical to find a progestin option for women taking hormone therapy 
and birth control that will protect against estrogen induced endometrial 
hyperplasia but will not have adverse effects on cognition, such as those seen with 
MPA. Here we present two progestins, NETA and LEVO, as alternative options 
to be evaluated for cognition in women. Future research must be done to better 
understand how these two progestins interact with estrogens for cognition both in 
the clinic and in animal models, as well as the mechanisms behind divergent 
effects of progestins on cognition.   
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CHAPTER 5 
THE GABAA ANTAGONIST, BICUCULLINE, ATTENUATES 
PROGESTERONE, BUT NOT MPA, INDUCED MEMORY-IMPAIRMENTS  
Chapter 5a 
The GABAA antagonist bicuculline attenuates progesterone induced 
memory-impairments 
Nearly every woman will face the decision of whether to take exogenous 
hormones, either for contraception or for HT, and those with a uterus must 
include a progestogen in their regimen (Smith et al., 1975). The most commonly 
prescribed progestin component of HT, and the sole hormone component of the 
contraceptive Depo Provera, MPA, has been associated with memory 
impairments in rodent models (Braden et al., 2010, 2011, Chapters 2 & 3) and 
adverse in vitro cellular effects (Nilsen et al., 2006; Nilsen & Brinton, 2002a, 
2002b). In postmenopausal women, combination HT treatment including MPA 
lead to an increase in risk of dementia (Shumaker et al., 2003). There is evidence 
in women that, like MPA, natural progesterone is associated with detrimental 
effects on cognition in both the phenomenon of “maternal amnesia” (Brett & 
Baxendale, 2001) and in a controlled study of healthy women receiving a large 
dose of oral progesterone (Freeman et al., 1992). Progesterone has also been 
shown to impair memory in rodent models (Bimonte-Nelson et al., 2004b; Braden 
et al., 2010, Chapter 2; Sun et al., 210) and reverse the beneficial effects of 17β-
estradiol in vivo (Bimonte-Nelson et al., 2006; Harburger et al., 2007) and in vitro 
(Nilsen & Brinton, 2002a; Aguirre & Baudry, 2009). These findings are 
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particularly salient since the use of progesterone (specifically, natural 
progesterone in its micronized form to be orally bioavailable) as the progestogen 
component of HT has only become an option for women in the United States as 
recently as 1998 (Langer, 1999), and is a promising new candidate to replace 
MPA as the progestogen component in HT (Langer, 1999; Sherwin & Grigorova, 
2011).  
A potential mechanism for progesterone-induced memory impairments in 
the rodent model is the GABAergic system. Indeed, we have shown that 
progesterone impacts the GABAergic system of cognitive brain regions in the 
Ovx rat (Braden et al., 2010, Chapter 2). However, it remains to be determined, 
through direct pharmacological manipulation, whether the GABAergic system is a 
mechanism of progesterone’s effects on cognition during aging in the Ovx rat. 
Evidence suggests that progesterone impairs memory by increasing GABAA 
stimulation in the hippocampus, in turn resulting in greater inhibition of the 
hippocampus, and thereby detrimentally affecting cognition. We propose to 
address the question of whether progesterone’s effects on memory are, in part, 
due to GABAA modulation by administering the GABAA receptor antagonist, 
bicuculline, to progesterone-treated animals. We hypothesize that bicuculline will 
prevent progesterone’s negative effects on cognition. In this study, we also aim to 
determine if in vivo treatment with progesterone and/or bicuculline alters the 
number GABA-producing cells in the hippocampus. We predict that the number 
of GABA-producing cells will be down regulated by progesterone treatment, 
similarly to the protein changes observed in Braden et al. (2010, Chapter 2), and 
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that this will be reversed by concomitant treatment with bicuculline, mirroring the 
expected behavioral outcomes.  
Contrary to the negative effects of long-term progesterone treatment on 
cognition in normal aging (Bimonte-Nelson et al., 2004b; Braden et al., 2010, 
Chapter 2), short-term progesterone treatment after traumatic brain injury has 
been associated with favorable outcomes in both humans and animal models 
(Stein, 2012). Specifically, in cortical contusion models, progesterone improves 
cognitive performance and reduces oedema and neuronal degeneration (Roof et 
al., 1993, 1994, 1996). The mechanism of these effects may be modulation of 
Cox-2, a key enzyme in the formation of prostaglandins in the inflammatory 
response (Breder et al., 1995) that is induced in glutamate excitotoxicity (Tocco et 
al., 1997). Previous research indicates progesterone can result in upregulation or 
downregulation on this system; indeed, one study found a progesterone-induced 
decrease of Cox-2 expression following cortical contusion (Cutler et al., 2007) 
and another an increase after LPS-induced inflammation (Sunday et al., 2006). In 
the current study, we aimed to determine if changes in Cox-2 expression in the 
frontal cortex, a brain area intimately involved in working memory (Jones, 2002), 
are related to memory-impairing effects of progesterone in the middle-aged Ovx 
rat. Investigating the GABAergic and neuroinflammatory system’s relationship to 
the cognitive impact of progesterone in an animal model is an early step in 
answering questions of the mechanisms by which natural progesterone impairs 
cognition. With this knowledge, we can move forward in the field of hormone 
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treatment with prosgetogens that do not share these pharmacological 
characteristics, and are thus potentially safer alternatives for inclusion in HTs.  
Methods 
Subjects  
Subjects were 37, 13 month old Fischer-344 female rats born and reared at 
the aging colony of the National Institute on Aging at Harlan Laboratories 
(Indianapolis, IN). Rats were acclimated for several weeks before surgery, had 
access to food and water ad-lib, and were maintained on a 12-hour light/dark 
cycle at the Arizona State University animal facility. All procedures were 
approved by the local IACUC committee and adhered to NIH standards. 
Hormone Treatment and Ovariectomy 
Rats were randomly assigned to one of four treatment groups: 
Ovx+Vehicle, Ovx+Progesterone (Ovx+Prog), Ovx+Bicuculline (Ovx+Bic), or 
Ovx+Prog+Bic. Identical to Study 3b (Chapter 4), at 13 months of age all rats 
were anesthetized via isofluorane inhalation, underwent bilateral dorsolateral 
incisions in the skin and peritoneum, and the ovaries and tips of uterine horns 
were ligatured and removed. Muscle and skin were then sutured. Two days after 
surgery all drugs were administered via two daily subcutaneous injections in the 
scruff of the neck. For the first injection, animals received either a control vehicle 
solution (0.4mL sesame oil + 0.02mL dimethyl sulfoxide [DMSO], both from 
Sigma-Aldrich, St. Louis, MO, USA) or progesterone (0.7 mg, Sigma-Aldrich St. 
Louis, MO, USA; dissolved in 0.4mL sesame oil + 0.02mL DMSO) and for the 
second injection, animals received either a control vehicle solution (sesame oil + 
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10% DMSO) or bicuculline (3.5mg/kg; dissolved in sesame oil + 10% DMSO). 
Injections continued throughout behavior testing until sacrifice.  
Vaginal Smears and Uterine Weights 
 Vaginal smears were taken 12 and 13 days after Ovx and classified as 
proestrus, estrous, metestrus or diestrous per prior protocol (Acosta et al. 2009; 
Goldman et al. 2007). At sacrifice, the uteri of each subject was removed, 
trimmed of visible fat, and immediately weighed (wet weight), in order to 
examine hormone and drug effects on uterine tissues (Braden et al., 2010, 2011; 
Chapter 2 & 3). 
Water Radial-Arm Maze  
Thirteen days after initiation of injections, subjects were tested on the 
WRAM for 15 days to evaluate spatial working and reference memory, including 
performance as working memory load increased, as described previously 
(Bimonte & Denenberg, 2000; Bimonte et al., 2000, 2002). The maze contained 
escape platforms hidden under the water surface in the ends of 4 of the 8 arms. 
Each subject had different platform locations that remained fixed throughout the 
experiment. A subject was released from the start arm and had three minutes (m) 
to locate a platform. Once a platform was found, the animal remained on it for 15 
seconds (s), and was then returned to its heated cage for a 30s inter-trial interval 
(ITI) until its next trial. During the interval, the just-chosen platform was removed 
from the maze. The animal was then placed again into the start alley and allowed 
to locate another platform. For each animal a daily session consisted of four trials, 
with the number of platformed arms reduced by one on each subsequent trial. 
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Thus, the working memory system was increasingly taxed as trials progressed, 
allowing us to access working memory load. Each subject was given one session a 
day for 14 consecutive days. On Day 15, a 6 hour delay was administered 
between Trials 2 and 3 as in Studies 3a and 3b (Chapter 4). 
Quantification and blocking were based on prior studies (Bimonte & 
Denenberg, 2000; Bimonte et al., 2000, 2002; Hyde et al., 1998, 2000). An arm 
entry was counted when the tip of a rat’s snout reached a mark delineated on the 
outside of the arm (11 cm into the arm). Errors were quantified using the 
orthogonal measures of working and reference memory errors (Jarrard, Okaichi, 
Steward, & Goldschmidt, 1984), as done previously in WRAM studies (Bimonte 
et al., 2000, 2002; Hyde et al., 2000). Working Memory Correct (WMC) errors 
were the number of first and repeat entries into any arm from which a platform 
had been removed during that session. Trial 1 is not analyzed for WMC errors 
because no platform has yet been removed. Reference memory (RM) errors were 
the number of first entries into any arm that never contained a platform. Working 
Memory Incorrect (WMI) errors were repeat entries into a RM arm.  
Morris Maze  
The day after WRAM completion, subjects were tested on the MM for 6 
trials/day for 3 days using a tub (188 cm diameter) filled with black water made 
opaque using non-toxic paint. A hidden platform (10 cm wide) remained in a 
fixed location, thereby testing spatial reference memory (Bimonte-Nelson et al., 
2006; Morris et al., 1982). The rat was placed in the maze from the North, South, 
East, or West location, and had 60s to locate the hidden platform, which remained 
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in the Northeast quadrant throughout testing. Once the rat found the platform the 
trial was terminated. After 15s platform time, the rat was placed into its heated 
cage until its next trial. The approximate ITI was 10-15m. To evaluate whether 
rats localized the platform to the spatial location, after all test trials on day 3, a 
60s probe trial was given whereby the platform was removed. For each trial, a 
camera suspended above the maze tracked each rat’s path and a tracking system 
(Ethovision 3.1, Noldus Instruments) analyzed each rat’s tracing. 
MM performance was assessed by swim path distance (cm) and latency (s) 
to the platform. For probe trial data, percent of total distance in the previously 
platformed (target) quadrant was compared to the quadrant diagonally opposite 
the platform. Rats that learned the platform location were expected to spend the 
greatest percent distance in the target quadrant (Stavnezer et al., 2002). 
Visible Platform Maze 
 To confirm that all subjects had intact vision and could perform the 
procedural task components of MM and WRAM spatial navigation without 
difficulty, subjects were tested on a VP water-escape task. A rectangular tub (39 x 
23 in) was filled with clear water and a black platform (10 cm wide) was elevated 
above the water surface. Opaque curtains covered extramaze cues. The drop off 
location remained the same across trials, and the platform location for each trial 
varied in space semi-randomly. Animals had to locate the protruding platform, 
and were given 6 trials in one day. Performance was assessed by latency (s) to the 
platform.  
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Tissue Preparation 
After the conclusion of behavioral testing, rats were anesthetized with 
isofluorane. Brains were removed, blocked anterior to the hippocampus, and post-
fixed in PFA for 48 hours. After 48 hours the brains were moved to PB and stored 
at 4 °C. Two days prior to sectioning, brains were placed in a 30% sucrose 
solution for 48 hours. Brains were coronally sectioned at 40 µm on a cryostat 
(Microtome HM 500 OM Cryostat) at -20 °C, and free floating sections were 
collected for immunohistochemistry.  
Immunohistochemistry and Quantification of GAD 67 
Dorsal hippocampal sections in the posterior block of brains (Plates 33 – 
37; Paxinos and Watson, 1998) were washed three times for 5m each in PBS, and 
then incubated in 1% H2O2 diluted in PBS for 30m at room temperature (RT). 
Next, sections were washed three times (all GAD 67 washes = 10m for the 
remainder of staining) and placed in blocking buffer (5% normal goat serum, 
2.5% BSA, 0.2% Triton-X, in 1x PBS) for 30m at RT. Incubation in a 1:500 
dilution of mouse anti-GAD 67 primary antibody (MAB5406; Millipore, 
Billerica, MA, USA) diluted in blocking buffer, for 48 hours at 4°C, followed. 
Next, sections were washed four times in PBS and incubated in a 1:500 dilution 
of Alexa Fluor 568 goat anti-mouse IgG (H+L) (A-21206; Invitrogen, Grand 
Island, NY), diluted in blocking buffer, for two hours at RT, followed by a second 
round of four washes. Finally, sections were mounted on slides, left to air dry, and 
coverslipped using anti-fading mounting medium (Vectashield, Vector Labs, 
Burlingame, CA, USA). Control procedures were run excluding primary and 
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secondary antibodies. Exclusion of the primary antibody resulted in no cell 
staining, and exclusion of secondary antibody resulted in a lack of fluorescent 
development. 
One experimenter, blind to treatment group status of the animals, 
performed all image analysis procedures. Images were acquired using Olympus 
DP70 digital camera fitted on an Olympus BX-50 microscope using DP-BSW 
Software (version 2.02, Olympus America Inc., Center Valley, CA). A 10X 
objective was used to capture representative images, bilaterally, from the CA1, 
CA3, and DG of the hippocampus. Captured images were manually counted using 
the Cell Counter plugin under NIH ImageJ software (Rasband, 1997–2004) in 
three sections of the dorsal hippocampus of five animals per treatment group, 
similarly to procedures used previously in our laboratory (Acosta et al., 2009). A 
cell was included as positive for GAD labeling if the interior was greater than 
75% filled with a pixel intensity darker than the background.  
Immunohistochemistry and Quantification of Cox-2 
Frontal cortex sections in the anterior block of brains (Plates 9 – 17; 
Paxinos and Watson, 1998) were washed twice (all Cox-2 washes = 5m) in PBS 
then incubated in 0.2% H2O2 diluted in PBS for 15 m at RT. Next, sections were 
washed twice and placed in blocking buffer (1% BSA, 0.2% Triton-X in 1x PBS) 
for 30m at RT. Incubation in a 1:250 dilution of rabbit anti-Cox-2 primary 
antibody (ab15191; Abcam Inc., Cambridge, MA, USA) diluted in blocking 
buffer, for two hours at RT, followed. Next, sections were washed three times for 
in PBS and incubated in a 1:500 dilution of biotin-conjugated goat anti-rabbit 
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(111-065-003; Jackson Immuno Research, West Grove), diluted in blocking 
buffer, for one hour at RT, followed by a second round of three washes. Finally, 
sections were treated with ABC reagent (Vector Laboratories, Burlingame, CA) 
and incubated for 45m at RT. Sections were washed three times in PBS, and then 
incubated with DAB Peroxidase Substrate (Vector). After the desired color was 
achieved (dark purple) brain sections were washed three times in PBS, mounted 
on slides, dehydrated, and coverslipped. Control procedures were run excluding 
primary and secondary antibodies. Exclusion of the primary antibody resulted in 
no cell staining, and exclusion of secondary antibody resulted in a lack of DAB 
Peroxidase Substrate color development.  
One experimenter, blind to treatment group status of the animals, 
performed all image analysis procedures. Images were acquired using an 
Olympus DP70 digital camera fitted on an Olympus BX-50 microscope using DP-
BSW Software (version 2.02, Olympus America Inc., Center Valley, CA). A 4X 
objective was used to capture images. Captured images were manually counted 
using the Cell Counter plugin under NIH ImageJ software (Rasband, 1997–2004), 
bilaterally, in 12 sections of the frontal cortex of 4-5 animals per treatment group, 
similarly to procedures used previously in our laboratory (Acosta et al., 2009). A 
cell was included as positive for Cox-2 labeling if the interior of the cell had a 
pixel intensity of four standard deviations greater than the mean pixel intensity of 
the region of interest, as other protocols have done (Parent, Vexler, Gong, 
Derugin, & Ferriero, 2002). 
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Statistical Analyses  
For behavior assessments, data were analyzed separately for each maze. 
To evaluate learning and potentially complex higher order Treatment interactions 
with Days or Trials, we utilized an omnibus repeated measures ANOVA 
including all groups, with Treatment as the between variable and blocks of Days 
and/or Trials as the within variable/s. For uterine weights, GAD cell counts, and 
Cox-2 cell counts, Treatment effects were assessed via ANOVA. When ANOVA 
yielded a significant effect of Treatment, two group comparisons using t-tests 
were used to investigate group differences. For all analyses, alpha was two-tailed 
and set at 0.05.  
Results 
Water Radial-Arm Maze 
Learning 
Across all testing days (Days 1-14), and including all treatment groups, 
there was a day main effect for each error type for the omnibus ANOVA [WMC: 
F(13, 429) = 5.828; p < .0001 (Figure 23a); WMI: F(13, 429) = 11.638; p < .0001 
(Figure 23c); RM: F(13, 429) = 12.839; p < .0001 (data not shown)], with errors 
decreasing across days, demonstrating learning.  
Treatment Effects 
To evaluate Treatment effects and interactions, days 1-14 were blocked 
into 2-3 day blocks. We traditionally block data into two large blocks (e.g. 
Bimonte & Denenberg, 1999); however, for the current study we further divided 
blocks to provide a finer tuning of when effects occur, based on our prior 
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progesterone data showing effects on learning (Bimonte-Nelson et al., 2004b; 
Braden et al., 2010, Chapter 2). For WMC errors, there was a significant omnibus 
ANOVA main effect of Treatment [F(3, 33) = 2.955; p < .05], and a Treatment x 
Trial interaction [F(6, 66) = 4.092; p < .005] for Block 3 (Days 6-8). For Block 3, 
the Ovx+Prog+Bic group committed fewer errors than all other treatment groups 
[Ovx+Vehicle vs. Ovx+Prog+Bic : t(17) = 2.222; p < .05; Ovx+Prog vs. 
Ovx+Prog+Bic: t(16) = 3.061; p < .01; Ovx+Bic vs. Ovx+Prog+Bic: t(16) = 
2.125; p < .05 (Figure 23a)], demonstrating a working memory enhancement of 
the combination of progesterone and bicuculline. On Trial 4 alone, at the highest 
working memory load, there was a main effect of Treatment [F(3, 33) = 5.367; p 
< .005] with Ovx+Prog animals committing more errors than Ovx+Vehicle [t(17) 
= 2.186; p < .05 (Figure 23b)]. Interestingly, Ovx+Prog animals also committed 
more errors than Ovx+Prog+Bic [t(16) = 3.146; p < .01] animals, demonstrating 
that the progesterone-induced working memory impairment is reversed by the 
addition of bicuculline (Figure 23b). Ovx+Bic animals also committed more 
errors than Ovx+Vehicle [t(17) = 2.399; p < .05] and Ovx+Prog+Bic [t(16) = 
3.528; p < .005] animals on Trial 4 during Block 3, demonstrating a bicuculline-
induced working memory impairment that is reversed by progesterone (Figure 
23b). For WMI errors, there was also a significant omnibus ANOVA main effect 
of Treatment [F(3, 33) = 4.007; p < .05] and Treatment x Trial interaction [F(9, 
99) = 3.096; p < .005] for Block 3. For Block 3, the Ovx+Prog group committed 
more errors than all other treatment groups [Ovx+Prog vs. Ovx+Vehicle: t(17) = 
2.364; p < .05; Ovx+Prog vs. Ovx+Prog+Bic: t(16) = 2.21; p < .05; Ovx+Prog vs. 
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Ovx+Bic: t(16) = 2.878; p < .05 (Figure 23c)]. In Block 3, there was a main effect 
of treatment at the highest working memory load (Trial 4) [F(3, 33) = 4.117; p < 
.05], where the same pattern was evident, with the Ovx+Prog group committing 
more errors than all other treatment groups [Ovx+Prog vs. Ovx+Vehicle: t(17) = 
2.386; p < .05; Ovx+Prog vs. Ovx+Prog+Bic: t(16) = 2.734; p < .01; Ovx+Prog 
vs. Ovx+Bic: t(16) = 2.561; p < .05 (Figure 23d)]. These WMI effects further 
demonstrate a progesterone-induced working memory impairment that is reversed 
by the addition of bicuculline. There were no significant effects for RM errors 
during any block.  
Delay 
 After regular testing, a 6 hour delay was administered between trials 2 and 
3. For WMC errors, we compared baseline performance on Trial 3 (Day 14, last 
day of regular testing) to Trial 3 immediately after the delay on Day 15, within 
each group. The Ovx+Prog group was the only group to significantly increase 
errors after the delay [Ovx+Prog: t(8) = 3.162; p < .05], demonstrating a 
susceptibility to delay-induced working memory impairments in progesterone-
treated animals (Figure 24). The progesterone-induced impairment was obviated 
with the addition of bicuculline [Ovx+Prog+Bic: t(8) = .634; p = .54]. No group 
displayed a delay-induced increase in WMI or RM errors.  
Morris Maze 
Learning 
 For the omnibus ANOVA including all treatment groups, there was a Day 
main effect for Distance and Latency [Distance: F(2, 66) = 259.666; p < .0001 
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(Figure 25a); Latency: F(2, 66) = 138.796; p < .0001 (data not shown)], with 
scores decreasing across days, demonstrating learning of the task.  
Treatment Effects 
 Trials were blocked into three trial blocks, as done previously (Talboom et 
al., 2010). For Block 5, there was a main effect of Treatment [F(3, 33) = 2.903; p 
< .05]. Ovx+Prog+Bic animals swam a shorter distance to the platform than 
Ovx+Vehicle animals for block 5 [t(17) = 2.448; p < .05], demonstrating a 
reference memory enhancement induced by the combination of progesterone and 
bicuculline (Figure 25a). 
Probe 
The probe trial revealed a main effect of Quadrant [F(1, 33) = 182.603; p 
< .0001] and no main effect of, or interactions with, Treatment. Each group spent 
a greater percent Distance in the target NE quadrant as compared to the opposite 
SW quadrant, showing localization of the platform location for all groups 
[Ovx+Vehicle: t(9) = 4.861; p < .001; Ovx+Prog: t(8) = 7.997; p < .0001; 
Ovx+Bic: t(8) = 10.783; p < .0001; Ovx+Prog+Bic: t(8) = 5.782; p < .0005 
(Figure 25b)]. 
Visible Platform 
There was a Trial main effect [F(5, 165) = 16.642; p < .0001 (Figure 26)], 
with Latency decreasing across all trials, demonstrating learning of the task. The 
omnibus ANOVA effect for Treatment was not significant for latency to the 
visible platform. By the fourth trial, all groups found the VP within 9s, confirming 
visual and motor competence to perform swim maze tasks for all groups.  
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Vaginal Smears  
Twelve and 13 days after Ovx, vaginal smears were taken and classified as 
proestrus, estrous, metestrus or diestrous, per prior protocol (Acosta et al., 2009; 
Goldman et al., 2007). As expected, all animals, regardless of treatment, showed 
leukocytic smears, indicative of the diestrous phase.  
Uterine Weights 
The omnibus ANOVA effect of treatment was not significant for uterine 
weight, and there were no significant uterine weight effects for each prog and/or 
bic group as compared to Vehicle. (Table 6). 
Frontal Cortex Cox-2 Cell Counts 
The omnibus ANOVA effect of treatment was not significant for frontal 
cortex Cox-2 cell counts, and there were no significant Cox-2 cell count effects 
for each prog and/or bic group as compared to Vehicle. (Table 7). 
Hippocampal GAD Cell Counts 
The Treatment effect for the omnibus ANOVA for GAD cells counts was 
not significant for CA1, CA3, or DG. Within each region there were no 
significant effects for each prog and/or bic treated group compared to Vehicle 
(Table 7). 
Discussion 
Natural progesterone is a clinically used component of HT, and a 
promising new candidate to replace MPA as the most commonly used 
progestogen component in HT (Sherwin & Grigorova, 2011; Langer, 1999). We 
have previously shown that both progesterone and MPA impair memory in the 
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menopausal rat model (Bimonte-Nelson et al., 2004b; Braden et al., 2010, 2011, 
Chapters 2 & 3), and the results from this study further support our previous 
findings. Herein, progesterone treatment impaired working memory performance 
and exacerbated a delay-induced impairment on the WRAM. This study intended 
to evaluate the mechanism by which progesterone impairs memory, in the 
menopausal rat model, building on previous research that progesterone’s 
metabolites interact with the GABAergic system acting as positive allosteric 
modulators (Lan & Gee, 1994). Thus, we hypothesized that progesterone-
mediated cognitive impairments may be initiated via pro-GABAergic actions, and 
that concomitant treatment with the GABAA receptor antagonist, bicuculline, 
would block these impairments. We found that both the progesterone impairment 
on working memory performance and delay retention, as evaluated by the 
WRAM, were reversed by the addition of bicuculline. Further, the combination of 
Prog+Bic enhanced working and reference memory performance on the WRAM 
and MM, with respect to vehicle, indicating a synergistic effect of these two 
compounds for memory enhancement.  
We have previously shown that both long-term (two months) progesterone 
and MPA treatment in aged Ovx rats decreased protein levels of CA1/2 
hippocampal GAD (Braden et al., 2010, Chapter 2); in the current study, we 
aimed to determine if short-term (2 weeks) progesterone treatment affects number 
of GABA-producing cells in the hippocampus. Neither progesterone nor 
bicuculline treatment alone, nor the combination together, had an effect on any of 
the hippocampal regions that were quantified (CA1, CA3, DG). In accordance 
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with our findings, others have also found progesterone to alter GAD mRNA 
levels in the CA1, but not number of GABA-producing cells (Weiland et al., 
1992). Moreover, progesterone has been shown to decrease mRNA levels of the 
α4 subunit of the GABAA receptor in the CA1 and increase γ2 mRNA (Pazol et 
al., 2009; Weiland & Orchinik, 1995). Thus, the mechanism of progesterone-
induced memory impairments, and bicuculline reversal, may simply be changes in 
GAD protein levels (Braden et al., 2010, Chapter 2) or mRNA (Wallis & Luttge, 
1980), or alterations in GABAA receptor subunit expression.  
It is noteworthy that, behaviorally, bicuculline completely reversed the 
memory-impairing effects of progesterone and synergized with this hormone to 
enhance memory. Presumably, progesterone and bicuculline have opposing 
actions on the GABAergic system, with progesterone metabolites acting as 
positive allosteric modulators (Lan & Gee, 1994) and bicuculline acting as an 
antagonist (Brickley, Cull-Candy, & Farrant, 1996). Other steroid hormones that 
can exert memory enhancing effects, specifically 17β-estradiol, have been shown 
to act on the GABAergic system in the hippocampus in order to increase the 
dynamic range of the hippocampus, as a mechanism of cognitive enhancement 
(Rudick & Woolley, 2001). Increasing the dynamic range of the hippocampus, 
and thus expanding the potential of this systems response to synaptic input and 
memory formation, may also be the mechanism by which the combination of 
progesterone and bicuculline enhances cognition. Future investigations are 
warranted to further elucidate this mechanism. 
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Based on prior research in cerebrovascular insult models, we hypothesized 
that another potential mechanism of progesterone-induced memory impairments 
is the modulation of Cox-2, a key enzyme in the formation of prostaglandins in 
the inflammatory response (Breder et al., 1995). However, in our study, 
progesterone or bicuculline, alone or together, had no effect on number of Cox-2 
positive cells in the frontal cortex. Previous research testing progesterone after 
cortical contusion or LPS insult shows mixed results, with one study finding that 
progesterone decreased Cox-2 expression in the frontal cortex after cortical 
contusion (Cutler et al., 2007), while another found a progesterone-induced 
increased of Cox-2 in cerebral blood vessels following LPS insult (Sunday et al., 
2006). These findings support the possibility that progesterone does not 
exacerbate neuronal inflammation in an animal without an experimental traumatic 
incident. Indeed, to our knowledge this is first examination of the effects of 
progesterone on a marker of neuronal inflammation in an animal that did not 
undergo a model of physiological trauma, unlike Cutler et al. (2007) and Sunday 
et al. (2006).  
In conclusion, we determined that, 1) short-term progesterone treatment 
impairs working memory performance and exacerbates a delay-induced 
impairment on the WRAM, 2) progesterone impairments are reversed by 
concomitant treatment with the GABAA receptor antagonist, bicuculline, 3) 
compared to vehicle treated animals, the combination of progesterone and 
bicuculline enhances working and reference memory performance on the WRAM 
and MM. Future investigations should aim to elucidate the mechanism of short-
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term progesterone-induced memory impairments, with initial investigations 
looking at changes in the subunits of the GABAA receptor. This work will be 
integral to the mechanistic understanding of progestogen-induced cognitive 
impairments in order to one day determine safe progestogen use for combination 
birth control and HT prescribed to women.   
Chapter 5b 
The GABAA antagonist bicuculline does not attenuate medroxyprogesterone 
acetate-induced memory-impairments but reverses changes in number of 
GABA-producing cells in the hippocampus and Cox-2 positive cells in the 
frontal cortex. 
Nearly every woman will face the decision of whether to take exogenous 
hormones, either for contraception or for HT, and those with a uterus must 
include a progestogen to their regimen (Smith et al., 1975). Medroxyprogesterone 
acetate (MPA) is the most commonly used progestogen component of HT, and it 
is the sole hormone component of the contraceptive Depo Provera. In 
postmenopausal women, MPA may be a key factor that lead to an increased risk 
of dementia in the WHIMS trials, as a significant increase was observed after 
combination HT treatment including MPA, but not with conjugated equine 
estrogen-only HT treatment (Shumaker et al., 2003; 2004). Further, a documented 
case study linked use of MPA in Depo Provera with amnesia (Gabriel & Fahim, 
2005). In the rat model, we and others have shown that MPA alone (Braden et al., 
2010; 2011, Chapters 2 & 3), or in combination with 17β-estradiol (Lowry et al., 
2010), induces cognitive impairments. Finally, in vitro MPA exacerbates neuronal 
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death by glutamate-induced excitotoxicity (Nilsen, Morales, & Brinton, 2006), 
reduces 17β-estradiol-mediated neural protection against excitotoxicity (Nilsen & 
Brinton, 2002b), and completely blocks the glutamate-stimulated calcium increase 
produced by 17 β-estradiol, a positive mechanism by which estrogens may 
modulate cognitive functioning (Nilsen & Brinton, 2002a). 
A potential mechanism for MPA-induced memory impairments in the 
rodent model is the GABAergic system. Indeed, we have shown that in Ovx rats 
who had demonstrated MPA-induced cognitive impairments, MPA also impacted 
the GABAergic system in cognitive brain regions (Braden et al., 2010, Chapter 2). 
However, it remains to be determined, through direct pharmacological 
manipulation, whether the GABAergic system is indeed a mechanism underlying 
MPA’s effects on cognition during aging in the Ovx rat. Evidence suggests that 
MPA increases GABAA stimulation in the hippocampus, in turn resulting in an 
increase of inhibition of the hippocampus, compared to control treatment (Belelli 
& Herd, 2003), which may be the mechanism of MPA’s detrimental effects on 
cognition. We propose to address the question of whether MPA’s effects on 
memory are, in part, due to GABAA modulation, by administering the GABAA 
receptor antagonist bicuculline to MPA-treated animals. We hypothesize that 
bicuculline administration will prevent MPA’s negative effects on cognition. In 
this study, we also aim to determine if in vivo treatment with MPA and/or 
bicuculline alters the number GABA-producing cells in the hippocampus. We 
predict that the number of GABA-producing cells will be down regulated by 
MPA treatment, similarly to the protein changes observed in Braden et al. (2010, 
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Chapter 2), and that this will be reversed by concomitant treatment with 
bicuculline, mirroring the expected behavioral outcomes.  
Additionally, MPA has been shown to modulate Cox-2, a key enzyme in 
the formation of prostaglandins in the inflammatory response (Breder et al., 1995) 
that is induced in glutamate excitotoxicity (Tocco et al., 1997). We aim to 
determine in this study if in vivo treatment with MPA and/or bicuculline alters 
Cox-2 positive cells in the frontal cortex. Only one study has examined the link 
between MPA and Cox-2; findings in Ovx rats showed an MPA-induced 
exacerbation of Cox-2 expression in cerebral blood vessels following LPS-
induced inflammation (Sunday et al., 2006). This suggests that MPA may have 
neuroinflammatory-producing properties that may be related to cognitive 
impairments. Indeed, MPA does not improve cognitive performance in young 
rodent models of cortical contusion (Wright et al., 2008), while natural 
progesterone does (Roof et al., 1994). Thus, in the current experiment, we predict 
that MPA treatment will increase the number of Cox-2-positive cells, relative to 
vehicle treatment, in the frontal cortex, a brain region important for working 
memory (Jones, 2002). The frontal cortex is also a brain area where natural 
progesterone has been shown to modulate Cox-2 protein levels after cortical 
contusion (Cutler et al., 2007). By answering the question of the mechanism by 
which MPA impairs cognition in the female rodent, we can move forward to 
identify progestogens that do not share these pharmacological characteristics, and 
may represent safer alternatives for inclusion in birth control and HTs.  
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Methods 
Subjects  
Subjects were 38, 13 month old Fischer-344 female rats born and reared at 
the aging colony of the National Institute on Aging at Harlan Laboratories 
(Indianapolis, IN). Rats were acclimated for several weeks before surgery, had 
access to food and water ad-lib, and were maintained on a 12-hour light/dark 
cycle at the Arizona State University animal facility. All procedures were 
approved by the local IACUC committee and adhered to NIH standards. 
Hormone Treatment and Ovariectomy 
Rats were randomly assigned to one of four treatment groups: 
Ovx+Vehicle, Ovx+MPA, Ovx+Bicuculline (Ovx+Bic), or Ovx+MPA+Bic. 
These are the same Ovx+Vehicle and Ovx+Bic animals used in Study 4a. 
Identical to Study 3b (Chapter 4), at 13 months of age all rats were anesthetized 
via isofluorane inhalation, underwent bilateral dorsolateral incisions in the skin 
and peritoneum, and the ovaries and tips of uterine horns were ligatured and 
removed. Muscle and skin were then sutured. Two days after surgery all drugs 
were administered via two daily subcutaneous injections in the scruff of the neck. 
In the first injection, animals received either a control vehicle solution (0.4mL 
sesame oil + 0.02mL dimethyl sulfoxide [DMSO], both from Sigma-Aldrich, St. 
Louis, MO, USA) or MPA (0.7 mg, Sigma-Aldrich, St. Louis, MO, USA; 
dissolved in 0.4mL sesame oil + 0.02mL DMSO), and for the second injection, 
animals received either a control vehicle solution (sesame oil + 10% DMSO) or 
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bicuculline (3.5mg/kg; dissolved in sesame oil + 10% DMSO). Injections 
continued throughout behavior testing until sacrifice.  
Vaginal Smears and Uterine Weights 
 Vaginal smears were taken 12 and 13 days after Ovx, and classified as 
proestrus, estrous, metestrus or diestrous per prior protocol (Acosta et al. 2009; 
Goldman et al. 2007). At sacrifice, the uteri of all subjects was removed, trimmed 
of visible fat, and immediately weighed (wet weight), in order to examine drug 
effects on uterine tissues (Braden et al., 2010, 2011, Chapters 2 & 3). 
Water Radial-Arm Maze  
Thirteen days after initiation of injections, subjects began testing on the 
WRAM for 15 days to evaluate spatial working and reference memory, including 
performance as working memory load increased, as described previously 
(Bimonte & Denenberg, 2000; Bimonte et al., 2000, 2002). The maze contained 
escape platforms hidden under the water surface in the ends of 4 of the 8 arms. 
Each subject had different platform locations that remained fixed throughout the 
experiment. A subject was released from the start arm and had three minutes (m) 
to locate a platform. Once a platform was found, the animal remained on it for 15 
seconds (s), and was then returned to its heated cage for a 30s inter-trial interval 
(ITI) until its next trial. During the interval, the just-chosen platform was removed 
from the maze. The animal was then placed again into the start alley and allowed 
to locate another platform. For each animal a daily session consisted of four trials, 
with the number of platformed arms reduced by one on each subsequent trial. 
Thus, the working memory system was increasingly taxed as trials progressed, 
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allowing us to access working memory load. Each subject was given one session a 
day for 14 consecutive days. On Day 15, a 6 hour delay was administered 
between Trials 2 and 3 as in Experiments 3a and 3b (Chapter 4). 
Quantification and blocking for analyses were based on prior studies 
(Bimonte & Denenberg, 2000; Bimonte et al., 2000, 2002;Hyde et al., 1998, 
2000). An arm entry was counted when the tip of a rat’s snout reached a mark 
delineated on the outside of the arm (11 cm into the arm). Errors were quantified 
using the orthogonal measures of working and reference memory errors (Jarrard 
et al., 1984), as done previously in WRAM studies (Bimonte et al., 2000, 2002; 
Hyde et al., 2000). Working Memory Correct (WMC) errors were the number of 
first and repeat entries into any arm from which a platform had been removed 
during that session. Trial 1 is not analyzed for WMC errors because no platform 
has yet been removed. Reference memory (RM) errors were the number of first 
entries into any arm that never contained a platform. Working Memory Incorrect 
(WMI) errors were repeat entries into a RM arm.  
Morris Maze  
The day after WRAM completion, subjects began testing on the MM for 6 
trials/day for 3 days using a tub (188 cm diameter) filled with black water made 
opaque using non-toxic paint. A hidden platform (10 cm wide) remained in a 
fixed location, thereby testing spatial reference memory (Bimonte-Nelson et al., 
2006; Morris et al., 1982). The rat was placed in the maze from the North, South, 
East, or West location, and had 60s to locate the hidden platform, which remained 
in the Northeast quadrant throughout testing. Once the rat found the platform the 
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trial was terminated. After 15s platform time, the rat was placed into its heated 
cage until its next trial. The approximate ITI was 10-15m. To evaluate whether 
rats localized the platform to the spatial location, after all test trials on day 3, a 
60s probe trial was given whereby the platform was removed. For each trial, a 
camera suspended above the maze tracked each rat’s path and a tracking system 
(Ethovision 3.1, Noldus Instruments) analyzed each rat’s tracing. 
MM performance was assessed by swim path distance (cm) and latency (s) 
to the platform. For probe trial data, percent of total distance in the previously 
platformed (target) quadrant was compared to the quadrant diagonally opposite 
the platform. Rats that learned the platform location were expected to spend the 
greatest percent distance in the target quadrant (Stavnezer et al., 2002). 
Visible Platform Maze 
 To confirm that all subjects had intact vision and could perform the 
procedural task components of MM and WRAM spatial navigation without 
difficulty, subjects were tested on a VP water-escape task. A rectangular tub (39 x 
23 in) was filled with clear water and a black platform (10 cm wide) was elevated 
above the water surface. Opaque curtains covered extramaze cues. The drop off 
location remained the same across trials, and the platform location for each trial 
varied in space semi-randomly. Animals had to locate the protruding platform, 
and were given 6 trials in one day. Performance was assessed by latency (s) to the 
platform.  
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Tissue Preparation 
After the conclusion of behavioral testing, rats were anesthetized with 
isofluorane. Brains were removed, blocked anterior to the hippocampus, and post-
fixed in PFA for 48 hours. After 48 hours the brains were moved to PB and stored 
at 4 °C. Two days prior to sectioning, brains were placed in a 30% sucrose 
solution for 48 hours. Brains were coronally sectioned at 40 µm on a cryostat 
(Microtome HM 500 OM Cryostat) at -20 °C, and free floating sections were 
collected for immunohistochemistry.  
Immunohistochemistry and Quantification of GAD 67 
Dorsal hippocampal sections in the posterior block of brains (Plates 33 – 
37; Paxinos & Watson, 1998) were washed three times for 5m each in PBS, then 
incubated in 1% H2O2 diluted in PBS for 30m at room temperature (RT). Next, 
sections were washed three times (all GAD 67 washes = 10m for the remainder of 
staining) and placed in blocking buffer (5% normal goat serum, 2.5% BSA, 0.2% 
Triton-X, in 1x PBS) for 30m at RT. Incubation in a 1:500 dilution of mouse anti-
GAD 67 primary antibody (MAB5406; Millipore, Billerica, MA, USA) diluted in 
blocking buffer, for 48 hours at 4°C, followed. Next, sections were washed four 
times in PBS and incubated in a 1:500 dilution of Alexa Fluor 568 goat anti-
mouse IgG (H+L) (A-21206; Invitrogen, Grand Island, NY), diluted in blocking 
buffer, for two hours at RT, followed by a second round of four washes. Finally, 
sections were mounted on slides, left to air dry, and coverslipped using anti-
fading mounting medium (Vectashield, Vector Labs, Burlingame, CA, USA). 
Control procedures were run excluding primary and secondary antibodies. 
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Exclusion of the primary antibody resulted in no cell staining, and exclusion of 
secondary antibody resulted in a lack of fluorescent development. 
One experimenter, blind to treatment group status of the animals, 
performed all image analysis procedures. Images were acquired using Olympus 
DP70 digital camera fitted on an Olympus BX-50 microscope using DP-BSW 
Software (version 2.02, Olympus America Inc., Center Valley, CA). A 10X 
objective was used to capture representative images bilaterally from the CA1, 
CA3, and DG of the hippocampus. Captured images were manually counted using 
the Cell Counter plugin under NIH ImageJ software (Rasband, 1997–2004) in 
three sections of the dorsal hippocampus of five animals per treatment group, 
similarly to procedures used previously in our laboratory (Acosta et al., 2009). A 
cell was included as positive for GAD labeling if the interior was greater than 
75% filled with a pixel intensity darker than the background.  
Immunohistochemistry and Quantification of Cox-2 
Frontal cortex sections in the anterior block of brains (Plates 9 – 17; 
Paxinos and Watson, 1998) were washed twice (all Cox-2 washes = 5m) in PBS 
then incubated in 0.2% H2O2 diluted in PBS for 15m at RT. Next, sections were 
washed twice and placed in blocking buffer (1% BSA, 0.2% Triton-X in 1x PBS) 
for 30m at RT. Incubation in a 1:250 dilution of rabbit anti-Cox-2 primary 
antibody (ab15191; Abcam Inc., Cambridge, MA, USA) diluted in blocking 
buffer, for two hours at RT, followed. Next, sections were washed three times for 
in PBS and incubated in a 1:500 dilution of biotin-conjugated goat anti-rabbit 
(111-065-003; Jackson Immuno Research, West Grove), diluted in blocking 
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buffer, for one hour at RT, followed by a second round of three washes. Finally, 
sections were treated with ABC reagent (Vector Laboratories, Burlingame, CA) 
and incubated for 45m at RT. Sections were washed three times in PBS, and then 
incubated with DAB Peroxidase Substrate (Vector). After the desired color was 
achieved (dark purple) brain sections were washed three times in PBS, mounted 
on slides, dehydrated, and coverslipped. Control procedures were run excluding 
primary and secondary antibodies. Exclusion of the primary antibody resulted in 
no cell staining, and exclusion of secondary antibody resulted in a lack of DAB 
Peroxidase Substrate color development.  
One experimenter, blind to treatment group status of the animals, 
performed all image analysis procedures. Images were acquired using an 
Olympus DP70 digital camera fitted on an Olympus BX-50 microscope using DP-
BSW Software (version 2.02, Olympus America Inc., Center Valley, CA). A 4X 
objective was used to capture images. Captured images were manually counted 
using the Cell Counter plugin under NIH ImageJ software (Rasband, 1997–2004) 
bilaterally in 12 sections of the frontal cortex of 4-5 animals per treatment group, 
similar to procedures used previously in our laboratory (Acosta et al., 2009). A 
cell was included as positive for Cox-2 labeling if the interior of the cell had a 
pixel intensity of four standard deviations greater than the mean pixel intensity of 
the region of interest, as other protocols have done (e.g. Parent et al., 2002).  
Statistical Analyses  
For behavior assessments, data were analyzed separately for each maze. 
To evaluate learning and potentially complex higher order Treatment interactions 
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with Days or Trials, we utilized an omnibus repeated measures ANOVA 
including all groups, with Treatment as the between variable and blocks of Days 
and/or Trials as the within variable/s. For GAD cell counts, Cox-2 cell counts, and 
uterine weights, Treatment effects were assessed via ANOVA. When ANOVA 
yielded a significant effect of Treatment, two group comparisons using t-tests 
were used to investigate group differences. For all analyses, alpha was two-tailed 
and set at 0.05.  
Results 
Water Radial-Arm Maze 
Learning 
Across all testing days (Days 1-14), and including all treatment groups, 
there was a day main effect for each error type for the omnibus ANOVA [WMC: 
F(13, 442) = 7.909; p < .0001 (Figure 27a); WMI: F(13, 442) = 11.502; p < .0001 
(Figure 27b); RM: F(13, 442) = 12.432; p < .0001 (Figure 27c)], with errors 
decreasing across days, demonstrating learning.  
Treatment Effects 
 For RM errors, there was a significant omnibus ANOVA main effect of 
Treatment [F(3, 34) = 3.717; p < .05] for Block 2 (Days 3-5), with 
Ovx+MPA+Bic animals committing more errors than Ovx+Vehicle [t(17) = 
2.947; p < .01] and Ovx+MPA [t(17) = 2.64; p < .05] animals, demonstrating a 
reference memory impairment induced by the combination of MPA and 
bicuculline (Figure 27c). There were no significant effects for WMC or WMI 
errors during any block. 
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Delay 
 After regular testing, a 6 hour delay was administered between trials 2 and 
3. We compared baseline performance on Trial 3 (Day 14, last day of regular 
testing) to Trial 3 immediately after the delay on Day 15, within each group. The 
Ovx+MPA and Ovx+MPA+Bic groups were the only groups to significantly 
increase WMC errors after the delay [Ovx+MPA: t(9) = 3; p < .05: 
Ovx+MPA+Bic: t(8) = 2.828; p < .05], demonstrating a susceptibility to delay-
induced working memory impairments in MPA-treated animals that is not 
reversed by bicuculline (Figure 28). Ovx+Vehicle and Ovx+Bic animals were not 
impaired on WMC errors with the delay, and no group displayed a delay-induced 
increase in WMI or RM errors.  
Morris Maze 
Learning 
 For the omnibus ANOVA including all treatment groups, there was a Day 
main effect for Distance and Latency [Distance: F(2, 68) = 143.064; p < .0001 
(Figure 29a); Latency: F(2, 68) = 184.2; p < .0001 (data not shown)], with scores 
decreasing across days, demonstrating learning of the task.  
Treatment Effects 
  For Block 6, there was a main effect of Treatment [F(3, 34) = 3.062; p < 
.05]. Ovx+MPA+Bic animals swam a longer distance to the platform as compared 
to Ovx+Vehicle [t(17) = 2.345; p < .05] and Ovx+Bic [t(16) = 2.737; p < .05] 
animals on Block 6, demonstrating a reference memory impairment induced by 
the combination of MPA and bicuculline (Figure 29a). 
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Probe 
The probe trial revealed a main effect of Quadrant [F(1, 34) = 108.254; p 
< .0001] and no main effect of, or interactions with, Treatment. Each group spent 
a greater percent Distance in the target NE quadrant as compared to the opposite 
SW quadrant, showing localization of the platform for all groups [Ovx+Vehicle: 
t(9) = 4.861; p < .001; Ovx+MPA: t(9) = 3.462; p < .01; Ovx+Bic: t(8) = 10.783; 
p < .0001; Ovx+MPA+Bic: t(8) = 4.984; p < .005 (Figure 29b)]. 
Visible Platform 
There was a Trial main effect [F(5, 170) = 19.951; p < .0001 (Figure 30)], 
with Latency decreasing across all trials, demonstrating learning of the task. The 
omnibus ANOVA for Treatment was not significant for latency to the visible 
platform. By the fourth trial, all groups found the VP within 9s, confirming visual 
and motor competence to perform swim maze tasks for all groups.  
Vaginal Smears  
Twelve and 13 days after Ovx, vaginal smears were taken and classified as 
proestrus, estrous, metestrus or diestrous per prior protocol (Acosta et al., 2009; 
Goldman et al., 2007). As expected, all animals, regardless of treatment, showed 
leukocytic smears, indicative of the diestrous phase.  
Uterine Weights 
There was a significant omnibus ANOVA effect of Treatment [F(3, 34) = 
15.398; p < .0001]. Similar to our prior findings (Braden et al. 2010; 2011, 
Chapters 2 & 3), animals treated with MPA had heavier uteri than vehicle animals 
[Ovx+Vehicle vs. Ovx+MPA: t(18) = 5.529; p < .0001], and this was not reversed 
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by the addition of bicuculline [Ovx+Vehicle vs. Ovx+MPA+Bic: t(17) = 6.486; p 
< .0001] (Table 8).  
Frontal Cortex Cox-2 Cell Counts 
 There was a significant omnibus ANOVA main effect of Treatment [F(3, 
15) = 22.311; p < .0001]. Ovx+MPA animals had more cells labeled positive for 
Cox-2 in the frontal cortex than every other treatment group [Ovx+MPA vs. 
Ovx+Vehicle: t(8) = 23.717; p < .005; Ovx+MPA vs. Ovx+MPA+Bic: t(8) = 
25.35; p < .005; Ovx+MPA vs. Ovx+Bic: t(7) = 20.815; p < .005 (Figure 31a)], 
indicating that MPA administration induced an increase in number of Cox-2 cells 
in the frontal cortex, and that this was reversed by concomitant bicuculline 
treatment. There were no significant differences between any other groups. 
Hippocampal GAD Cell Counts 
 There was a significant omnibus ANOVA main effect of Treatment in the 
CA1 for number of cells labeled positive for GAD [F(3, 16) = 3.602; p < .05]. 
Ovx+MPA animals had more cells labeled positive for GAD in the CA1 region of 
the hippocampus than Vehicle [t(8) = 2.416; p < .05] and Ovx+MPA+Bic [t(8) = 
2.595; p < .05 (Figure 32a)] animals, indicating that this MPA-induced increase in 
CA1 GAD is reversed by bicuculline. Ovx+Bic animals did not differ 
significantly from any group, and there were no significant effects of Treatment 
for CA3 or DG (Table 9).  
Discussion 
The synthetic progestin, MPA, is the most commonly used progestogen 
component of HT and the sole hormone component in the contraceptive Depo 
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Provera. We have previously shown that MPA impairs memory in the surgically 
menopausal rat model (Braden et al., 2010, 2011, Chapters 2 & 3). The results 
from this study support our previous behavioral findings; however, it is 
noteworthy that the impairing effects of MPA in the current report were observed 
on only one memory measure, where previously we have seen impairments on 
multiple memory measures, after MPA treatment (Braden et al., 2010, 2011, 
Chapters 2 & 3). In the current study, MPA treatment exacerbated a delay-
induced memory-retention impairment on the WRAM. The goal of this study was 
to evaluate a plausible mechanism by which MPA impairs memory, using the 
rationale that previous research has shown that MPA interacts with the 
GABAergic system, enhancing GABAA receptor-mediated inhibition (Belelli & 
Herd, 2003). We hypothesized that MPA-mediated cognitive impairments were 
associated with pro-GABAergic actions, and that concomitant treatment with the 
GABAA receptor antagonist, bicuculline, would block these impairments. Our 
hypothesis was not supported; we found that the MPA delay-induced retention 
impairment on the WRAM was not reversed by the addition of bicuculline. 
Further, the combination of MPA and bicuculline impaired reference memory 
performance on the WRAM and MM, indicating an unexpected synergistic effect 
of these two compounds for memory impairment. 
We have previously shown that long-term MPA treatment (two months) in 
aged Ovx rats decreased protein levels of GAD in the CA1/2 hippocampal region 
(Braden et al., 2010, Chapter 2). In the current study, we aimed to determine if 
MPA treatment affects the number of GABA-producing cells in the hippocampus. 
  122 
Results showed that MPA treatment increased number of GAD-positive cells, and 
thus the number of GABA-producing cells, in the CA1 of the hippocampus, 
compared to vehicle treatment, an effect reversed by the addition of the GABAA 
antagonist, bicuculline. The MPA effect observed herein is in the opposite 
direction of our previous finding, showing that MPA treatment resulted in a 
decrease of GAD protein levels in the CA1/2 hippocampal region (Braden et al., 
2010, Chapter 2). In cultured hippocampal neurons, others have found that a 
change in number of GAD-positive cells is mirrored by a change in GAD protein 
levels, demonstrating a direct correlation in the two GABAergic measures 
(Murphy, Cole, Greenberger, & Segal, 1998). A critical difference between our 
current and past studies that could have resulted in the different effects observed 
on the GABAergic system, is the amount of time MPA was given. In our first 
investigation, MPA treatment of a longer duration (two months), resulted in a 
decrease of hippocampal GABAergic markers (Braden et al., 2010, Chapter 2), 
and in our current investigation, a shorter duration of MPA treatment (two weeks) 
resulted in an increase of hippocampal GABAergic markers. Interestingly, 17β-
estradiol treatment has also been associated with divergent effects on 
hippocampal GABAergic markers at different time points after treatment (Rudick 
& Woolley, 2001). Specifically, in young Ovx rats, 17β-estradiol initially (24 
hours after treatment) decreases number of hippocampal GABA-producing cells; 
and 48 hours after treatment, 17β-estradiol increases number of hippocampal 
GABA-producing cells, compared to vehicle (Rudick & Woolley, 2001).  
Although our MPA investigations are measuring GABAergic makers after longer 
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treatment durations (two weeks versus two months) than the work with 17β-
estradiol (24 hours versus 48 hours), it seems that as time progresses, MPA 
treatment may induce an inverse of GABAergic effects on the hippocampus 
compared to the effects induced by 17β-estradiol treatment. Explicitly, 17β-
estradiol initially decreases and later increases hippocampal GABAergic markers 
(Rudick & Woolley, 2001), while MPA initially increases and later decreases 
hippocampal GABAergic markers (current data and Braden et al., 2010, Chapter 
2). MPA has been shown to have opposite effects to 17β-estradiol on the 
hippocampal glutamatergic system as well. Specifically, MPA treatment 
exacerbates NMDA-induced excitotoxic cell death while 17β-estradiol protects 
against it (Nilsen et al., 2006). Thus, MPA may exert inverse effects on the 
hippocampal GABAergic and glutamatergic systems as compared to 17β-
estradiol, and this may be related to the cognitive enhancing properties of 17β-
estradiol in rodents and women (Frick, 2009; Maki & Sundermann, 2009) and the 
cognitive impairing properties of MPA, alone or in combination with estrogens, in 
rodents and women (Braden et al., 2010, 2011, Chapters 2 & 3; Lowery et al., 
2010; Maki & Sundermann, 209).  
We hypothesized that another potential mechanism of MPA-induced 
memory impairments is the modulation of Cox-2, a key enzyme in the formation 
of prostaglandins in the inflammatory response (Breder et al., 1995) that is 
induced in glutamate excitotoxicity (Tocco et al., 1997).  This hypothesis was 
supported, as we found that MPA treatment increased number of Cox-2 positive 
cells in the frontal cortex, compared to vehicle. Notably, bicuculline reversed this 
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MPA-induced increase. MPA’s effects on Cox-2  have only been investigated in 
one previous study, and consistent with our findings, MPA-induced an 
exacerbation of Cox-2 expression in cerebral blood vessels of Ovx rats, following 
LPS inflammatory insult (Sunday et al., 2006). Our results are also consistent 
with in vitro work, showing that MPA exacerbates glutamate-induced excitotoxic 
cell death (Nilsen et al., 2006), and are the first evidence that, in vivo, MPA may 
be damaging to neurons independent of experimentally-induced insult.  
In reconciling behavioral outcomes with our previous research, as well as 
changes in neurochemical markers observed in this study, we encountered some 
unexpected findings that will require follow-up investigations. First, in the current 
study MPA treatment did not impair cognition on multiple measures of learning 
and memory, as we have previously shown (Braden et al., 2010, 2011, Chapters 2 
& 3). This is most likely due to differences in treatment duration. For this study, 
MPA was given approximately two weeks prior to test, versus two months before 
test in Braden et al., (2010, 2011, Chapters 2 & 3) where we showed potent MPA-
induced cognitive detriments on multiple maze tasks. This suggests that longer 
MPA treatment durations are associated with greater cognitive impairments, and 
future investigations are warranted to methodically test this hypothesis. Results 
from this study also suggests that an MPA-induced increase in GABA-producing 
cells in the CA1 of the hippocampus, or Cox-2 positive cells in the frontal cortex, 
as we found herein, does not necessarily lead to robust memory changes. Further, 
bicuculline did not attenuate MPA-induced memory impairments, but completely 
blocked GAD and Cox-2 changes, suggesting that reversal of an MPA-induced 
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increase in GABA-producing cells in the CA1 of the hippocampus or Cox-2 
positive cells in the frontal cortex may not be the mechanism of bicuculline’s 
reversal of the MPA-induced memory retention impairment. Finally, the 
combination of MPA and bicuculline, two compounds presumable having 
opposing actions on the GABAergic system (Belelli & Herd, 2003; Brickley et 
al., 1996) synergized to impair memory in middle-aged Ovx animals, with respect 
to vehicle. Future investigations are warranted to further elucidate the memory-
impairing mechanisms of MPA, and MPA in combination with bicuculline, in the 
surgically menopausal rodent model.  
The results from the current study indicate that, in middle-aged Ovx rats: 
1) short-term MPA treatment exacerbates a delay-induced impairment on the 
WRAM, increases number of GABA-producing cells in the CA1 of the 
hippocampus, and increases Cox-2 positive cells in the frontal cortex, 2) 
bicuculline treatment reverses MPA-induced increases in GAD and Cox-2-positve 
cells, but does not prevent delay-induced memory impairments, 3) the 
combination of MPA and bicuculline impairs reference memory performance on 
the WRAM and MM. Future investigations should aim to elucidate the timeline of 
MPA changes on cognition and the GABAergic system. We now have evidence 
showing that 1) two weeks of MPA treatment in middle-aged Ovx rats induces a 
modest memory impairments and an increase in the number of GABA-producing 
cells in the hippocampus (current report) and 2) two months of MPA treatment in 
middle-aged or aged rats induces robust memory impairments and decreases 
levels of GAD protein in the hippocampus (Braden et al., 2010, 2011, Chapters 2 
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& 3). Future studies are needed to investigate the effects of MPA treatment at 
multiple time points in between two weeks and two months (i.e. four weeks and 
six weeks) on cognition and GABAergic markers. Further, measuring these 
GABAergic markers (number of GABA-producing cells and GAD protein levels) 
in the hippocampi of the same rats, will allow direct evaluation of the correlation 
between these two measures, in the surgically menopausal rat model. This 
information will add to the understanding of whether or not it is possible to have 
an MPA-induced up-regulation in number of GABA-producing cells concomitant 
with a down-regulation of GAD protein levels. Continuing this work in 
behaviorally tested animals will allow researchers to relate MPA-induced 
GABAergic changes with changes in cognition. Specifically, we need to 
understand the MPA-induced GABAergic milieu (number of GABA-producing 
cells and GAD protein levels) of the hippocampus that is present at the onset of 
robust memory impairments, in the aging Ovx rat model.  This work will be 
integral to the mechanistic understanding of MPA-induced cognitive impairments 
in order to one day determine safe progestin use for combination birth control and 
HT prescribed to women.   
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CHAPTER 6 
HIPPOCAMPAL AND ENTORHINAL CORTEX VOLUMES OF POST-
MENOPAUSAL WOMEN ARE MODULATED BY HORMONE THERAPY 
STATUS: CORRELATIONS WITH AGE AND COGNITIVE MEASURES  
Menopause-induced hormone loss has been linked to many symptoms that 
affect quality of life in women including hot flashes, urogenital atrophy, and 
memory decline (Freedman, 2002; Nappi et al., 1999; Sherwin, 1988). HT is 
given to menopausal and post-menopausal women to attenuate menopause-
induced symptoms and clinical studies have demonstrated that estrogen-
containing HT can prevent (Sherwin, 1988; Phillips & Sherwin, 1992) or improve 
memory decline in healthy women (Campbell & Whitehead, 1977; Duka et al., 
2000; Joffe et al., 2006; Linzmayer et al., 2001; Maki & Sundermann, 2009; 
Phillips & Sherwin, 1992; Wolf et al., 1999), Further, AD is more prevalent in 
women than men (Anderson et al., 1999), and there is some evidence to suggest 
that a loss of ovarian hormones at menopause puts women at a greater risk 
(Solerte et al., 1999). Indeed, a history of estrogen-containing HT can reduce AD 
risk (Zandi et al., 2002), and as a treatment, estrogen can enhance cognition in 
post-menopausal women with AD (Asthana et al., 1997) 
Over the last decade, the cognitive effectiveness of HT has been of much 
debate, due to the unexpected findings of the large, placebo-controlled, 
randomized WHIMS conducted by the National Institute of Health. Post-
menopausal women taking Conjugated Equine Estrogens (CEE) alone did not 
differ significantly from those taking placebo for dementia diagnoses (Shumaker 
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et al., 2004). In contrast, twice as many women receiving CEE + MPA were 
diagnosed with dementia as compared to the placebo group, a significant effect 
(Shumaker et al., 2003). Recently, Maki and Sundermann (2009) conducted a 
systematic review of randomized clinical trials of hormone therapy’s effects on 
verbal memory, decline in which is the earliest predictor of AD. Findings 
indicated that there is a beneficial effect associated with estrogen-only HT on 
verbal memory in younger menopausal women and a detrimental effect of 
CEE+MPA on verbal memory in menopausal women (Maki and Sundermann, 
2009). This review brings back into question the complex role estrogen-
containing HT plays in normal cognitive aging, and risk of AD, in women.   
Loss of hippocampal volume is another hallmark brain change seen in AD 
progression (Buckner et al., 2005; Scahill et al., 2002) and is related to cognitive 
functioning in AD patients (Jack et al., 1999; 2000). A subset of women who 
participated in the WHIMS underwent a follow-up MRI regional volume study, 
including evaluation of the hippocampus, 1.4 - 3 years after the completion of the 
WHIMS trial (Resnick et al., 2009). Results were consistent with findings 
showing HT-associated changes in dementia risk, and specifically CEE treatment 
alone, lead to no significant changes in hippocampal volumes compared to 
placebo (p=.18); however, in women receiving CEE+MPA, there was a 
marginally significant effect (p=.09), with HT-treated women having smaller 
hippocampi than placebo (Resnick et al., 2009). Just as findings from the WHIMS 
dementia assessment are in disagreement with many other trials measuring the 
cognitive impact of estrogen-containing HT, so are findings from the follow-up 
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volumetric study. Eberling et al. (2003) reported that estrogen-containing HT was 
associated with no hippocampal volume loss in a mix of healthy and demented 
women. Further, Yue et al. (2007) found that in women at genetic risk for 
developing AD, a history of HT was associated with larger hippocampal volumes, 
as compared to women at the same genetic risk that had not used HT.  
Much effort has been put into reconciling the negative WHIMS findings 
of HT-associated dementia risk and hippocampal volume loss, with positive 
effects on both measures associated with HT use demonstrated in other studies. 
Several hypotheses have emerged, including the critical window hypothesis, that 
HT initiation at or near the time of menopause is related to cognitive benefits, 
while delayed initiation is not (Khoo et al., 2009; Maki, 2006; Sherwin, 2005).  
The critical window hypothesis seems to also be important for determining 
whether HT is associated with a protection of hippocampal volume. A longer 
interval between menopause and HT initiation is associated with smaller 
hippocampal volumes, while participants initiating HT at time of menopause 
seem to have larger hippocampal volumes than never users (Erickson et al., 
2010). Further, current versus past HT use seems to differentially affect 
hippocampal volume size, but the literature is mixed, with some showing largest 
volumes of middle temporal gyrus structures in current users (Lord et a., 2008) 
and others in past users (Boccardi et al., 2006). Still other research has shown no 
differences in hippocampal volumes correlated with current or past HT use (Low 
et al., 2006), or a decrease in overall gray matter associated with HT (Greenberg 
et al., 2006), in line with findings from the WHIMS.  
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The entorhinal cortex is a brain structure heavily implicated in AD 
(Hyman et al., 1984; Braak and Braak, 1991) and cognitive performance, 
including memory, (Fernandez et al., 1999), but much less studied for 
responsiveness to HT-induced atrophy protection. The entorhinal cortex was 
evaluated in a voxel based morphometry study by Boccardi et al. (2006), where 
HT use was associated with larger entorhinal cortex volumes, as compared to 
non-users. More research evaluation of the effects of HT on preserving entorhinal 
cortex volumes, in addition to hippocampal volumes, may add to the 
understanding of divergent findings within the field of HT and cognitive aging.  
The overarching aim of this study was to further investigate the 
relationship between HT, mesial temporal lobe structure volumes (hippocampus 
and entorhinal cortex), and cognition. Post-menopausal women were recruited, 
divided into three HT groups based on continuous, discontinuous, and never use, 
and underwent a cognitive battery and MRI scans to determine regional volumes 
of the hippocampus and entorhinal cortex. We hypothesized that HT use would be 
associated with favorable outcomes for cognitive measures and hippocampal and 
entorhinal cortex volumes, as opposed to never using HT. Further, based on the 
findings of Boccardi et al., (2006) we hypothesized that within HT use, the 
greatest benefits for hippocampal and entorhinal cortex volumes would be seen 
with discontinuous use, as compared to continuously or never using HT. We 
hypothesized that this distinction would transfer into cognition as well, with 
discontinuous users outperforming continuous and never users. This prediction 
was based on the relationship between hippocampal volumes and memory 
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performance (Jack et al., 2000) and findings relating past, but not current, HT use 
with a decrease in dementia risk (Zandi et al., 2002). Finally, it is well known that 
mesial temporal lobe volumes and cognitive performance undergo age-related 
decline. We aimed to indirectly determine if prior HT use prevents age-related 
decline in these variables, by investigating correlations between age and volumes 
and/or cognitive scores, within HT groups. We hypothesized that in continuous or 
discontinuous HT groups age would not correlate with mesial temporal lobe 
volumes and cognitive performance 
Methods 
Participants 
Participants were recruited from three participating institutions of the 
Arizona Alzheimer’s Consortium; Barrow Neurological Institute, Sun Health 
Research Institute, and Mayo Clinic-Arizona. All participants provided written 
consent which was approved by the individual institutions’ Internal Review 
Boards. The data included participants from several separate imaging studies on 
aging performed at Barrow Neurological Institute from 2000-2007, all of which 
include cognitive assessments and MRI structural scans.  There were 50 
postmenopausal women. General inclusion criteria for study participants were: 1) 
Age 50 or greater; 2) No clinical diagnosis of Mild Cognitive Impairment or 
dementia from the treating neurologist and Mini Mental State Exam (MMSE) 
score of 26 or greater, in order to exclude those participants with significant 
cognitive impairment; and 3) No evidence of depression as measured by either the 
Geriatric Depression Scale (GDS) or Beck Depression Inventory-II (BDI). 
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Post-menopausal was defined as one year or more since the final menstrual 
period.  Detailed histories of endogenous and exogenous estrogen exposure were 
gathered from all participants and included age at menopause, history of partial or 
complete hysterectomy, years on and type of HT (estrogen and/or progesterone 
use), and age at which HT was initiated and terminated. Participants were divided 
into three groups based on lifetime estrogen exposure; continuous users (CU), 
discontinuous users (DU), and never-users (NU). CU (n = 16) were women who 
began HT at menopause and had consistently taken HT since therapy initiation.  
DU (n = 22) had used HT for varying periods of time during their postmenopausal 
years (minimum of 1 year of use), but their use was not continuous.  NU (n = 12) 
had never taken HT, or if they did, the period of time did not exceed six-months 
(n = 2).   
Image Acquisition 
All participants underwent imaging on a 1.5- or 3-tesla GE scanner at 
Barrow Neurological Institute. Images of the whole brain were collected using an 
axial SPGR (spoiled gradient) T1-weighted, 3-dimensional acquisition with the 
following parameters: TR (repetition time) = 24 ms, TE (echo time) = 6 ms, flip 
angle= 40 degrees, NEX (number of excitations) = 1, slice thickness = 1.9 mm, 0 
skip between slices, Field of view = 240 mm, in plane resolution =.9375 square 
mm voxels. 
Volumetric Data 
Hippocampal and entorhinal cortex volumes were manually traced. The 
outlines of the hippocampus and entorhinal cortex were traced from the three-
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dimensional SPGR images using ANALYZE (version 7.5). Both structures were 
visualized in all three planes, landmarked in the sagittal plane, and drawn in the 
coronal plane. We employed the guidelines of Machulda et al. (2001) to define 
the hippocampal boundaries. The anterior boundary was defined by observing the 
white matter band and/or the cerebrospinal fluid space between the amygdala and 
hippocampus in the sagittal plane. The posterior aspect of the posterior region was 
initially landmarked in the sagittal plane by locating the posterior edge of the 
hippocampus and then checking in the coronal plane to ensure that the fornices 
were completely visualized.  
We employed the guidelines of Insausti et al (1998) to define the 
entorhinal cortex boundaries. In the sagittal plane, the most anterior portion of the 
entorhinal cortex was marked where the uncus transformed into the gyrus 
ambiens. At this area in the coronal plane, the superior border of the entorhinal 
cortex was the gyrus ambiens and the inferior border was the collateral sulcus. In 
the posterior portion of the entorhinal cortex the hippocampal fissure was used as 
the superior border. Finally, the crus cerebri was landmarked in the sagittal plane 
and served as the most posterior area of the entorhinal cortex. For hippocampal 
and entorhinal cortex size, values are presented as % of total intracranial volume 
(TIV). Total intracranial volume was generated using Statistical Parametric 
Mapping (SPM8; http://www.fil.ion.ucl.ac.uk/spm/) 
Cognitive Assessment 
Participants were administered either the California Verbal Learning Test 
(CVLT-II) or the Rey Auditory Verbal Learning Test (RAVLT), which are both 
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auditory learning and memory tasks consisting of a supraspan word list that is 
repeated 5 times for a total word recall learning measure as well as a free recall 
trial 20-30 minutes later to assess delayed, or retained memory (Delis, Freeland, 
Kramer, & Kaplan, 1988; Rey, A., 1964).  Participants were also administered the 
Trail Making Test (TMT) parts A and B (‘TrailsA and TrailsB”), which are 
measures of psychomotor speed and executive functioning, respectively (Reitan 
and Wolfson, 1985).   
Statistical Analyses 
Memory performance was expressed as percentage of the maximum 
possible (Total Words (words learned over 5 trials): 80 for the CVLT and 75 for 
the RAVLT; Delayed Memory: 16 for the CVLT and 15 for the RAVLT). 
ANOVA was run to assess group differences on control demographic variables 
(age, years of education, years since menopause, and MMSE) and TIV. Two 
group planned comparisons using t-test were run to evaluate group differences on 
measures of interest. Specifically, planned comparisons included: 1) CU vs. NU, 
2) DU vs. NU, and 3) CU vs. DU on the dependent measures: 1) Left 
hippocampal volume, 2) Right hippocampal volume, 3) Left entorhinal cortex 
volume, 4) Right entorhinal cortex volume, 5) Total Words, 6) Delayed memory, 
7) TrailsA and, 8) TrailsB. Significance was defined as a p value less than 0.05; a 
p value between 0.05 and 0.10 was deemed a marginal effect. For all planned 
comparisons, it was noted that type I error correction is not necessary (Keppel & 
Wickens, 2004).  
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Intragroup correlations using Pearson’s r coefficient were run between age 
and 1) Left hippocampal volume, 2) Right hippocampal volume, 3) Left 
entorhinal cortex volume, 4) Right entorhinal cortex volume, 5) Total Words, 6) 
Delayed memory, 7) TrailsA and, 8) TrailsB.  Correlations were also run between 
each volume (1. Left hippocampal volume, 2. Right hippocampal volume, 3. Left 
entorhinal cortex volume, 4. Right entorhinal cortex volume) and cognitive scores 
(1. Total Words, 2. Delayed memory, 3. TrailsA and, 4. TrailsB). Due to multiple 
comparisons, significance for correlations was defined as a p value less than 0.01, 
similar to Braden et al., (2011, Chapter 3) and a p value less than 0.05 was 
deemed a trend. 
Results 
Demographics 
 There were no group differences on age [F(2, 47)=0.852; p=0.433], years 
of education [F(2, 47)=0.117; p=0.890], or postmenopause length of time [F(2, 
47)=0.647; p=0.528]. The age range of participants was 53 – 91 years. Groups 
also did not differ on MMSE scores [F(2, 47)=1.263; p=0.292]. Participants were 
either Caucasian (90%) or Latino (10%) and 70% had undergone hysterectomy 
(Table 10). Of the women who had used HT, 76.3% had a known history of 
taking unopposed estrogens only (CU: 81.3%; DU: 72.7; Table 10). 
Volumetric Data 
Total Intracranial Volume (TIV) 
 There was no difference between groups for TIV [F(2, 47)=0.509; 
p=0.604 (Table 11)]. 
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Hippocampal Volumes 
For both hippocampi (left and right), DU had significantly larger volumes 
than NU [Left: t(32)=2.74; p=0.01 (Figure 33a); Right: t(32)=2.39; p=0.023 
(Figure 33b)]. For the right hippocampus only, CU had marginally larger volumes 
than NU [t(26)=1.80; p=0.082 (Figure 33b)]. CU did not differ from NU on left 
hippocampal volumes [t(26)=1.01; ns] and DU did not differ from CU on either 
hippocampal volume [Left: t(36)=1.34; ns; Right: t(36)=0.25; ns] (Table 11).     
Entorhinal Cortex Volumes 
For the right entorhinal cortex, CU had significantly larger volumes than 
NU [t(26)=2.12; p=0.044 (Figure 33d)] and DU had marginally larger volumes 
than NU [t(32)=1.95; p=0.06 (Figure 33d)]. For the left entorhinal cortex, CU had 
marginally larger volumes than NU [t(26)=2.02; p=0.054 (Figure 33c)] and DU 
did not differ from NU [t(32)=1.23; ns]. DU did not differ from CU on either 
entorhinal cortex volume [Left: t(36)=1.20; ns; Right: t(36)=0.54; ns] (Table II).  
Cognitive Assessment 
For Delayed Memory, DU remembered a marginally higher percentage of 
words than NU [t(32)=1.95; p=0.06 (Figure 34)] and CU did not differ from either 
group[CU vs. DU: t(36)=1.10; ns; CU vs. NU: t(26)=1.02; ns]. No group 
differences were observed for Total Words or for Trails A or B tests (Table 12).  
Correlations  
Continuous Users 
 Figure 35 depicts the relationships between brain volume measures, 
cognitive performance, and age for the CU group. Both the left and right 
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hippocampi were negatively correlated with age [Left: r(16)=−0.623, p=0.0084; 
Right: r(16)=−0.621, p=0.0088 (Figure 35)], indicating a decrease in bilateral 
hippocampal volume as age increases. There were no significant correlations 
between hippocampal volume and cognitive scores for CU. Further, age did not 
significantly correlate with cognitive scores or entorhinal cortex volumes, and 
entorhinal cortex volumes did not correlate with cognitive scores (data not 
shown). 
Discontinuous Users 
 Figure 36 depicts the relationships between brain volume measures, 
cognitive performance, and age for the DU group. Age negatively correlated with 
Total Words [r(20)=−0.542, p=0.0082 (Figure 36)] and there was a trend for a 
negative correlation between age and Delayed Memory [r(20)=−0.499, p=0.017 
(Figure 36)], indicating lower cognitive scores as age increases. Right 
hippocampal volumes also showed a trend towards positively correlating with 
Delayed Memory [r(20)=0.479, p=0.023 (Figure 36)], indicating an association 
between larger right hippocampi and better scores on delayed memory 
performance. Age and hippocampal volumes did not significantly correlate and 
Trails A and B and entorhinal cortex volumes did not correlate with each other or 
any other measure (data not shown). 
Never Users 
 Figure 37 depicts the relationships between brain volume measures, 
cognitive performance, and age for the NU group. Age negatively correlated with 
Total Words [r(10)=−0.749, p=0.0036 (Figure 37)], Delayed Memory 
  138 
[r(10)=−0.731, p=0.0052 (Figure 37)], and right hippocampal volume 
[r(10)=−0.714, p=0.0073 (Figure 37)], indicating an association between an 
increase in age with a decline in memory scores and hippocampal volumes. Age 
positively correlated with Trails A [r(10)=0.763, p=0.0046 (Figure 37)] and Trails 
B [r(10)=0.793, p=0.0023 (Figure 37)] speed, indicating an association between 
an increase in age and an increase in processing speed and executive functioning. 
Hippocampal volumes did not correlate with cognitive scores, and entorhinal 
cortex volumes did not correlate with any other measure (data not shown). 
Discussion 
This study investigated the effects of prior HT use on mesial temporal lobe 
structure volumes (hippocampus and entorhinal cortex), and cognition. HT status 
as continuous, discontinuous, or never use differentially impacted hippocampal 
and entorhinal cortical volumes. For hippocampal volumes, discontinuous HT use 
was associated with the most favorable outcome. Indeed, discontinuous HT users 
demonstrated a bilateral preservation of hippocampal volumes as compared to 
women who never used HT. Continuous HT appeared to be less protective than 
discontinuous HT, with continuous HT users showing only a marginal 
hippocampal volume protection as compared to never users for the right 
hippocampus only. These findings are in accordance with others who have shown 
positive effects of estrogen-containing HT on hippocampal volumes in 
menopausal women (Eberling et al., 2003; Yue et al., 2007; Erickson et al., 2010; 
Lord et al., 2008; Boccardi et al., 2006). Further, our disparate findings between 
continuous and discontinuous users align with a voxel-based morphometry study 
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by Boccardi et al. (2006), detailing that past HT use is associated with greater 
volumes of gray matter, including the hippocampal complex, than current HT use.  
Conversely to hippocampal results, for entorhinal cortex volumes, 
continuous HT use was associated with the most favorable outcome. Continuous 
users had significantly larger right and marginally larger left entorhinal cortex 
volumes, as compared to never users. Discontinuous HT use demonstrated no 
protection of entorhinal cortex volume loss, as compared to never users, but also 
did not differ from continuous users. Again, our findings are in accordance with 
Boccardi et al. (2006) who found that when grouping past and current HT users 
together, HT protected against entorhinal cortex volume loss as compared to non-
users, but was not a region that showed greater protection in past users as 
compared to current users. To our knowledge, only one study has previously 
evaluated the ability of estrogen-containing HT to protect against age-related 
reduction in entorhinal cortex volume through manual tracings. Results from this 
longitudinal study are difficult to interpret because at the five year follow-up, 
neither the HT group nor the control group exhibited a significant decrease in 
entorhinal cortex volume (Raz, Rodrigue, Kennedy, & Acker, 2004).  
The volumetric results reported are corrected for TIV as is convention in 
most reports of regional volumetric analyses. Since total intracranial volume is an 
estimate of general brain size, it is interesting that no significant group differences 
were observed on this measure, suggesting that HT did not have a generalized 
effect on brain size in our study.   
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We found HT status to have a modest impact on verbal memory 
performance. There was a marginal benefit to discontinuous HT use compared to 
never using HT, as demonstrated by a higher percentage of words remembered 
after a delay. Continuous HT use did not demonstrate the same modest delayed 
memory performance enhancement, as compared to never use, but also did not 
differ from discontinuous HT user’s performance. These findings are in 
accordance with others showing that past, but not current, HT use protects against 
a longitudinal MMSE decline (Matthews, Cauley, Yaffe, & Zmuda, 1999) and an 
increased risk of dementia (Zandi et al., 2002). In our study, psychomotor speed 
and executive functioning, as measured by the TrailsA and TrailsB, did not seem 
to be affected by HT status, which is in accordance with other findings as well 
(Etnier & Sibley, 2004; Pefanco et al., 2007).  
Our sample size precluded formal analyses of complex interactions of HT, 
cognition, and brain volumes; however, we performed separate correlation 
analyses by group to visualize possible differences in the expected age-related 
declines in both brain structure volumes and cognition.  These correlations 
revealed that HT status appears to modulate the relationship between age, 
hippocampal volumes, and cognition. Specifically, women who had never used 
HT showed the expected age-related decline in hippocampal volume and 
cognition as measured by verbal memory, psychomotor speed (TrailsA), and 
executive function (TrailsB). HT use on any timeframe (continuous or 
discontinuous) showed differential effects on the relationship between age and 
either hippocampal volumes or cognitive measures. In continuous users, age was 
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negatively correlated with bilateral hippocampal volume, but there was no 
significant age-related decline on any cognitive measure. This suggests that 
continuously using HT alters the age-related decline in cognitive performance, 
but, remarkably, not hippocampal volume loss. In discontinuous users, age-related 
decline was observed for verbal memory performance, but did not show a 
significant relationship with hippocampal volumes. This suggests that a history of 
HT use produces some protection against the expected age-related declines in 
hippocampal volume but did not protect against a decline in verbal memory 
performance with age. Interestingly, the discontinuous HT users were also the 
only group to demonstrate a relationship, albeit modest, between hippocampal 
volume and memory performance, which may indicate that discontinuous HT use 
could have a biological effect to more strongly relate hippocampal volume with 
verbal memory performance. This is particularly noteworthy since discontinuous 
HT use was associated with the most favorable outcomes on both hippocampal 
volume and verbal memory performance. Future studies are warranted to 
elucidate the differential roles, and potentially mechanisms by which, continuous 
and discontinuous HT use ameliorates age-related declines in hippocampal 
volumes and cognitive performance.   
Entorhinal cortex volumes showed no correlation in any group with age or 
cognitive measures. The lack of correlation with age is not surprising since others 
have also demonstrated a decline in hippocampal volumes with age, but not in 
entorhinal cortex volumes (Knoops, Gerritsen, van der Graaf, Mali, & Geerlings, 
2012). Entorhinal cortex volumes did not correlate with cognitive measures in any 
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group. Further, although continuous HT use was associated with the largest 
benefit in entorhinal cortex volume, this group did not demonstrate a cognitive 
enhancement, relative to never users, on any measure. Instead, the only cognitive 
benefits seen herein were related to discontinuous HT use, the group that also 
showed the most benefit in hippocampal volumes. Studies in humans (Fell, 
Klaver, Elger, & Fernandez, 2002) and animals (Ferreira et al., 1992) suggest that 
the hippocampus and entorhinal cortex have different roles in memory formation 
based on encoding phase. Perhaps the tasks used in this study are not sensitive to 
the cognitive enhancements associated with larger entorhinal cortex volumes. 
Future research is warranted to elucidate the functional consequences of larger 
entorhinal cortex volumes in continuous versus never HT users. 
Our sample size precluded us from obtaining statistical power to evaluate 
two other factors that are important to consider, which are content of HT and 
hysterectomy. Collective findings from the WHIMS suggests that women who 
had undergone hysterectomy and received HT containing CEE only did not show 
the HT-associated detriments in dementia risk and brain volumes (Shumaker et 
al., 2003; Resnick et al., 2009). Women who had not undergone hysterectomy, 
and were thus assigned to receive CEE+MPA, did exhibit HT-associated 
detriments in dementia risk and brain volumes (Shumaker et al., 2004; Resnick et 
al., 2009). It is possible that the less favorable outcomes on delayed memory and 
hippocampal and entorhinal cortex volumes seen in the never users in our study, 
are a result of fewer incidents of hysterectomy in this group, versus both 
continuous and discontinuous users. Indeed, animal models of transitional 
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menopause demonstrate detrimental effects associated with the retention of the 
follicular deplete ovary (Acosta, Mayer, Talboom, Tsang, et al., 2009). 
Additionally, our HT population in this study primarily consisted of women who 
had a history of using estrogens without progestogens. This may partially explain 
why our study showed HT-related benefits for brain volumes and cognition 
contrary to the WHIMS CEE+MPA trial (Shumaker et al. 2003; Resnick et al., 
2009). Moreover, the review by Maki and Sundermann (2009), showing 
beneficial effects associated with estrogen-only HT, but detrimental effects of 
CEE+MPA, on verbal memory in menopausal women, further support this 
hypothesis. Future studies with larger sample sizes are warranted to determine the 
contributions hysterectomy and content of HT have on brain volumes and 
cognition in postmenopausal women. 
In conclusion, HT use is associated with larger volumes of mesial 
temporal structures, with greater benefits observed for hippocampal volume with 
discontinuous HT use and greater benefits for entorhinal cortex with continuous 
HT use, both as compared to no HT use. Discontinuous HT use was associated 
with a modest verbal memory advantage that was also positively correlated with 
hippocampal volume. Finally, continuous and discontinuous HT use differentially 
modulated age-related decline in hippocampal volumes and cognitive 
performance. Thus, here, we provide further evidence that HT treatment in 
menopausal women can have favorable outcomes on the preservation of mesial 
temporal structure volumes and cognitive performance. Future investigations are 
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warranted to further elucidate the parameters under which HT can ameliorate the 
symptoms of menopause and benefit cognitive aging in women. 
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CHAPTER 7 
BROAD-BASED NUTRITIONAL SUPPLEMENTATION IN 3XTG MICE 
CORRECTS MITOCHONDRIAL FUNCTION AND INDICATES SEX-
SPECIFICITY IN RESPONSE TO ALZHEIMER'S INTERVENTION  
Alzheimer’s disease (AD) is a neurodegenerative condition that is the 
most prevalent cause of dementia in the elderly. Due to shifting demographics, it 
is projected that the number of AD cases worldwide will increase dramatically 
during the first half of the 21st century (Ferri et al., 2005). While study of early-
onset AD has uncovered genetic mutations that modulate production of the 
betaamyloid (Aβ) protein thought to be key in the disease, the vast majority 
(>98%) of AD cases are late-onset and idiopathic. Because of the limited 
knowledge of the underlying cellular and molecular causes of late-onset AD, 
detailed examination of risk factors is essential fordeveloping a stronger 
understanding of the pathogenic process. Based on the existence of dozens of 
epidemiological studies demonstrating that nutrition is an important factor in 
susceptibility to AD (Morris et al., 2009), several ongoing or recently completed 
human trials have investigated the neuroprotective capacities of many different 
nutrients (Kamphuis et al., 2010). In addition to these human trials, the wide-
availability of AD rodent models has allowed for multiple experimental studies, 
with a significant body of work supporting the role of nutrients in modulating 
disease-related cognitive decline and pathology: blueberry supplementation can 
avert both cognitive decline and deficits in signal transduction (Joseph et al., 
2003), curcumin demonstrates an ability to prevent cognitive decline (Yang et al., 
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2005), green tea can slow cognitive decline through multiple mechanisms (Lee et 
al., 2009), and both cinnamon extracts (Frydman-Marom et al., 2011) and grape 
polyphenol extracts (Wang et al., 2008), can inhibit Aβ oligomerization and 
cognitive decline. Additionally, omega-3 fatty acids can reduce Aβ burden (Green 
et al., 2007; Grimm et al., 2011; Lim et al., 2005; Oksman et al., 2006), improve 
cognition (Arsenault, Julien, Tremblay, & Calon, 2011), and protect from 
dendritic pathology (Calon et al., 2004; Green et al., 2007). Medical food 
“cocktails” can reverse cognitive decline and attenuate soluble Aβ pathology 
(Parachikova, Green, Hendrix, & LaFerla, 2010), and the nutritional supplement 
S-adenosyl methionine has recently been shown to be effective in delaying tau or 
Aβ pathology in 3xTG mice (Lee, Lemere, Frost, & Shea, 2012) and may have 
wide-ranging effects on amyloid levels, tau phosphorylation, and DNA 
methylation (Fuso & Scarpa, 2011).  
Whereas, until recently, most studies of dietary intervention in animal 
models largely have been focused on examining the effects of a single nutrient, 
the Memory Preservation Nutrition Supplement Program (MPNSP) used here 
combines three separate broad-based supplements: a phyto-nutrient powder, high-
quality fish oil, and an amalgam of herbs and spices based on an evidence-based 
integrated whole foods program, Memory Preservation Nutrition (Emmerson 
Lombardo et al., 2005). The MPNSP was designed to delay the onset and slow the 
progression of AD in humans by providing broad-based nutritional 
supplementation targeting multiple organs and pathways. In this study, we 
administered this supplementation regimen to the 3xTG mouse, which is the first 
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transgenic mouse harboring the PS1M146V, APPSwe, and tauP301L transgenes, 
and therefore recapitulates several hallmarks of AD, including concomitant 
plaque and tangle formation in AD vulnerable regions (Oddo et al., 2003). The 
dietary cocktail was chosen for the possibility that multiple nutrients could extend 
and enhance the established successes shown in single nutrient studies due to 
additive and synergistic effects across the multiple nutrients. As a further benefit, 
these products have been demonstrated to be well-tolerated (Capodice et al., 
2009; Freund-Levi et al., 2006) and are considerably less expensive than most 
conventional pharmaceutical treatments. We hypothesized that the MPNSP would 
prevent or reverse the brain regional glucose uptake declines we have shown in a 
variety of murine models of AD (Nicholson et al., 2010; Reiman et al., 2000; 
Valla, Gonzalez-Lima, & Reiman, 2008; Valla, Schneider, & Reiman, 2006). 
 Human fluorodeoxyglucose positron emission tomography (FDG PET) 
studies show that regionspecific alterations in the cerebral metabolic rate for 
glucose (CMRgl) are found in AD, with hypometabolism present in the posterior 
cingulate-precuneus (PCC), parieto-temporal, and prefrontal regions (Minoshima, 
Foster, & Kuhl, 1994; Reiman et al., 1996). Interestingly, decrements in CMRgl 
are localized to these same regions in aged pre-symptomatic homozygotes 
(Reiman et al., 1996) and young-adult carriers (Reiman et al., 2004) of the APOE 
4 allele, the primary genetic risk factor for late-onset AD. We extended these 
findings to demonstrate reduced mitochondrial function, as measured by 
cytochrome c oxidase activity (Complex IV of the electron transport chain), in 
postmortem PCC as well as isolated platelets from living AD patients (Valla, 
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Berndt, & Gonzalez-Lima, 2001; Valla, Schneider, Niedzielko, et al., 2006). 
Further, the same deficiency was measured in platelets from patients with mild 
cognitive impairment (MCI) (Valla et al., 2006), and in the PCC of young-adult 
18-40 yearold) carriers of the APOE 4 allele in the absence of AD histopathology 
(Valla et al., 2010), the latter thus indicating that, along with the CMRgl changes, 
energy metabolism decline may be among the earliest detectable brain changes 
associated with AD risk. This indicates that mitochondrial functional decline, 
measured via cytochrome oxidase (Complex IV), is effective at detecting some of 
the earliest cellular-level changes in AD pathogenesis or vulnerability and is 
therefore an attractive biomarker for use in evaluation of interventions and 
therapeutics, particularly those aimed at preclinical and early-stage AD. Thus, in 
addition to behavioral cognition and brain regional fluorodeoxyglucose uptake, 
we analyzed mitochondrial cytochrome oxidase activity, as well as fibrillar and 
soluble AD pathology and neuroinflammatory markers.  
Methods 
This study was performed under protocols approved by the respective 
Institutional Animal Care and Use Committees at the Barrow Neurological 
Institute, St. Joseph’s Hospital and Medical Center and Arizona State University 
(ASU). 3xTG and wildtype (WT) controls (129/sv x C57BL6) were bred in our 
colony at the Barrow Neurological Institute from founders received from the 
University of California, Irvine. Transgene and diet status were blinded until 
analyses were complete. 3xTG (N=28, 14/condition) and wildtype (N=28, 
14/condition) mice were placed in age- and sex-matched 4-mouse cohorts, with 
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one mouse of each genotype fed supplementation and the other standard diet 
(below). Mice were group housed in Plexiglas shoebox-style cages prior to study 
start and housed in singly or in pairs once supplementation began, with access to 
food (supplemented or standard) and water ad libitum. 
Supplementation 
Dietary supplementation was initiated at an average age of 38 weeks 
(range 29-46 weeks) and continued for 25 weeks, until the mice were euthanized. 
Mice on the supplemented condition were fed LabDiet 5001 (Purina, St. Louis, 
MO) containing the supplemental phyto-nutrient powder, herbal/spice amalgam, 
and cod liver oil integrated into the chow (for respective compositions see Table 
13). Dose calculations were based on the MPNSP-recommended dose to an 80 kg 
human scaled to a 35 g mouse consuming 4 g/day. Mice on the nonsupplemented 
condition were fed LabDiet 9F 5020 (Purina, St. Louis, MO). Daily food 
consumption was monitored for the first three weeks, and mice were weighed 
every third week for the duration of the study. After approximately 18 weeks, all 
mice were transferred from the Barrow Neurological Institute to ASU to undergo 
behavioral testing; they remained at ASU until euthanized. Figure 38 provides a 
flowchart of the experimental protocols. 
Delayed Match to Position Three Choice Task 
Mice were tested on the Delayed Match to Position (DMP) Three Choice 
Task for 6 trials/day for 10 days, evaluating spatial working and short-term 
memory retention. A black Plexiglas maze (each arm was 38.1 cm x 12.7 cm) 
with four open arms, was filled with water made opaque using non-toxic paint, 
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average temperature 17.5°C, and contained one escape platform. The platform 
was moved to a new arm each day, but remained in the same arm within a day. 
Trial 1 was the information trial informing the animal where the platform was for 
that day’s session, trial 2 was the working memory test trial, and trials three 3-6 
were recent memory test trials (Frick, Baxter, Markowska, Olton, & Price, 1995). 
Mice were given 90 s to find the platform. Once located, the animal remained on 
the platform for 15 s. The inter-trial interval (ITI) was 30 s. An arm entry was 
counted when the tip of a mouse’s snout reached a mark 11 cm into the arm. First 
errors were first entries into an arm without a platform, and Repeat errors were 
repeat entries into an arm without a platform. The dependent variables were the 
number of Total errors (First + Repeat errors), First errors, and Repeat errors 
across testing (i.e., days 1-10, trials 2-6) for each treatment group. To investigate 
the effects of learning vs. asymptotic phases of testing, errors were blocked into 
days 1-5 vs. days 6-10. For all measures of regular testing, an omnibus ANOVA 
was run to investigate main effects and interactions. When significant, analyses 
were followed by post hoc t-tests, with the a priori hypothesis that diet condition 
would influence cognitive performance. On day 11, mice were given a delay 
challenge of a 30 min ITI between trials 5 and 6. Planned comparisons to analyze 
effects of the delay were run comparing errors on the baseline day/trial of day 10, 
trial 6 (the last day of regular testing) versus the post delay trial given on day 11, 
trial 6. Effects of p≤0.05 were considered significant. Effects of p < 0.05 were 
considered significant. 
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Morris Maze 
Two days after DMP concluded, each mouse received 4 trials/day for 6 
days using a tub (188 cm diameter) filled with opaque water using non-toxic paint 
(average temperature 17.5°C). The hidden platform (10 cm wide) remained in a 
fixed location, thereby testing spatial reference memory (Bimonte-Nelson et al., 
2006; Morris et al., 1982). Mice were placed in the maze from the North, South, 
East, or West location, and had 60 s to locate the platform in the Northeast 
quadrant. Once the mouse found the platform the trial was terminated and the 
mouse remained there for 15 s. The mouse was then placed into its heated cage 
until its next trial with an approximate ITI of 10m. Performance was assessed by 
swim path distance (cm) and latency (s) to the platform. To evaluate whether mice 
localized the platform to the spatial location, after all test trials on day 6, a 60s 
probe trial was given with the platform removed. Percent of total distance in the 
previously platformed (target) quadrant was compared to the quadrant diagonally 
opposite the platform. For each trial, a camera suspended above the maze tracked 
each mouse’s path and a tracking system (Ethovision 5.1, Noldus Instruments) 
analyzed each mouse’s tracing. Distance and latency across all days of testing and 
percent distance in the target and opposite quadrants during the probe trial were 
analyzed via an omnibus ANOVA to investigate main effects and interactions. 
When significant, analyses were followed by post hoc t-tests. Effects of p < 0.05 
were considered significant. 
 
 
  152 
Tissue Processing  
Each animal was given an i.p. injection of 18 µCi/100 g body weight 
[14C]-fluorodeoxyglucose (FDG; American Radiolabeled Chemicals, St. Louis, 
MO) in sterile saline. During the subsequent 45 min uptake period each animal 
was placed into an empty individual cage in a dark and quiet cabinet. Mice were 
then decapitated, and the brain rapidly extracted and frozen. Brains were stored at 
-20°C until sectioned. 40 µm coronal sections were taken in four series, creating 
three matched slide sets and an aliquot of tissue divided into 3 pools (anterior to 
hippocampal formation, containing hippocampal formation, and posterior to 
hippocampal formation) for each subject. At each level of the series, 4 sections 
were also cut at 20 µm and dried for later immunohistochemistry. FDG 
autoradiography and CO histochemistry and subsequent densitometric imaging 
proceeded as performed previously (Nicholson et al., 2010). 
Image Analysis 
Defined regions-of-interest (ROIs) corresponded to those presented in 
Paxinos & Franklin, (2001), with the exception that the retrosplenial gyrus was 
divided into three defined anteroposterior ROIs to localize any reductions in PCC, 
based on previous work (Nicholson et al., 2010): posterior cingulate 
(approximately bregma –1.4), posterior cingulate level 2 (bregma –2.1), and 
retrosplenial (bregma –2.6). Autoradiographic and histochemical data were 
analyzed independently; based on the behavioral outcomes, sex was included as a 
variable in omnibus 2x2x2 (genotype by supplementation by sex) analyses of 
variance, with α = 0.05. Significant effects were followed by post hoc Student’s t-
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tests at α = 0.05: we did not correct for multiple comparisons but report the 
calculated p values; while this does not minimize Type I errors, the results are 
consistent with our previous analyses. Individual ROI scores showing a 
Studentized residual >3.0 in the ANOVA were deemed to be outliers and 
removed from the final analysis. 
Fibrillar Amyloid & Tau Pathology 
For Thioflavin S staining for amyloid plaques, slides were fixed with 4% 
buffered paraformaldehyde (PFA), rinsed with tap water, rinsed in distilled H2O, 
immersed in 4% thioflavin S in distilled H2O for 5 min, differentiated in 70% 
ethanol, rinsed twice with distilled H2O, and coverslipped with aqueous mounting 
media. Immunohistochemistry for hyperphosphorylated tau (clone AT8) was 
performed on frozen coronal sections. Frozen sections were fixed with 4% PFA, 
blocked with hydrogen peroxide (3% for 5 min) and 3% bovine serum albumin 
(BSA) and 2% goat serum (1 hour), and probed on-slide with an antibody for 
phosphorylated tau (AT8; Pierce) and visualized with diaminobenzidine-
hydrochloride (DAB; Dako LSAB+ System). Assessments of both were 
performed by a single rater, blinded to conditions, on an Olympus BX61 
microscope using a 3-point scale (heavy – moderate - light) in the areas of highest 
deposition/tangle density (hippocampal subiculum, CA1, CA3). 
Brain tissue extract for ELISA and Western blotting 
Ten of the cryostat-cut coronal sections, from each of the 3 levels, were 
homogenized in 200 µl of 50 mM Tris-HCl at pH 8.0, with 1mM EDTA and a 
cocktail of protease and phosphatase inhibitors (Pierce); these were aliquoted and 
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stored until the ELISA. For Aβ ELISA, samples were further extracted with 
guanidine HCl, whereas for glial fibrillar acidic protein (GFAP) and 
synaptophysin ELISA, samples were further extracted in 4 volumes of 5x RIPA 
buffer. 
Aβ ELISA 
Thirty µL of Tris buffer-extracted brain homogenates were extracted 
further with 7M guanidine- HCl to obtain a final concentration of 5M guanidine-
HCl. Extraction was performed at 4oC for 17 hours on shaker. Protein 
concentrations of these samples were determined by MicroBCA assay. ELISA 
kits for human Aβ42 and Aβ40 (Invitrogen) were used according to 
manufacturer’s instructions. For both Aβ42 and Aβ40 ELISA, 1200 ng of protein 
were loaded to each well, and duplicate wells from the same samples were 
assayed and averaged. 
GFAP ELISA 
The GFAP ELISA was developed in-house, using a capture antibody of 
purified anti-GFAP cocktail (BD Biosciences) used at 0.25 µg in 100 µL per well, 
and a detection antibody of rabbit polyclonal anti-GFAP (DAKO) used at 
1:10,000 dilution. Anti-rabbit IgG-conjugated horseradish peroxidase (rabbit IgG-
HRP; Pierce) was used at 1:20,000 dilution. Purified GFAP (Calbiochem) was 
used to manufacture standards to cover a range from 0.156 to 10 ng/mL. Capture 
antibody coating buffer was sterile PBS, pH 7.4. Wash buffer was composed of 
PBS with 0.05% Tween 20 (PBST), pH 7.4. Sample dilution buffer was PBST 
with 1% skim milk while blocking buffer contained 3% skim milk powder. Plates 
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were coated with capture antibody for 18 hours at 4oC, followed by washing 5 
times with wash buffer installed in a plate washer. Plates were blocked for 1 hour 
using blocking buffer at room temperature, followed by washing 5 times. RIPA 
bufferextracted brain samples were loaded at 100 µg per 100 µL per well for 2 
hours, and detection antibody incubation was carried out for 2 hours after washing 
5 times. Anti-rabbit IgG-HRP diluted in wash buffer was applied to the wells for 
2 hours followed by 5x wash. Colorimetric enzymatic reaction was achieved by 
incubating 30 m with substrate for anti-rabbit HRP (R&D Systems). Reaction was 
stopped by 1M sulfuric acid solution. Optical absorbance for the color products in 
each well was read by a spectrophotometer at 450 nm. Data was calculated 
according to the linear regression of the protein standards and absorbance. 
Synaptophysin ELISA 
Synaptophysin ELISA was also developed in-house, using a capture 
antibody of mouse antisynaptophysin IgM antibody (Covance, clone SP17) used 
at 1:4000; detection antibody was rabbit anti-synaptophysin IgG (Chemicon) used 
at 1:2000. Synaptophysin protein standard (Abnova) was used in a range from 
0.156 to 5 ng/mL. Samples were loaded to each well at 1 µg protein per 100 µL 
per well. Anti-rabbit IgG-HRP (Pierce) was used at 1:3000. Wash buffer was 0.1 
M Tris buffer, pH 7.4, containing 0.05% Tween 20 (TBT). Sodium carbonate 
buffer, pH 9.6, was used as coating buffer for the capture antibody. Blocking 
buffer was TBT containing 5% skim milk, while sample diluent was TBT 
containing 2% skim milk powder. Incubation schedule was performed as 
described above. 
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Western blot detection of microglial markers 
Protein (10 µg/lane) from brain samples prepared for ELISA was prepared 
for electrophoresis with LDS loading buffer and reducing reagent DTT (1 µg/µL) 
and run on NuPage 10-14% Bis- Tris mini gels with MES running buffer 
(Invitrogen). Separated proteins were transferred to nitrocellulose membranes at 
30 volts for 60 m. Membranes were air-dried and blocked with 50 mM Tris-
buffered saline, pH 8.0, containing 0.05% Tween 20 (TBS-T) and 5% nonfat 
dried milk powder. Microglial specific marker Iba-1 (ionized calcium binding 
adapter protein 1) was detected with a rabbit polyclonal antibody (Wako 
Chemicals U.S.A., Richmond, VA). Microglial alternative activation markers 
Ym1 (chitinase 3-like 3), MMR1 (macrophage mannose receptor 1), and ARG1 
(arginase 1) were detected with polyclonal antibodies raised in either goat or 
sheep (R&D Systems, Minnesota), followed by secondary antibodies conjugated 
with horseradish peroxidase (HRP) of appropriate species. Blots were then 
reacted with Dura chemiluminescent substrate for HRP (Thermo Scientific) and 
imaged. Specific bands were identified by appropriate molecular weight and the 
density of immunoreactive bands was measured with Alpha View software (Cell 
Biosciences) and normalized to β-actin.  
Results 
MPNSP supplementation was generally well-tolerated. Mortality during 
the study appeared unrelated to supplementation: 1 WT mouse and 3 3xTG mice 
died or were euthanized prematurely due to illness while on supplementation, 2 
WT and 4 3xTG mice died or were euthanized while on the standard diet. Data 
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from these animals are included when possible and when not obviously impacted 
by illness preceding death. Final sample sizes under supplementation were N=12 
3xTG (6M, 6F) and N=10 WT (4M, 6F), and nonsupplemented were N=13 3xTG 
(5M,8F) and N=13 WT (5M, 8F). Consumption of the two diets did not differ 
during the initial 3-week monitoring period; overall, each supplemented mouse 
consumed 3.8±0.5 g/day and each mouse on standard chow 3.8±0.6 g/day 
(p=0.89, 2-tailed t-test; Figure 39a). Mean body weight in the two groups 
diverged early in the feeding (3-6 weeks) and then stabilized, with supplemented 
mice weighing less in comparison at each point (Figure 39b), but there was no 
indication of increasing divergence between the groups over time. Given the 
relatively broad range in age of mice at initiation of supplementation, we first 
explored the possibility of age-related effects by analyzing behavioral, FDG, and 
CO data by similarly-aged cohorts (approximately 29-35 weeks, 36-41 weeks, and 
42-46 weeks at initiation), and via ANCOVA with age as covariate; no significant 
effects of age were found (data not shown). In contrast, analysis of the behavioral 
results demonstrated that sex accounted for more measured variability than age; 
thus, all subsequent analyses included sex as a variable. 
Delayed Match to Position Three Choice Task  
Across all days of regular testing, there was a main effect of genotype for 
each type of error [Total: F(1, 45) = 6.103, p<0.05 (Figure 40); First: F(1, 45) = 
8.359, p <0.01; Repeat: F(1, 45) = 4.694 p<0.05] with 3xTG mice making more 
errors than WT mice. To investigate the effects of learning vs. asymptotic phases 
of testing, errors were blocked by days 1-5 vs. days 6-10. Here there was a 
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significant interaction between block, genotype, and sex [F(1, 41) = 7.390, 
p<0.01]. Because our a priori hypothesis was that diet would impact cognitive 
performance, we further investigated diet effects within the significant block, 
genotype, and sex interaction. During the asymptotic phase, the supplemented 
male 3xTG mice made fewer total errors than the nonsupplemented male 3xTG 
mice [t(8) = 5.267, p=0.05 (Figure 40)]. The female 3xTG mice did not differ by 
supplement status. 
On Day 11 there was a 30 min delay given between trials 5 and 6. No 
group significantly increased the number of errors committed between Trial 6 of 
the last day of regular testing (Day 10) and Trial 6 after the delay (Day 11). 
Morris Maze 
Across all days of testing, there was a main effect of Day for Distance and 
Latency in the WT and 3xTG mice [WT Distance: F(5, 130) = 117.887; 
p<0.0001; WT Latency: F(5, 130) = 104.124; p<0.0001; 3xTG Distance: F(5, 90) 
= 21.396; p<0.0001; 3xTG Latency: F(5, 90) = 15.428; p<0.0001], with scores 
decreasing across days, demonstrating learning of the task for both genotypes. 
There was a main effect of genotype for each measure [Distance: F(1, 44) = 
9.671, p<0.005; Latency: F(1, 44) = 7.995, p<0.01] with 3xTG mice swimming a 
longer distance and exhibiting a greater latency to locate the platform, than WT 
mice (Figure 41). There were no supplementation effects, sex effects, day x 
supplementation interactions, nor day x sex interactions for performance as 
measured by either measure. The probe trial, assessing learning of the platform 
location (NE quadrant), revealed a main effect of Quadrant [t (36) = 15.5; 
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p<0.0001] and a Quadrant x Genotype interaction [t (36) = 3.13; p<0.005]. Each 
group spent more percent distance in the target NE quadrant as compared to the 
opposite SW quadrant, showing localization of the platform location [WT: F(1, 
22) = 392.851; p<0.0001; 3xTG: F(1, 18) = 40.375; p<0.0001]; however, WT 
mice spent significantly more percent distance in the target NE quadrant [t(40) = 
14.747; p<0.0005] and significantly less percent distance in the opposite quadrant 
SW [t(36) = 4.747; p<0.05] than 3xTG mice, suggesting that WT mice showed 
better localization to the platform location than 3xTG mice. 
FDG Autoradiography 
The omnibus 2x2x2 ANOVA revealed a significant main effect (p<0.05) 
of genotype in 44 of 55 ROIs, consistent with our previous results in these mice at 
a slightly older age (18 months; Nicholson et al., 2010). Also consistent with 
previous results, our usual data normalization to average whole brain activity was 
precluded by the widespread gene-related changes in glucose uptake, so analysis 
proceeded with nonnormalized FDG uptake data. Modestly significant main 
effects of supplement status were found (reticular thalamus, nucleus basalis, and 
medial geniculate), and within these, significant interactions between genotype 
and supplementation (medial geniculate) and genotype, supplementation, and sex 
(nucleus basalis). Completion of post hoc 2-tailed ttests revealed that significant 
effects in medial geniculate were mediated by a supplementdriven increase in WT 
mice (supplemented vs. nonsupplemented: 871±210 vs. 657±122, mean±standard 
deviation, p=0.009), particularly the males (supplemented vs. nonsupplemented: 
921±176 vs. 605±40, p=0.025). A similar trend was apparent in male WT nucleus 
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basalis (supplemented vs. nonsupplemented: 826±167 vs. 498±68, p=0.020). Four 
other ROIs showed the identical relationship: middle cingulate gyrus (p=0.012), 
anteroventral thalamus (p=0.020), reticular thalamus (p=0.033), and mediodorsal 
thalamus (p=0.041). Only one ROI showed a similar effect in WT females, the 
mammillary bodies (1226±148 vs. 869±249, p=0.011). Of note, significant effects 
of the supplementation were seen across the expanse of the WT cingulate gyrus: 
anterior (p=0.047), middle (p=0.039), posterior (p=0.039), retrosplenial 
(p=0.034), except posterior level 2 (p=0.094), and also in the heavily 
interconnected hippocampal subiculum (p=0.042). WT somatosensory barrel 
fields, lateral posterior thalamus, and pontine nuclei also showed significant 
effects of supplementation (p<0.05). All significant changes were increases, and 
collectively, all WT ROI values were increased in the supplemented group. No 
significant post hoc effects were seen across the 3xTG groups or between 
comparisons of sex within the 3xTG; all apparent regional glucose uptake effects 
were mediated by changes in WT mice. 
Cytochrome Oxidase Histochemistry  
Previous analyses of 3xTG mice from our colony have demonstrated 
significant CO activity declines in several brain regions (unpublished data), 
similar to our findings in other AD mouse models (Valla et al., 2007). The 
omnibus 2x2x2 ANOVA revealed many regional significant main effects (Table 
14). Several strong interactions with sex were identified, prominently including 
the entorhinal cortex and hippocampal formation subregions. Significant 
differences between subgroups of 3xTG mice were again confirmed by post hoc 
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2-tailed t-tests. In contrast to FDG uptake, the CO changes under supplementation 
were mediated almost exclusively by 3xTG mice: supplementation induced 
significant increases in several brain regions, to approximately WT levels (Table 
15), most significantly in posterior cingulate (3xTG supplemented vs. 
nonsupplemented: p<0.001), primary somatosensory (p=0.001) and barrel field 
(p=0.009) cortex, mediodorsal thalamus (p=0.003), lateral hypothalamus 
(p=0.007), and lateral posterior thalamus (p=0.013). A similar trend was apparent 
in basolateral amygdala. The directionality and effect size of these changes was 
roughly the same in 3xTG males and females. However, an alternate pattern 
emerged when comparing across sex in areas showing other significant ANOVA 
effects (Table 15): in entorhinal cortex, male and female 3xTG showed a 
significant difference after supplementation (201±16 and 166±20, p=0.039), but 
3xTG males increased significantly to WT levels, while 3xTG females decreased 
nonsignificantly from WT levels, indicating a profound difference in regional 
function. Such a trend was also apparent in CA1 and the medial mammillary 
nuclei. Similarly, in CA3 and dentate gyrus, supplementation elicited little change 
in 3xTG males but caused the females to significantly decline from WT levels 
(Table 15).  
Fibrillar Amyloid & Tau Pathology  
Thioflavin staining for amyloid deposition revealed a consistent 
involvement of the hippocampal formation, particularly the anterodorsal 
subiculum and CA1, but often extending through ventroposterior aspects and to 
the amygdala. Lesser deposition was also seen in the basal forebrain and frontal 
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cortices. This pattern is consistent with our previous report (Nicholson et al., 
2010). All wildtype mice were negative, and no apparent differences were 
observed between supplementation conditions in the 3xTG mice. AT8-positive 
structures resembling neurofibrillary tangles were consistently located in 3xTG 
hippocampal CA1 and CA3; in images captured from these areas, no apparent 
difference in the density or composition of these tangles was seen between 
supplementation conditions. In the case of both Aβ and tau, deposition tended to 
worsen with increasing age across the range studied here.  
Biochemical measurements of Aβ, synaptophysin, and glial activation 
markers  
ELISA measurement of Aβ40 and Aβ42 in 3xTG mouse brain tissues at 
the level containing hippocampus showed a trend toward lower levels in 
supplemented mice. Analyzing by gender, it was apparent that the trend was 
driven by female mice, which showed significantly higher levels compared to the 
males. Further analysis of the 3xTG female subgroup (age at sacrifice [weeks]: 
supplemented: 64.1±2.5; nonsupplemented: 67.0±2.0, N=5/group) showed a 
significant reduction in Aβ42 (Table 16; p<0.038). This phenomenon was not 
observed in Aβ40 or male mice, although the trend in Aβ40 was similar in 3xTG 
females. The concentration of synaptophysin was not affected by supplementation 
(Table 16). Activated astroglial marker, GFAP, was used as an initial indicator of 
neuroinflammation. Supplementation did not lead to differential GFAP levels in 
either WT or 3xTG mice (Table 16). To determine the effects of diet treatment on 
microglial activation, we measured whether there were changes in the levels of 
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Iba1, Ym1, MMR1, and ARG1 expressions. Iba1 has been used widely as a 
marker for brain microglia across a spectrum of activation states, whereas Ym1, 
MMR 1, and ARG1 have been used specifically to identify alternatively-activated 
microglia in AD and APP transgenic mouse brains (Colton et al., 2006). Western 
blotting results showed a lack of effect of supplementation on most of the 
microglial markers except on ARG1 in female 3xTG mice (p<0.05, Table 16). 
Discussion 
We have confirmed that MPNSP supplementation can modulate markers 
of brain energy metabolism and alter other indicators of cognition and 
pathophysiology in a mouse model of AD, depending on sex. MPNSP 
supplementation prevented or reversed cognitive decline, with the modality 
affected dependent upon sex in this model. In post hoc analyses, MPNSP 
supplementation increased WT FDG uptake in several regions, including 
retrosplenial cingulate, posterior cingulate, and subiculum, but showed few effects 
in the 3xTG mice, who maintained significant FDG decreases in most ROIs. In 
contrast, analysis of regional CO activity in the 3xTG demonstrated several key 
regions in which the enzyme activity was corrected to WT levels. Following on 
the behavioral analysis, a breakdown by sex revealed striking differences in brain 
regional effects, particularly in regions in and closely connected to the 
hippocampal formation (e.g., entorhinal cortex). 
Deposition of fibrillar plaques and AT8-positive tau did not appear to be 
ameliorated by the supplementation, possibly a function of the timing of 
intervention: evidence of intracellular and extracellular Aβ in the 3xTG mice has 
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been reported at 4 and 6 months, respectively (Billings, Oddo, Green, McGaugh, 
& LaFerla, 2005). Memory impairment has been reported at 4 months (Billings et 
al., 2005) and synaptic dysfunction at 6 months (Oddo et al., 2005). Our earliest 
intervention began at approximately 7 months, after these processes should be 
underway; that said, biochemical measurements of the levels of human Aβ40 and 
Aβ42 in 3xTG mice showed supplementation-induced changes, with a strong 
trend toward differences dependent upon sex. A significant Aβ42-lowering effect 
was observed in the female subgroup, which had much higher Aβ levels overall as 
reported in this model previously (Hirata-Fukae et al., 2008). Our analyses 
indicate that our sample may have been underpowered for detection of several of 
the tested effects; alternatively, an earlier start time or higher dosing may be 
required to maximize the benefit of broad-based nutritional supplementation. 
Our earlier regional FDG analyses of mouse models of AD, including this 
model (Nicholson et al., 2010), indicated consistent declines in brain regional 
FDG uptake, some similar to those seen in human AD (Reiman et al., 1996; 
Minoshima et al., 2004). We were surprised to find that the supplementation did 
not correct this aberrant FDG uptake, which is an extremely plastic marker of 
brain activity, while it did correct mitochondrial CO function, also a plastic 
marker but much less so, in many of the same regions. One possible explanation 
for this dichotomy may be that aspects of the transgene-induced changes have 
direct and perhaps irreversible effects on mechanisms of FDG uptake, while the 
mitochondrial changes may be more amenable to our treatment, which includes 
compounds thought to be mitochondrial enhancers (Lagouge et al., 2006).  
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Concerning cognition, we were able to detect robust differences between 
the WT and 3xTG groups for both spatial working and short-term memory on the 
DMP task, and spatial reference memory on the MM, establishing an excellent 
paradigm for the evaluation of interventions in the 3xTG AD model. Importantly, 
MPNSP supplementation generated significant changes in short-term spatial 
memory as demonstrated in the DMP task, but not for spatial reference memory 
on the MM. These divergent effects may represent a specificity of memory type 
enhancement through MPNSP supplementation, aiding more in short-term 
working memory functional recovery rather than reference memory. Indeed, these 
effects are in line with the brain region-specific recovery of CO activity in 
supplemented male 3xTG entorhinal cortex, an area that may be more important 
for short-term working memory processing than long-term reference memory, as 
shown in patients with MCI using MRI voxel-based morphometry (Schmidt-
Wilcke, Poljansky, Hierlmeier, Hausner, & Ibach, 2009). Although behavioral 
analysis often revealed only marginal effects of the supplementation, we could 
determine that subject sex contributed substantially to variability and, when 
analyzed accordingly, differences between the sexes were indeed significant. 
Further, in the subsequent imaging and pathology analyses, including sex as a 
covariate illuminated other sex-specific changes. Specifically, in entorhinal 
cortex, medial mammillary nuclei, and in the CA3 and dentate gyrus of the 
hippocampus, a pattern emerged whereby in these regions supplementation 
corrected CO activity to WT levels in 3xTG males only, and decreased levels in 
supplemented 3xTG females only. Given the prominent role of these nuclei in the 
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behavioral tasks tested, these regional effects may reflect the sex-specific 
performance differences we observed. It follows then, that these network 
differences may reflect differences between male and female correction and/or 
compensation of functional deficits; i.e., 3xTG females activate different 
pathways than males in order to perform the task, or suffer enhanced regional 
vulnerability (or differences in recovery) which forces them to do so. That the 
entorhinal cortex and hippocampus appeared central to this sex-specific network 
change in mitochondrial activity was no surprise; previous research from our 
group has indicated that these regions are particularly sensitive to sex steroid-
induced alterations in female rodents (Braden et al., 2010, Chapter 2). In fact, 
estrogen and progesterone have been shown to modulate AD pathology and 
hippocampal-dependent behavioral function in 3xTG mice (Braden et al., 2010, 
Chapter 2), and female 3xTG mice display larger deficits in hippocampal-
dependent behavior than matched males (Carroll et al., 2010). The CO biomarker 
identified changes in areas (including the hippocampal formation) relevant to the 
apparent preservation of cognitive function that resulted from supplementation in 
3xTG males. This lends support to further examination of CO as an endpoint in 
preclinical interventional studies, and our concomitant work in humans (Valla et 
al., 2001, 2006, 2010) indicates that CO may be a useful biomarker early in the 
disease process and a quantifiable endpoint for the effects of consequential 
intervention.  
As many components of the supplement diet used in this study may 
possess anti-inflammatory properties, we also examined whether the diet could 
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alter the activation of glial cells. We found that in female 3xTG mice the 
supplementation significantly increased the expression levels of ARG1, a marker 
for alternative activation of microglia. This result suggested that the 
supplementation might have potential to shift a subpopulation of microglia from 
classical to alternative activation phenotype. Alternatively-activated microglia 
have an enhanced ability to phagocytize Aβ (Colton et al., 2006). However, 
ARG1 expression could also be increased with severity of AD as indicated by 
previous data obtained in AD brains and in 70 week-old Tg2576 mice, an animal 
model for amyloid pathology in AD (Valla et al., 2007). Increases in ARG1 have 
also been observed in the lipopolysaccharide-induced inflammatory response in 
the rTG2510 transgenic mice, an animal model overexpressing P301L tau (D. C. 
Lee et al., 2010)(Lee et al., 2010). 
This study has demonstrated that broad-based nutritional supplementation 
can positively impact certain parameters of cognition, mitochondrial function, and 
pathophysiology in a transgenic mouse model of AD. There were no indications 
that the supplementation carried unwanted side effects; indeed, these supplements 
have a long history of safe use in humans, including in formal clinical trials 
(Kamphuis et al., 2010; Capodice et al., 2009). Further research is needed to 
establish the optimal time for such supplementation to begin and its optimal dose 
(in both mice and humans). The youngest mice in this study at initiation were 
approx 7 months old, and cognitive deficits, Aβ accumulation, and bioenergetic 
deficits have been previously reported in this model prior to that age; nonetheless, 
MPNSP supplementation induced several potentially beneficial effects. And, 
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while not directly addressed in this study, it is possible that supplementation may 
be more effective as a preventative therapy, possibly via mechanisms bolstering 
brain reserve (i.e., increasing metabolic capacity via effects on mitochondrial 
function) or keeping levels of pathological species of tau or Aβ below critical 
thresholds. Given the relative safety and low cost of such intervention relative to 
current traditional pharmaceutical treatments with similar efficacy, broadbased 
supplementation such as the MPNSP or comprehensive diet plans of similar 
design hold great promise in the prevention and potential treatment of AD. 
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CHAPTER 8 
GENERAL DISCUSSION 
The work in this dissertation used the surgically menopausal rat to 
evaluate the cognitive effects and mechanisms of multiple progestogens clinically 
used in women. Findings suggest that MPA and progesterone may not be the best 
candidates for the progestogen component of HT and birth control, and point 
towards alternatives, such as NETA and LEVO. Moreover, in a clinical 
translation, this work suggests that a history of HT use is associated with positive 
impacts in volumes of mesial temporal lobe structures and memory measures in 
menopausal women. Finally, data herein suggest that sex is a variable that can 
alter outcome when evaluating the impact of a dietary intervention in a mouse 
model of AD.  
Cognitive Effects 
MPA 
 This series of experiments was the first to test the synthetic progestin, 
MPA, for learning and memory in the female rodent. MPA is the most commonly 
utilized progestin component of HT given to women in the United States (Hersh 
et al., 2004) and the only hormone found in the injectable contraceptive Depo 
Provera. In Chapter 2, we found that MPA impaired cognition in the aged 
surgically menopausal rat. Next, in Chapter 3, we investigated the possible long-
term effects of MPA administration during young adulthood, and/or interactions 
with subsequent MPA administration in post-Ovx middle-age, on cognition. 
Specifically, MPA given in either young adulthood, middle-age, or both, impaired 
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cognition, and MPA given at both time points was particularly detrimental to 
cognitive performance, as evidenced by an impairment on multiple memory 
measures. Further, we were able to confirm through blood serum analyses that, 
even in the absence of circulating MPA levels at the time of test, MPA 
administration during young adulthood resulted in long lasting working memory 
impairments evident later in life (middle-age). Finally, in Chapters 4b and 5b, we 
found that a shorter duration of MPA treatment impaired performance during the 
latter part of testing (Chapter 4b), or exacerbated a delay-induced memory 
retention impairment (Chapter 5b) on the WRAM. The current findings are in 
agreement with clinical and basic science evidence implicating MPA as 
detrimental to the brain and its function in women (Gabriel & Fahim, 2005; 
Shumaker et al., 2003), animals (Lowry et al., 2010), and cell culture (Nilsen et 
al., 2006).  
NETA 
With evidence mounting that MPA is not the optimal progestin choice for 
women, we turned our efforts to evaluating the cognitive effects of other popular 
progestins for HT and contraception that are of a different progestin class than 
MPA. First, in Chapter 3a we tested two doses of tonically administered NETA in 
the middle-age Ovx rat, and found that both doses impaired cognitive 
performance, with greater impairments observed in the higher dosed group. 
However, in Chapter 3b, when we administered NETA via daily injections for a 
shorter duration, this same moderate dose of NETA that previously impaired 
cognition when given tonically, had no effect. Moreover, a high NETA dose 
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improved cognitive performance under these treatment parameters. Collectively, 
our findings suggest that the cognitive impact of NETA, in the middle-aged Ovx 
rat, depends on the parameters involved in treatment (dose, schedule of treatment, 
and treatment duration). Divergent NETA results have also been observed 
clinically, with studies suggesting that NETA-containing HT can have positive 
effects (Tierney et al., 2009), or no impact (Gambacciani et al., 2003) on memory 
function.  
LEVO 
In Chapter 4b, we were the first to evaluate the cognitive effects of LEVO 
in any basic science or clinical setting. Here, we found that while LEVO did not 
have a robust impact on cognition, at the high dose, via daily injections, it did 
prevent a delay-induced impairment on the WRAM, suggesting that LEVO may 
enhance memory retention. While there has been no other research on the effects 
of this hormone for memory or any marker of brain function, these findings do 
support our hypothesis that progestins with a different chemical structure than the 
cognitively-impairing MPA can enhance cognition in the middle-age Ovx rat. 
Progesterone 
In Chapter 2, we replicated previous findings that natural progesterone 
impairs performance on the WRAM in the aged Ovx rodent (Bimonte-Nelson, 
Singleton et al., 2004). Further, we replicated our previous findings, the herein 
being our third report, that Ovx is beneficial in aged rats, by improving 
performance on the WRAM (Bimonte-Nelson et al., 2006), likely mediated in part 
by the removal of high endogenous progesterone levels (Bimonte-Nelson et al., 
  172 
2004b). In Chapter 5a, we extended these findings to the middle-aged Ovx 
animal, showing that daily injections of progesterone, beginning two weeks 
before test, impaired performance on the WRAM. Our data concur with findings 
in humans, that administration of progesterone or its metabolite, 
allopregnanolone, is detrimental to memory in healthy women (Freeman et al., 
1992; Kask et al., 2008).  
Mechanism 
GABA 
The findings from Chapter 2 demonstrate that in aged Ovx animals both 
natural progesterone and the synthetic MPA either significantly or marginally 
alter GAD levels in the hippocampus and entorhinal cortex. GAD is the 
synthesizing enzyme and rate limiting step of GABA synthesis, and is routinely 
used as a neuronal marker for GABAergic function (Bauer et al., 2000; Milbrandt 
et al., 2000). Our progesterone findings are in line with others who have shown 
that progesterone decreased GAD activity in the dorsal hippocampus (Wallis & 
Luttge, 1980). In middle-aged Ovx animals, while there was no main effect of 
MPA treatment on GAD levels in any of the brain regions analyzed, we found a 
negative correlation between serum MPA levels and GAD in the dorsal 
hippocampus (Chapter 3). In animals receiving MPA treatment at test, higher 
MPA levels correlated with less GAD in the dorsal hippocampus, which is in 
agreement with our findings of MPA-induced decreases in GAD in the dorsal 
hippocampus in aged Ovx animals (Chapter 2).  
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Previous research demonstrating that progesterone metabolites (Lan & 
Gee, 1994) and MPA (Belelli & Herd, 2003) can increase GABA-mediated 
inhibition in the hippocampus, as well as progestogen-induced changes that we 
have observed in GABA markers (Chapter 2), led us to pharmacologically 
investigate the role of the GABAergic system in progestogen-induced memory 
impairments. In Chapter 5a, we found that in middle-aged Ovx animals, 
concomitant treatment with the GABAA antagonist bicuculline, completely 
reversed progesterone-induced memory impairments. This suggests that 
progesterone-induced memory impairments may be via activation of the 
GABAergic system. In this study we also measured changes in number of GABA-
producing cells in the hippocampus of behaviorally tested animals. Progesterone 
and/or bicuculline had no effect, suggesting that a change in number of GABA-
producing cells in the hippocampus may not be the mechanism of progesterone-
induced memory impairments or the bicuculline reversal.  
In contrast to effects with progesterone, in Chapter 5b, we found that 
concomitant treatment with bicuculline had no effect on MPA-induced memory 
impairments in middle-aged Ovx animals. This suggests that MPA-induced 
memory impairments may not be via activation of the GABAergic system. 
However, when we examined MPA and/or bicuculline-induced changes in 
number of GABA-producing cells in the hippocampus, we found that MPA 
treatment increased the number of GABA-producing cells, an effect reversed by 
bicuculline. Here, we see a dissociation between bicuculline’s ability to block 
MPA-induced changes in hippocampal GABAergic markers and cognitive 
  174 
impairments, further suggesting other mechanisms of MPA-induced memory 
changes. Moreover, this increase in a hippocampal GABAergic marker seen after 
short-term MPA treatment (two weeks) is in the opposite direction of our 
previously established MPA-induced decrease in GAD protein levels in the 
hippocampus after long-term treatment (two months; Chapter 2). This suggests 
that MPA may exert differential effects on the hippocampal GABAergic system 
depending on duration of treatment.  
Neuronal Health 
Cox-2 
 Progesterone and MPA have both been shown to modulate Cox-2 
expression after insult (Cutler et al., 2007; Sunday et al., 2006). Previous research 
of progesterone’s effects on Cox-2 is mixed, with one study finding a 
progesterone-induced decrease in Cox-2 expression (Cutler et al., 2007), and 
another a progesterone-induced exacerbation of Cox-2 (Sunday et al., 2006), both 
after insult. In Chapter 5a, we found no effect of progesterone on number of Cox-
2 positive cells in the frontal cortex, suggesting that inflammation in the frontal 
cortex is likely not the mechanism of progesterone-induced memory impairments. 
MPA, however, has only been associated with an exacerbation of Cox-2 
expression after experimental procedures to increase inflammation (Sunday et al., 
2006), and indeed we found in Chapter 5b, that MPA treatment increased number 
of Cox-2 positive cells in the frontal cortex. Interestingly, although the GABAA 
antagonist bicuculline did not reverse the memory-impairing effects of MPA in 
this study, it did completely block the MPA-induced increase in frontal cortex 
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Cox-2-positive cells, suggesting that this may not be the mechanism of MPA-
induced memory impairments in the Ovx middle-aged rat, at least as tested on the 
WRAM and MM. However, an important research question should be to 
determine if an MPA-induced increase in Cox-2 positive cells in the frontal cortex 
has functional consequences on tasks that tap memory types that were not 
evaluated in the tasks we used to test cognition herein. For example, the frontal 
cortex is thought to mediate behavioral flexibility, among other cognitive 
functions, and damage to this area can lead to perserverative behaviors (Kesner & 
Churchwell, 2011).MPA-induced increases in frontal cortex Cox-2 positive cells 
may be related to a deficit in reversal learning and strategy switching that could 
be measured by the plus maze (Young & Shapiro, 2009). Future investigations 
elucidating the functional consequences of MPA-induced increases in frontal 
cortex Cox-2 positive cells on cognition are warranted. 
BDNF 
Although previous literature shows that progesterone increases 
neurotrophins in cerebral cortex slice cultures (Kaur et al., 2007) and counteracts 
17β-estradiol-induced increases in neurotrophins in the entorhinal and frontal 
cortices (Bimonte-Nelson et al., 2004a), and hippocampal slice cultures (Aguirre 
& Baudry, 2009), in Chapter 2 we found no effects of progesterone or MPA 
treatment on neurotrophin levels in several cognitive brain regions. Perhaps in 
vivo, progestogens do not have independent, but only regulatory actions, of 
estrogen’s effects on neurotrophins. This could be methodologically evaluated by 
cognitively testing progesterone and 17β-estradiol alone, and together, in a single 
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study, with an endpoint of evaluating neurotrophic markers. Results would add 
further mechanistic understanding of the role neurotrophins have in the cognitive 
effects of these two clinically used hormones. 
Hormone Therapy, Cognition, and Mesial Temporal Lobe Volumes 
 In Chapter 6, we found that HT use is associated with larger volumes of 
mesial temporal structures, and a modest verbal memory enhancement, in post-
menopausal women. Effects were dependent on HT status, with discontinuous 
users demonstrating larger hippocampal volumes bilaterally, and continuous users 
only a marginally larger right hippocampal volume, both as compared to women 
who never used hormone therapy. Continuous users, however, had significantly 
larger right and marginally larger left entorhinal cortex volumes, as compared to 
never users. Discontinuous HT use was not related to a change in entorhinal 
cortex volume, as compared to continuous or never use. Our effects are consistent 
with previous research showing that HT use is associated with larger hippocampal 
(Boccardi et al., 2006; Eberling et al., 2003; Erickson et al., 2010; Lord et al., 
2008; Yue et al., 2007) and entorhinal cortex (Boccardi et al., 2006) volumes, 
with deferential effects depending on previous or current HT status (Boccardi et 
al., 2006). We showed that discontinuous HT users were the only HT group to 
show a verbal memory enhancement, as compared to never users, and these 
results are also in line with findings from others on HT effects on dementia risk 
(Zandi et al., 2002) and MMSE (Mathews et al., 1999).  
 
 
  177 
Alzheimer’s Disease, Sex, and Dietary Intervention 
 In Chapter 7, we investigated the ability of a broad-based nutritional 
supplement to reverse the cognitive deficits seen in transgenic AD model mice, as 
compared to WT mice. Interestingly, we found that effects of the diet depended 
on sex, with cognitive benefits seen in male transgenic mice only, as compared to 
non-supplemented male transgenic mice. Multiple mechanisms of AD-associated 
cognitive impairments and dietary intervention correction were investigated in 
subsequent imaging and pathology analyses. One variable revealed sex-specific 
changes. Across both sexes, AD mice exhibited altered CO activity, a marker for 
mitochondrial function, in several brain areas, as compared to WT mice. 
However, in the entorhinal cortex, medial mammillary nuclei, and in the CA3 and 
dentate gyrus of the hippocampus, supplementation corrected CO activity to WT 
levels in AD male mice only, and decreased levels in supplemented AD female 
mice. Changes in mitochondrial function of cognitive brain regions thus represent 
a potential mechanism by which dietary intervention enhances cognition in male 
AD mice, and creates a vulnerability in female AD mice. Whether these effects in 
an animal model translate to AD patients is an important question, especially 
because incidence of AD is greater in women, as aging ensues (Anderson et al., 
1999). 
Final conclusions  
Several lines of evidence converge to suggest that naturally circulating and 
synthetic hormones affect cognition and related brain mechanisms in women and 
animal models. Specifically, 1) sex can modulate responsiveness to dietary 
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intervention in an animal model of AD, 2) HT use is related to increased volumes 
of mesial temporal lobe structures and a verbal memory enhancement in post-
menopausal women, 3) progesterone has negative effects on cognition in the 
menopausal rodent model, which may be related to the GABAergic system, 4) 
MPA has negative effects on cognition in the menopausal rodent model, and 
alters the GABAergic system, which increasing evidence suggests may not be the 
mechanism of MPA-induced cognitive impairments, 5) NETA can impair or 
improve cognition, depending on parameters used, in the menopausal rat model, 
and 6) LEVO can improve cognition in the menopausal rat model. Optimizing 
cognitive aging in women has been the overarching goal of this dissertation, and 
more specifically, I hope this research aids in the determining of a progestogen 
component, for birth control and HT, that is safe for brain health and function.  
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Table 1   
Mean neurotrophin levels in pg/mg in the Cingulate Cortex, Hippocampus, 
Entorhinal Cortex, and Frontal Cortex.  
  
  202 
Table 2 
Mean blood serum concentrations of MPA in ng/mL (±SE) and mean uterine 
weights in g (±SE).  
  
 Table 3  
Summary of significant behavior effects.
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Table 4  
Mean uterine and body weights in g (±SE).  * p < .05 vs. Control 
 Table 5  
Mean GAD protein levels in % control (
 
 
 205 
±SE). 
 
 Table 6 
Mean uterine weights in g (
 
 
 206 
±SE).   
 
 Table 7 
Mean frontal cortex cox-2 cell counts and hippocampal GAD cell counts (
 
 
 207 
 
±SE).   
 Table 8 
Mean uterine weights in g (
 
  
 
 208 
±SE). *p < .05 vs. Ovx+Vehicle 
 
 Table 9 
 
Mean hippocampal GAD cell counts (
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±SE).        
 Table 10 
Demographic information by group.
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 Table 11 
Brain volumes by group. 
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*p < .05 vs. NU; # p < .10 vs. NU 
 
 Table 12 
Cognitive scores by group. # 
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p < .10 vs. NU 
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Table 13.  
Summary of the 3 MPNSP supplements integrated into the mouse chow. Each was 
purchased over-the-counter at a local grocery. 
 
Freeze-dried phyto-nutrient powder (target: 5.25 mg/day/mouse)    
  
blueberry   cranberry   parsley    
brown rice*  ginger*    pomegranate*    
brussels sprout* green cabbage* red cabbage*    
chicory*   kale    rose hip*  
  
cinnamon*   okra*    spinach    
Concord grape* papaya*   turmeric*    
      
*cultured with following probiotic species, 1 billion per serving at the time of 
manufacture:  
L. casei, L. plantarum, L. salivarius, L. acidophilus, L. rhamnosus, S. thermophilus, 
B.bifidum, B. infantis, B. longum, & B. breve      
 
 
Herbal/spice liquid amalgam (target: 1.94 µl/day/mouse)      
Rosemary (leaf) - supercritical & ethanolic extracts (23% total phenolic antioxidants)  
Turmeric (rhizome) - supercritical (45% turmerones) & ethanolic extracts (7% 
curcuminoids) 
Ginger (rhizome) - supercritical (30% pungent compounds) & ethanolic extracts (3% 
pungent  compounds) 
Holy Basil (leaf) - ethanolic extract (2% ursolic acid) 
Green Tea (leaf) - hydroethanolic extract (45% polyphenols) 
Hu Zhang (root and rhizome) - hydroethanolic extract (8% resveratrols) 
Chinese Goldthread (root) - hydroethanolic extract (6% berberine) 
Barberry (root) - hydroethanolic extract (6% berberine) 
Oregano (leaf) - supercritical extract (4% total phenolic antioxidants) 
Baikal skullcap (root) - hydroethanolic extract (17-26% baicalein complex, 0.4-0.9% 
wogonin)  
Other: extra virgin olive oil, maltodextrin, silica, yellow beeswax, palm kernel oil 
 
 
Cod liver oil (target: 6.56 µl/day/mouse)       
DHA  EPA  Vitamin D 
20.40  16.10  15.00  mg / kg / day 
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Table 14.  
Comprehensive list of all regions-of-interest assessed and the calculated 
probability values for each main effect and interaction from the 2x2x2 ANOVA on 
the cytochrome oxidase imaging data. Regions showing significant (*  p<0.05) 
main effects and interactions were assessed with post hoc 2-tailed t-tests. 
 
ROI      Genotype (G) Diet (D)  Sex (S)  
Optic tract (opt)     0.751  0.280  0.172  
Cingulate gyrus, retrosplenial (RSG  0.028*  0.539  0.376  
Cingulate gyrus, posterior 2 (CGp2)  0.418  0.661  0.086  
Cingulate gyrus, posterior (CGp)   0.105  0.001*  0.380  
Cingulate gyrus, middle (CGm)   0.063  0.225  0.211  
Cingulate gyrus, anterior (CGa)   0.102  0.375  0.074  
Posterior parietal cortex (PPtA)   0.139  0.951  0.058  
Lateral entorhinal cortex (LEnt)   0.026*  0.316  0.560  
Primary somatosensory cortex (S1)   0.062  0.022*  0.389  
Primary somatosensory, BF (S1BF)  0.046*  0.066  0.225  
Secondary somatosensory cortex (S2)  0.090  0.064  0.149  
Primary auditory cortex (Au1)   0.020*  0.522  0.100  
Primary visual, monocular (V1)   0.002*  0.737  0.302  
Piriform cortex (Pir)    0.841  0.862  0.350  
CA1 (CA1)     0.002*  0.542  0.571  
CA3 (CA3)     0.005*  0.119  0.327  
Dentate gyrus (DG)    0.170  0.348  0.526  
Subiculum (S)     0.001*  0.606  0.061  
Medial mammillary nucleus (M)   0.869  0.359  0.563  
Substantia nigra (SNR)    0.131  0.964  0.273  
Basolateral amygdala (BLA)   0.372  0.056  0.262  
Anteroventral thalamus (AV)   0.958  0.828  0.779  
Reticular thalamus (Rt)    <0.001*  0.149  0.367  
Reuniens nucleus (Re)    0.639  0.461  0.278  
Ventromedial thalamus (VM)   0.296  0.127  0.137  
Ventrolateral thalamus (VL)   0.023*  0.021*  0.090  
Mediodorsal thalamus (MD)   0.116  0.009*  0.438  
Laterodorsal thalamus (LD)   0.051  0.391  0.267 
Lateral posterior thalamus (LP)   0.599  0.010*  0.620  
Parafascicular thalamus (PF)   0.112  0.792  0.062  
Ventroposterolateral thalamus (VPL)  0.230  0.183  0.609  
Ventroposteromedial thalamus (VPM)  0.168  0.677  0.057  
Posterior thalamus (Po)    0.155  0.310  0.227 
Lateral habenula (LHb)    0.806  0.683  0.450  
Rostral caudoputamen (rCPu)   0.181  0.018*  0.269  
Caudal caudoputamen (cCPu)   0.021*  0.790  0.224  
Lateral globus pallidus (LGP)   0.228  0.706  0.301  
Subthalamus (STh)    0.269  0.366  0.099  
Nucleus accumbens (Acb)    0.742  0.216  0.318  
Nuc. of vertical diagonal band (VDB)  0.409  0.205  0.303 
Medial septal nucleus (MS)   0.936  0.246  0.170  
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Lateral septal nucleus (LSI)   0.100  0.096  0.183  
Nucleus basalis (B)    0.043*  0.099  0.333  
Anterior hypothalamus (AH)   0.337  0.634  0.063  
Lateral hypothalamus (LH)   0.387  0.004*  0.478  
Dorsolateral geniculate (DLG)   0.196  0.291  0.102  
Medial geniculate (MG)    <0.001*  0.354  0.008*  
Superior colliculus (SC)    0.001*  0.281  0.052  
Pontine nuclei (PnC)    0.111  0.394  0.598  
Inferior colliculus, central (CIC)   0.267  0.051  0.500  
Periaqueductal gray (PAG)   0.114  0.226  0.975  
Vestibular nuclei (Ve)    0.956  0.048*  0.950 
Reticular nucleus, giganto (Gi)   0.605  0.095  0.633 
Cerebellar lobules 1-5 (Cb)   0.008*  0.763  0.133  
Simple lobule (Sim)    0.081  0.936  0.042*  
Crus 1 lobule (Crus1)    0.043*  0.349  0.191 
 
 
ROI  GxD  SxG  SxD  SxGxD 
opt  0.916  0.105  0.649  0.611 
RSG  0.648  0.909  0.350  0.058 
CGp2  0.690  0.269  0.505  0.655 
CGp  0.006*  0.298  0.829  0.635 
CGm  0.606  0.571  0.433  0.947 
CGa  0.321  0.772  0.654  0.927 
PPtA  0.754  0.562  0.691  0.554 
LEnt  0.394  0.689  0.008*  0.620 
S1  .018*  0.443  0.789  0.785 
S1BF  0.289  0.909  0.857  0.512 
S2  0.173  0.780  0.767  0.913 
Au1  0.821  0.453  0.508  0.916 
V1  0.986  0.299  0.989  0.025* 
Pir  0.764  0.648  0.805  0.171 
CA1  0.742  0.321  0.617  0.009* 
CA3  0.676  0.003*  0.989  0.018* 
DG  0.125  0.743  0.242  0.008* 
S  0.451  0.673  0.491  0.279 
M  0.505  0.251  0.275  0.008* 
SNR  0.600  0.457  0.019*  0.730 
BLA  0.168  0.924  0.938  0.882 
AV  0.517  0.485  0.398  0.623 
Rt  .402  0.471  0.553  0.013* 
Re  0.778  0.479  0.897  0.436 
VM  0.188  0.965  0.688  0.693 
VL  0.175  0.965  0.570  0.600 
MD  0.053  0.362  0.148  0.585 
LD  0.614  0.311  0.150  0.073 
LP  0.183  0.375  0.088  0.593 
PF  0.823  0.462  0.695  0.268 
VPL  0.400  0.710  0.919  0.153 
VPM  0.629  0.368  0.763  0.346 
Po  0.539  0.777  0.731  0.372 
LHb  0.380  0.935  0.454  0.448 
rCPu  0.837  0.539  0.755  0.735 
cCPu  0.360  0.643  0.991  0.242 
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LGP  0.928  0.797  0.963  0.999 
STh  0.689  0.276  0.909  0.727 
Acb  0.869  0.384  0.668  0.592 
VDB  0.277  0.875  0.514  0.749 
MS  0.376  0.803  0.840  0.947 
LSI  0.893  0.872  0.990  0.883 
 B  0.389  0.325  0.235  0.162 
 AH  0.708  0.150  0.602  0.935 
 LH  0.436  0.935  0.737  0.699 
 DLG  0.839  0.443  0.366  0.360 
 MG  0.080  0.236  0.022*  0.499 
 SC  0.120  0.516  0.055  0.968 
 PnC  0.362  0.744  0.826  0.132 
 CIC  0.420  0.278  0.365  0.003* 
 PAG  0.938  0.523  0.405  0.091 
 Ve  0.614  0.299  0.936  0.222 
 Gi  .930  0.958  0.258  0.865 
 Cb  0.858  0.870  0.244  0.592 
 Sim  0.370  0.994  0.160  0.393 
 Crus1  0.256  0.884  0.100  0.958 
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Table 15.  
Mean (±SD) from selected regions showing significant main effects and/or 
interactions in the cytochrome oxidase imaging analysis. WT=wildtype; 
TG=3xTG; Supp=on supplemented diet; NS=on standard diet; M=male; 
F=female. * Significantly different from same group nonsupplemented, 2-tailed t-
test, p<0.05. ** Significantly different from males of the same group, p<0.05. 
ROI    WT-Supp WT-NS  TG-Supp TG-NS 
Cingulate gyrus, posterior (CGp) 271±24  275±35  288±25 * 234±14  
Lateral entorhinal cortex (LEnt) 208±51  216±63  185±29  183±34  
Primary somatosensory cortex (S1) 242±28  242±27  247±25 * 207±13  
Primary somatosensory, BF (S1BF) 252±24  246±22  245±30 * 212±12  
CA1 (CA1)   208±16  212±27  190±31  186±28  
CA3 (CA3)   250±23  260±47  221±25  243±35  
Dentate gyrus (DG)  282±29  273±33  253±41  280±43  
Medial mammillary nuclei (M) 297±54  311±75  285±66  331±101 
Basolateral amygdala (BLA) 243±40  236±29  248±30 * 213±30  
Mediodorsal thalamus (MD) 262±45  255±33  268±35 * 219±20  
Lateral posterior thalamus (LP) 272±50  258±34  284±38 * 239±29  
Lateral hypothalamus (LH) 216±34  198±23  216±23 * 183±25  
ROI  TGM-Supp TGM-NS TGF-Supp TGF-NS 
CGp  286±30 * 234±15  290±21 * 233±15 
LEnt  201±16 * 166±20  166±31 ** 196±38 
S1  245±27  210±10  249±26 * 205±16 
S1BF  247±35  229±41  244±28  214±13 
CA1  195±26  173±38  174±28  200±23 
CA3  223±28  219±36  220±25 * 260±25 
DG  273±34  258±46  229±39 * 295±37 
M  316±61  263±57  240±49  366±104 
BLA  255±31  220±45  242±30 * 208±13 
MD  279±42 * 204±14  258±29  228±18 
LP  297±47 * 219±28  274±30  252±23 
LH  219±24  187±37  213±23 * 180±15 
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Table 16.  
Results from ELISA and Western blot analyses by sex (mean and SE). 
WT=wildtype; TG=3xTG; Supp=on supplemented diet; NS=on standard diet; 
M=male; F=female. *Significantly different between supplemented and 
nonsupplemented females, 2-tailed t-test, p<0.05. **Significantly different 
between supplemented and nonsupplemented, p<0.05. 
 
ELISA:   TGM-Supp TGM-NS TGF-Supp TGF-NS  
Human Abeta 42 (ng/mg) 10.0±5.55 3.20±1.13 33.47±8.70 * 60.50±2.19*  
Human Abeta 40 (ng/mg) 0.12±0.05 0.06±0.021  44.55±10.68 70.82±1.28  
Synaptophysin (pg/µg)  418.61±25.19 416.97±46.07  429.55±39.54 394.54±11.71  
GFAP (ng/µg)  10.56± 2.31 9.11±2.51 11.79±2.26 13.91±0.95 
Western Blot: 
IBA1 (17kD)  2.52±0.21 2.13±0.11  3.15±0.67 3.09±0.31  
ARG1   0.56±0.20 0.67±0.32 0.42±0.06** 0.36±0.08**  
YM1   1.35±0.27 1.69±0.14 0.67±0.08 0.59±0.07  
MMR   0.15±0.03 0.15±0.02 0.13±0.02 0.14±0.02 
 
ELISA:   WTM-Supp WTM-NS WTF-Supp WTF-NS 
Human Abeta 42 (ng/mg) n/a  n/a  n/a  n/a 
Human Abeta 40 (ng/mg) n/a  n/a  n/a  n/a 
Synaptophysin (pg/µg)  301.79±13.84 361.10±29.74  388.86±22.92 340.80±14.61 
GFAP (ng/µg)  12.61±0.75 10.33±2.02 9.64±1.79 12.65±1.28 
Western Blot: 
IBA1 (17kD)  2.71±0.26 2.34±0.11 2.83±0.15 2.91±0.19 
ARG1   0.56±0.11 0.67±0.15 0.55±0.08 0.48±0.10 
YM1   1.55±0.13 2.18±0.51 0.84±0.10 0.80±0.12 
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Figure 1. Mean error scores for WMC (+SE) on the water radial-arm maze for (a) 
day 12 and (b) delay day 13. *p < .05 
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Figure 2.  (a) Mean distance scores in centimeters (+SE) on Morris maze days 1- 
5. (b) Mean latency scores in seconds (+SE) on Morris maze days 1-5. (c) Mean 
Distance scores in centimeters (+SE) on Morris maze representing overnight 
forgetting. (d) Mean percent Distance (+SE) in the target NE quadrant as 
compared to the opposite SW quadrant during the probe trial (NW) over the 
opposite quadrant (SE) by any group. (e) Mean percent distance scores (+SE) 
spent in the annuli of the Morris maze during the probe trial. (f) A swim path of 
an animal during regular testing. (g) A swim path of an animal during the probe 
trial. (h) Mean escape scores (+SE) on Morris maze days 1-5. **p < .0001 
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Figure 3. Mean latency scores in seconds (±SE) on the visible platform maze.  
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Figure 4. (a) Mean % OVX by gel (+SE) of GAD protein expression and 
representative bands, as determined by Western blot luminescence, in the 
hippocampus. (b) Mean % OVX by gel (+SE) of GAD luminescence and 
representative bands, in the entorhinal cortex. *p < .05; #p < .10 
 
 
 
 
 
 
  
  227 
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Figure 5. A time line summarizing injections, ovariectomy, and behavioral testing 
for each group. 
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Figure 6. Mean error scores (+SE) on the water radial-arm maze. (a) WMC errors 
across all days of regular testing (days 1-11). (b) WMI errors across all days of 
testing. (c) WMC errors at the highest working memory load during the latter 
portion of testing (days 5-11). (d) WMI errors at the highest working memory 
load during the latter portion of testing (days 5-11). *p < .05  
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Figure 7. Mean distance scores in centimeters (+SE) on Morris maze initial 
testing days 1-4. (a) Distance scores across all days of initial testing (days 1-4). 
(b) Distance scores across the overnight interval. (c) Mean percent Distance in the 
target NE quadrant as compared to the opposite SW quadrant during the probe 
trial day 4. *p < .05 
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Figure 8. Mean Distance scores in centimeters (+SE) on Morris maze Platform 
Switch testing day 5. (a) Distance across all eight trials by new vs. original 
platform location. (b.) Percent Distance in the target SW quadrant as compared to 
the opposite NE quadrant during the probe trial day 5. *p < .05 
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Figure 9. Mean latency scores in seconds (+SE) on the visible platform maze. 
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Figure 10. Mean serum concentrations (+SE). (a) MPA concentrations. (b) 
Progesterone concentrations. (c) Allopregnanolone concentrations. *p < .05 vs. 
Control; ^p < .05 vs. Early-MPA  
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Figure 11. Relationship between MPA serum concentrations and GAD protein in 
the dorsal hippocampus in animals that had detectable levels of MPA at sacrifice 
(Late-MPA and Early+Late-MPA). 
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Figure 12. Chemical structures of (a) progesterone (b) medroxyprogesterone 
acetate (MPA) (c) norethindrone acetate (NETA) (d) levonorgesterel (LEVO). 
 
 
  
  
 
 243 
 
  244 
Figure 13. A time line for (a) Study 3a and (b) Study 3b summarizing injections, 
ovariectomy, and behavioral testing for each group. 
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Figure 14. Mean error scores (+SE) on the water radial-arm maze during the 
learning (days 2-6) and asymptotic (days 7-12) testing phases. (a) WMC errors. 
(b) WMI errors. (c) RM errors. *p < .05 
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Figure 15. Mean WMC error scores (+SE) on the water radial-arm maze for 
baseline (last day of regular testing trial 3) vs. delay (trial 3 immediately 
following a 6 hour delay). *p < .05 
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Figure 16. Mean Distance scores in centimeters (+SE) on Morris maze. (a) 
Distance scores across all days of testing (days 1-3). (b) Mean percent Distance in 
the target NE quadrant as compared to the opposite SW quadrant during the probe 
trial. *p < .05; ^p < .0001  
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Figure 17. Mean latency scores in seconds (+SE) on the visible platform maze. 
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Figure 18. Mean WMC error scores (+SE) on the water radial-arm maze. (a) 
WMC error scores during the learning (days 2-6) and asymptotic (days 7-12) 
testing phases. (b) Working memory load effect during the asymptotic testing 
phase. *p < .05 
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Figure 19. Mean error scores (+SE) on the water radial-arm maze during the latter 
portion of testing (days 11-12). (a) WMI error scores (b) RM error scores. *p < 
.05 
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Figure 20. Mean WMC error scores (±SE) on the water radial-arm maze for 
baseline (last day of regular testing trial 3) vs. delay (trial 3 immediately 
following a 6 hour delay). *p < .05 
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Figure 21. Mean Distance scores in centimeters (+SE) on Morris maze. (a) 
Distance scores across all days of testing (days 1-3). (b) Mean percent Distance in 
the target NE quadrant as compared to the opposite SW quadrant during the probe 
trial. *p < .05; ^p < .0001 
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Figure 22. Conclusions summary for Study 3a (tonic treatment) and 3b (injection 
treatment).  
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Figure 23. Mean error scores (+SE) on the water-radial arm maze. (a) WMC error 
scores across all days of regular testing in 2-3 day blocks. (b) WMC error scores 
on block 3 trial 4. (c). WMI error scores across all days of testing in 2-3 day 
blocks. (d) WMI error scores on block 3 trial 4. *p < .05 
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Figure 24. Mean WMC error scores (+SE) on the water radial-arm maze for 
baseline (last day of regular testing trial 3) vs. delay (trial 3 immediately 
following a 6 hour delay). *p < .05 
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Figure 25. Mean Distance scores in centimeters (+SE) on Morris maze. (a) 
Distance scores across all days of testing in 3 trial blocks. (b) Mean percent 
Distance in the target NE quadrant as compared to the opposite SW quadrant 
during the probe trial. *p < .05 
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Figure 26. Mean latency scores in seconds (+SE) on the visible platform maze. 
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Figure 27. Mean error scores (+SE) on the water-radial arm maze across all days 
of regular testing in 2-3 day blocks for (a) WMC error scores (b) WMI error 
scores and (c) RM error scores. *p < .05 
 
  
  
 
 273 
 
  274 
Figure 28. Mean WMC error scores (+SE) on the water radial-arm maze for 
baseline (last day of regular testing trial 3) vs. delay (trial 3 immediately 
following a 6 hour delay). *p < .05 
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Figure 29. Mean Distance scores in centimeters (+SE) on Morris maze. (a) 
Distance scores across all days of testing in 3 trial blocks. (b) Mean percent 
Distance in the target NE quadrant as compared to the opposite SW quadrant 
during the probe trial. *p < .05 
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Figure 30. Mean latency scores in seconds (+SE) on the visible platform maze. 
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Figure 31. (a) Mean frontal cortex Cox-2 Cell Counts per section (+SE). 
Representative images from (b) Ovx+Vehicle, (c) Ovx+MPA, (d) Ovx+Bic, and 
(e) Ovx+MPA+Bic. *p < .05 
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Figure 32. (a) Mean CA1 GAD Cell Counts per section (+SE). Representative 
images from (b) Ovx+Vehicle, (c) Ovx+MPA, and (d), Ovx+MPA+Bic. White 
arrows indicate positive GAD cells. *p < .05 
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Figure 33. Mean %TIV (+SE) for (a) left hippocampal volumes, (b) right 
hippocampal volumes, (c) left entorhinal cortex, and (d) right entorhinal cortex. 
*p < .05, #p < .10 
 
 
  
  
 
 285 
 
  286 
Figure 34. Mean % correct words (+SE) for delayed memory. #p < .10 
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Figure 35. Correlation matrix for continuous users showing correlations between 
age, brain volumes (hippocampus and entorhinal cortex), and cognitive scores 
(Total words, Delayed memory, TrailsA, and TrailsB). p values and Pearson r 
values listed for significant (p < .01) and marginal (p < .05) correlations.  
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Figure 36. Correlation matrix for discontinuous users showing correlations 
between age, brain volumes (hippocampus and entorhinal cortex), and cognitive 
scores (Total words, Delayed memory, TrailsA, and TrailsB). p values and 
Pearson r values listed for significant (p < .01) and marginal (p < .05) 
correlations.  
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Figure 37. Correlation matrix for never users showing correlations between age, 
brain volumes (hippocampus and entorhinal cortex), and cognitive scores (Total 
words, Delayed memory, TrailsA, and TrailsB). p values and Pearson r values 
listed for significant (p < .01) and marginal (p < .05) correlations.  
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Figure 38. Flowchart summarizing each stage of the study. The same animals 
were used for each analysis throughout the study, with tissues distributed from the 
behaviorally-tested animals. 
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Figure 39. (a) Mean (±SD) chow consumption (g/day) for each group during the 
first three weeks of supplementation. (b) Mean (±SD) starting and ending body 
weights (g) for each group. 
 
  
  
 
 297 
 
  298 
Figure 40. Mean error scores for total errors (±SE) on the delayed match to 
position for regular testing days 1-10, separated into learning (days 1-5) and 
asymptotic (days 6-10) phases. 
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Figure 41. Mean distance scores in centimeters (±SE) on Morris maze days 1-6. 
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APPENDIX B  
MINT JULEP 
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Ingredients 
10 mint leaves, stems removed 
1 tablespoon of powdered sugar 
1 1/2 ounce clean fresh spring water 
3 ounces premium Bourbon 
Crushed ice 
1 sprig of mint for garnish 
 
Directions 
 
Put the leaves in a 12 ounce cocktail glass and pour the sugar on top. Muddle 
them together gently with a muddler or the handle of a wooden spoon. When the 
leaves and wet sugar begin to turn to a little mushy, add the water and the 
bourbon, and stir. Top with crushed ice and  garnish with the sprig of mint. 
  
